The O
study O
demonstrated O
a O
decreased O
level O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
peripheral O
blood O
lymphocytes O
from O
hypercholesterolemic O
subjects O
, O
and O
an O
elevated O
level O
in O
patients O
with O
acute O
myocardial O
infarction O
. O

In O
the O
lymphocytes O
with O
a O
high O
GR B
number O
, O
dexamethasone O
inhibited O
[ O
3H O
] O
- O
thymidine O
and O
[ O
3H O
] O
- O
acetate O
incorporation O
into O
DNA O
and O
cholesterol O
, O
respectively O
, O
in O
the O
same O
manner O
as O
in O
the O
control O
cells O
. O

On O
the O
other O
hand O
, O
a O
decreased O
GR B
number O
resulted O
in O
a O
less O
efficient O
dexamethasone O
inhibition O
of O
the O
incorporation O
of O
labeled O
compounds O
. O

These O
data O
showed O
that O
the O
sensitivity O
of O
lymphocytes O
to O
glucocorticoids O
changed O
only O
with O
a O
decrease O
of O
GR B
level O
. O

Concentration O
of O
the O
receptors B
to O
1 O
. O
25 O
( O
OH O
) O
2D3 O
was O
elevated O
up O
to O
39 O
. O
7 O
fmole O
/ O
mg O
after O
I O
week O
of O
the O
treatment O
, O
whereas O
it O
was O
decreased O
to O
the O
initial O
level O
24 O
. O
8 O
fmole O
/ O
mg O
within O
4 O
weeks O
; O
simultaneous O
alteration O
in O
the O
cAMP O
content O
was O
observed O
in O
lymphocytes O
. O

The O
data O
obtained O
suggest O
that O
under O
conditions O
of O
glomerulonephritis O
only O
high O
content O
of O
receptors B
to O
1 O
. O
25 O
( O
OH O
) O
2D3 O
in O
lymphocytes O
enabled O
to O
perform O
the O
cell O
response O
to O
the O
hormone O
effect O
. O

In O
137 O
cases O
of O
childbearing O
- O
aged O
and O
pregnant O
women O
, O
free B
form I
E I
receptor I
levels O
( O
sE B
) O
in O
serum O
were O
measured O
by O
ELISA O
. O

The O
level O
of O
sE B
was O
significantly O
decreased O
during O
the O
first O
trimester O
, O
slightly O
higher O
in O
the O
second O
trimester O
, O
and O
recovered O
to O
normal O
in O
the O
third O
trimester O
. O

[ O
Determination O
of O
the O
sensitivity O
to O
glucocorticoids B
in O
vitro O
] O

The O
principal O
distinction O
of O
the O
method O
is O
standardization O
by O
the O
lymphocyte O
count O
in O
a O
sample O
( O
1 O
mln O
) O
and O
the O
labeled O
hormone B
concentration O
. O

Examinations O
of O
70 O
children O
aged O
4 O
to O
15 O
suffering O
from O
the O
nephrotic O
form O
of O
glomerulonephritis O
have O
made O
it O
possible O
to O
distinguish O
two O
groups O
of O
patients O
: O
with O
relatively O
high O
values O
of O
specific O
binding O
X O
= O
6820 O
. O
1 O
+ O
/ O
- O
530 O
. O
0 O
( O
n O
= O
30 O
, O
p O
= O
0 O
. O
95 O
, O
t O
= O
2 O
. O
04 O
) O
, O
this O
corresponding O
to O
a O
clinical O
form O
of O
hormone B
- O
sensitive O
glomerulonephritis O
, O
and O
with O
relatively O
low O
values O
of O
specific O
binding O
X O
= O
1815 O
. O
2 O
+ O
/ O
- O
302 O
. O
8 O
( O
n O
= O
40 O
, O
p O
= O
0 O
. O
95 O
, O
t O
= O
1 O
. O
96 O

) O
, O
that O
corresponds O
to O
hormone B
- O
resistant O
glomerulonephritis O
. O

These O
results O
permit O
regarding O
the O
specific O
binding O
value O
as O
a O
prognostic O
criterion O
in O
the O
assessment O
of O
corticosteroid B
therapy O
; O
this O
allows O
a O
wide O
employment O
of O
the O
described O
method O
in O
practical O
nephrology O
. O

The O
B O
- O
cell O
- O
type O
specificity O
of O
the O
immunoglobulin B
( O
Ig B
) O
heavy O
- O
chain O
and O
light O
- O
chain O
promoters O
is O
mediated O
by O
an O
octanucleotide B
( I
OCTA I
) I
element I
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA B
polymerase I
II I
promoters I
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

The O
B O
- O
cell O
- O
type O
specificity O
of O
the O
immunoglobulin B
( O
Ig B
) O
heavy O
- O
chain O
and O
light O
- O
chain O
promoters O
is O
mediated O
by O
an O
octanucleotide B
( I
OCTA I
) I
element I
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA B
polymerase I
II I
promoters I
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters B
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters B
. O

NFAT B
- I
1 I
, O
or O
a O
very O
similar O
protein O
, O
bound O
functional O
sequences O
of O
the O
long B
terminal I
repeat I
( O
LTR B
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O

NFAT B
- I
1 I
, O
or O
a O
very O
similar O
protein O
, O
bound O
functional O
sequences O
of O
the O
long B
terminal I
repeat I
( O
LTR B
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O

Functional O
silencer B
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer B
- I
DNA I
- I
protein I
complex I
in O
electrophoretic O
mobility O
shift O
assays O
with O
T O
- O
cell O
extracts O
. O

Although O
the O
enhanced O
NK O
cell O
activity O
and O
LDCC O
were O
closely O
associated O
with O
high O
levels O
( O
greater O
than O
31 O
fmol O
/ O
mg O
) O
of O
estrogen B
receptor I
( O
ER B
) O
content O
in O
the O
primary O
tumor O
, O
no O
other O
clinical O
or O
histologic O
correlation O
between O
the O
increase O
in O
either O
parameter O
of O
cytotoxic O
effector O
cell O
function O
could O
be O
found O
. O

Thus O
, O
ER B
levels O
greater O
than O
31 O
fmol O
/ O
mg O
might O
be O
associated O
with O
increased O
cytotoxic O
effector O
cell O
function O
in O
tumor O
- O
bearing O
patients O
with O
breast O
cancer O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B
receptors I
( O
GR B
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B
in O
peripheral O
mononuclear O
cells O
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B
in O
both O
patients O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B
receptors I
( O
GR B
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B
in O
peripheral O
mononuclear O
cells O
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B
in O
both O
patients O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B
receptors I
( O
GR B
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B
in O
peripheral O
mononuclear O
cells O
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B
in O
both O
patients O
. O

Reduced O
numbers O
and O
normal O
affinity O
of O
GR B
were O
found O
in O
the O
Epstein O
- O
Barr O
virus O
- O
transformed O
lymphocytes O
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR B
. O

Reduced O
numbers O
and O
normal O
affinity O
of O
GR B
were O
found O
in O
the O
Epstein O
- O
Barr O
virus O
- O
transformed O
lymphocytes O
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR B
. O

The O
thermal O
stability O
of O
GR B
and O
thermal O
activation O
of O
cytosolic B
receptors I
in O
both O
patients O
were O
found O
to O
be O
normal O
. O

Although O
the O
percentages O
of O
nuclear O
bound O
GR B
were O
similar O
in O
both O
patients O
and O
normal O
controls O
, O
the O
absolute O
amounts O
of O
nuclear O
bound O
GR B
of O
the O
patients O
were O
about O
one O
- O
half O
that O
of O
normal O
controls O
. O

Although O
the O
percentages O
of O
nuclear O
bound O
GR B
were O
similar O
in O
both O
patients O
and O
normal O
controls O
, O
the O
absolute O
amounts O
of O
nuclear O
bound O
GR B
of O
the O
patients O
were O
about O
one O
- O
half O
that O
of O
normal O
controls O
. O

These O
abnormal O
properties O
of O
GR B
( O
reduced O
numbers O
of O
GR B
) O
were O
preserved O
in O
the O
transformed O
cells O
from O
the O
patients O
. O

These O
abnormal O
properties O
of O
GR B
( O
reduced O
numbers O
of O
GR B
) O
were O
preserved O
in O
the O
transformed O
cells O
from O
the O
patients O
. O

However O
, O
OTF B
interaction O
with O
the O
heptamer B
sequence I
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif O
and O
occurred O
with O
a O
spacing O
of O
either O
2 B
or I
14 I
base I
pairs I
between O
the O
two O
elements O
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein O
- O
protein O
interactions O
. O

The O
degeneracy O
in O
sequences O
recognized O
by O
the O
OTFs B
may O
be O
important O
in O
widening O
the O
range O
over O
which O
gene O
expression O
can O
be O
modulated O
and O
in O
establishing O
cell O
type O
specificity O
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL O
2 O
- O
depleted O
cultures O
of O
CTL O
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone B
prior O
to O
the O
addition O
of O
IL B
2 I
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL B
2 I
. O

The O
action O
of O
these O
hormones B
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory B
protein I
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA O
synthesis O
. O

Our O
results O
indicate O
that O
these O
hormones B
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL B
2 I
activity O
. O

The O
octamer O
sequence O
5 O
' O
- O
ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream B
element I
in O
a O
variety O
of O
promoters B
and O
also O
occurs O
as O
a O
modular B
enhancer I
element I
. O

To O
explain O
the O
end O
- O
organ O
resistance O
to O
cortisol O
, O
the O
glucocorticoid B
receptors I
( O
GR B
) O
in O
peripheral O
mononuclear O
leukocytes O
and O
cultured O
skin O
fibroblasts O
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O

The O
patient O
' O
s O
GR B
in O
whole O
cell O
assays O
had O
an O
increased O
dissociation O
constant O
( O
Kd O
) O
. O

DNA B
binding O
of O
the O
GR B
complex I
after O
temperature O
- O
induced O
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O

These O
results O
suggest O
that O
the O
patient O
' O
s O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the O
receptor O
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR B
complex I
to O
DNA B
. O

Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 O
and O
was O
not O
changed O
by O
phosphodiesterase B
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate B
cyclase I
- O
phosphodiesterase B
system O
. O

Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 O
and O
was O
not O
changed O
by O
phosphodiesterase B
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate B
cyclase I
- O
phosphodiesterase B
system O
. O

Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti B
- I
CBG I
antibody I
are O
compatible O
with O
a O
role O
both O
of O
high O
- O
affinity O
glucocorticoid B
receptors I
and O
of O
CBG B
in O
mediating O
cortisol O
action O
on O
the O
human O
NK O
cell O
activity O
. O

We O
have O
also O
detected O
a O
DNA O
- O
protein O
interaction O
that O
may O
be O
involved O
in O
the O
cell O
- O
type O
specificity O
of O
immunoglobulin B
expression O
, O
and O
we O
have O
determined O
that O
a O
sequence O
upstream O
of O
the O
octamer O
participates O
in O
an O
interaction O
with O
a O
nuclear B
protein I
( O
s O
) O
. O

The O
promoters B
of O
the O
adenovirus B
2 I
major I
late I
gene I
, O
the O
mouse B
beta I
- I
globin I
gene I
, O
the O
mouse B
immunoglobulin I
VH I
gene I
and O
the O
LTR B
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

The O
promoters B
of O
the O
adenovirus B
2 I
major I
late I
gene I
, O
the O
mouse B
beta I
- I
globin I
gene I
, O
the O
mouse B
immunoglobulin I
VH I
gene I
and O
the O
LTR B
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

LTR B
was O
preferentially O
transcribed O
in O
the O
extracts O
of O
MT O
- O
2 O
although O
the O
other O
three O
genes O
were O
transcribed O
with O
relatively O
constant O
efficiencies O
in O
different O
extracts O
. O

The O
second O
element B
is O
found O
upstream O
of O
both O
heavy B
and I
kappa I
light I
- I
chain I
gene I
promoters I
. O

Acetylation O
and O
modulation O
of O
erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
activity O
by O
interaction O
with O
histone B
acetyltransferases I
. O

Erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
is O
a O
red B
cell I
- I
specific I
transcriptional I
activator I
that O
is O
crucial O
for O
consolidating O
the O
switch O
to O
high O
levels O
of O
adult O
beta O
- O
globin O
expression O
during O
erythroid O
ontogeny O
. O

EKLF B
is O
required O
for O
integrity O
of O
the O
chromatin O
structure O
at O
the O
beta B
- I
like I
globin I
locus I
, O
and O
it O
interacts O
with O
a O
positive B
- I
acting I
factor I
in O
vivo O
. O

We O
find O
that O
EKLF B
is O
an O
acetylated B
transcription I
factor I
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B
, O
p300 B
, O
and O
P B
/ I
CAF I
. O

We O
find O
that O
EKLF B
is O
an O
acetylated B
transcription I
factor I
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B
, O
p300 B
, O
and O
P B
/ I
CAF I
. O

We O
find O
that O
EKLF B
is O
an O
acetylated B
transcription I
factor I
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B
, O
p300 B
, O
and O
P B
/ I
CAF I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation O
region O
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation O
region O
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation O
region O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
enhance O
EKLF B
' O
s O
transcriptional O
activation O
of O
the O
beta B
- I
globin I
promoter I
in O
erythroid O
cells O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
enhance O
EKLF B
' O
s O
transcriptional O
activation O
of O
the O
beta B
- I
globin I
promoter I
in O
erythroid O
cells O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
enhance O
EKLF B
' O
s O
transcriptional O
activation O
of O
the O
beta B
- I
globin I
promoter I
in O
erythroid O
cells O
. O

These O
results O
establish O
EKLF B
as O
a O
tissue B
- I
specific I
transcription I
factor I
that O
undergoes O
post O
- O
translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF B
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta O
- O
globin O
expression O
within O
the O
beta B
- I
like I
globin I
cluster I
. O

These O
results O
establish O
EKLF B
as O
a O
tissue B
- I
specific I
transcription I
factor I
that O
undergoes O
post O
- O
translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF B
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta O
- O
globin O
expression O
within O
the O
beta B
- I
like I
globin I
cluster I
. O

Expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B
protein I
VP22 B
and O
the O
viral B
dUTPase I
, O
encoded O
by O
genes B
UL49 I
and I
UL50 I
, O
respectively O
, O
are O
T B
- I
cell I
antigens I
. O

Separate O
epitopes B
in O
VP22 B
were O
defined O
for O
T O
- O
cell O
clones O
from O
each O
of O
three O
patients O
. O

Separate O
epitopes B
in O
VP22 B
were O
defined O
for O
T O
- O
cell O
clones O
from O
each O
of O
three O
patients O
. O

Reactivity O
with O
the O
tegument B
protein I
encoded O
by O
UL21 B
was O
identified O
for O
an O
additional O
patient O
. O

Three O
new O
epitopes O
were O
identified O
in O
VP16 B
, O
a O
tegument B
protein I
associated O
with O
VP22 B
. O

Three O
new O
epitopes O
were O
identified O
in O
VP16 B
, O
a O
tegument B
protein I
associated O
with O
VP22 B
. O

Fibrinogen B
activates O
NF B
- I
kappa I
B I
transcription I
factors I
in O
mononuclear O
phagocytes O
. O

Cells O
stimulated O
with O
fibrinogen B
( O
10 O
- O
100 O
microg O
/ O
ml O
) O
/ O
Mn2 O
+ O
( O
50 O
microM O
) O
for O
2 O
h O
were O
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

NF B
- I
kappa I
B I
activation O
, O
minimal O
in O
unstimulated O
cells O
, O
was O
substantially O
up O
- O
regulated O
by O
fibrinogen B
. O

Fibrinogen B
also O
caused O
activation O
of O
AP B
- I
1 I
, O
but O
not O
SP1 B
or O
cAMP B
response I
element I
- I
binding I
protein I
( I
CREB I
) I
factors I
. O

Fibrinogen B
also O
caused O
activation O
of O
AP B
- I
1 I
, O
but O
not O
SP1 B
or O
cAMP B
response I
element I
- I
binding I
protein I
( I
CREB I
) I
factors I
. O

Blocking O
mAbs B
against O
CD18 B
and O
CD11b B
abrogated O
fibrinogen B
- O
induced O
NF B
- I
kappa I
B I
activation O
. O

Blocking O
mAbs B
against O
CD18 B
and O
CD11b B
abrogated O
fibrinogen B
- O
induced O
NF B
- I
kappa I
B I
activation O
. O

Blocking O
mAbs B
against O
CD18 B
and O
CD11b B
abrogated O
fibrinogen B
- O
induced O
NF B
- I
kappa I
B I
activation O
. O

Blocking O
mAbs B
against O
CD18 B
and O
CD11b B
abrogated O
fibrinogen B
- O
induced O
NF B
- I
kappa I
B I
activation O
. O

Cells O
were O
subsequently O
stimulated O
with O
1 O
) O
PMA O
for O
24 O
h O
, O
inducing O
CAT O
activity O
by O
2 O
. O
6 O
- O
fold O
, O
2 O
) O
fibrinogen B
/ O
Mn2 O
+ O
for O
2 O
h O
, O
inducing O
CAT O
activity O
by O
3 O
. O
2 O
- O
fold O
, O
or O
3 O
) O
costimulation O
with O
fibrinogen B
and O
PMA O
, O
inducing O
5 O
. O
7 O
- O
fold O
the O
CAT O
activity O
induced O
by O
PMA O
alone O
. O

Cells O
were O
subsequently O
stimulated O
with O
1 O
) O
PMA O
for O
24 O
h O
, O
inducing O
CAT O
activity O
by O
2 O
. O
6 O
- O
fold O
, O
2 O
) O
fibrinogen B
/ O
Mn2 O
+ O
for O
2 O
h O
, O
inducing O
CAT O
activity O
by O
3 O
. O
2 O
- O
fold O
, O
or O
3 O
) O
costimulation O
with O
fibrinogen B
and O
PMA O
, O
inducing O
5 O
. O
7 O
- O
fold O
the O
CAT O
activity O
induced O
by O
PMA O
alone O
. O

Amplified O
cDNA B
were O
sequenced O
by O
standard O
methods O
. O

Apoptosis O
induced O
by O
DNA O
damage O
and O
other O
stresses O
can O
proceed O
via O
expression O
of O
Fas B
ligand I
( O
FasL B
) O
and O
ligation O
of O
its O
receptor O
, O
Fas O
( O
CD95 O
) O
. O

We O
report O
that O
activation O
of O
the O
two O
transcription B
factors I
NF I
- I
kappa I
B I
and I
AP I
- I
1 I
is O
crucially O
involved O
in O
FasL B
expression O
induced O
by O
etoposide O
, O
teniposide O
, O
and O
UV O
irradiation O
. O

A O
nondegradable B
mutant I
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O

Thus O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
contributes O
to O
stress O
- O
induced O
apoptosis O
via O
the O
expression O
of O
FasL B
. O

The O
total O
populations O
of O
CD4 B
+ O
, O
CD8 B
+ O
and O
CD56 B
+ O
[ O
possible O
T O
- O
cell O
and O
natural O
killer O
( O
T O
/ O
NK O
) O
populations O
] O
in O
the O
BM O
of O
ST O
patients O
and O
MRD O
+ O
/ O
LT O
patients O
were O
significantly O
( O
p O
< O
. O
01 O
) O
low O
. O

The O
total O
populations O
of O
CD4 B
+ O
, O
CD8 B
+ O
and O
CD56 B
+ O
[ O
possible O
T O
- O
cell O
and O
natural O
killer O
( O
T O
/ O
NK O
) O
populations O
] O
in O
the O
BM O
of O
ST O
patients O
and O
MRD O
+ O
/ O
LT O
patients O
were O
significantly O
( O
p O
< O
. O
01 O
) O
low O
. O

The O
total O
populations O
of O
CD4 B
+ O
, O
CD8 B
+ O
and O
CD56 B
+ O
[ O
possible O
T O
- O
cell O
and O
natural O
killer O
( O
T O
/ O
NK O
) O
populations O
] O
in O
the O
BM O
of O
ST O
patients O
and O
MRD O
+ O
/ O
LT O
patients O
were O
significantly O
( O
p O
< O
. O
01 O
) O
low O
. O

These O
experiments O
are O
of O
prime O
importance O
considering O
that O
CD4 B
- O
expressing O
T O
lymphocytes O
represent O
the O
major O
virus O
reservoir O
in O
the O
peripheral O
blood O
of O
infected O
individuals O
. O

To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long B
terminal I
repeat I
( O
LTR B
) O
sequence O
diversity O
on O
LTR B
- I
directed I
gene I
expression O
in O
cells O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
and O
immune O
system O
, O
we O
amplified O
and O
cloned O
LTRs B
from O
proviral O
DNA O
in O
HIV O
- O
1 O
- O
infected O
peripheral O
blood O
. O

To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long B
terminal I
repeat I
( O
LTR B
) O
sequence O
diversity O
on O
LTR B
- I
directed I
gene I
expression O
in O
cells O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
and O
immune O
system O
, O
we O
amplified O
and O
cloned O
LTRs B
from O
proviral O
DNA O
in O
HIV O
- O
1 O
- O
infected O
peripheral O
blood O
. O

Sequence O
analysis O
of O
nineteen O
LTRs B
cloned O
from O
2 O
adult O
and O
3 O
pediatric O
patients O
revealed O
an O
average O
of O
33 O
nucleotide O
changes O
( O
with O
respect O
to O
the O
sequence O
of O
the O
LAI B
LTR I
) O
within O
the O
455 B
- I
bp I
U3 I
region I
. O

Transient O
expression O
analyses O
in O
cells O
of O
neuroglial O
and O
lymphocytic O
origin O
demonstrated O
that O
some O
of O
these O
LTRs B
had O
activities O
which O
varied O
significantly O
from O
the O
LAI B
LTR I
in O
U O
- O
373 O
MG O
cells O
( O
an O
astrocytoma O
cell O
line O
) O
as O
well O
as O
in O
Jurkat O
cells O
( O
a O
CD4 O
- O
positive O
lymphocyte O
cell O
line O
) O
. O

While O
LTRs B
which O
demonstrated O
the O
highest O
activities O
in O
U O
- O
373 O
MG O
cells O
also O
yielded O
high O
activities O
in O
Jurkat O
cells O
, O
the O
LTRs B
were O
generally O
more O
active O
in O
Jurkat O
cells O
when O
compared O
to O
the O
LAI B
LTR I
. O

While O
LTRs B
which O
demonstrated O
the O
highest O
activities O
in O
U O
- O
373 O
MG O
cells O
also O
yielded O
high O
activities O
in O
Jurkat O
cells O
, O
the O
LTRs B
were O
generally O
more O
active O
in O
Jurkat O
cells O
when O
compared O
to O
the O
LAI B
LTR I
. O

Differences O
in O
LTR B
sequence I
also O
resulted O
in O
differences O
in O
transcription O
factor O
recruitment O
to O
cis B
- I
acting I
sites I
within O
the O
U3 B
region I
of O
the O
LTR B
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

Transcriptional O
regulation O
of O
the O
gene O
for O
the O
myeloid B
calcium I
binding I
protein I
, O
MRP14 B
, O
was O
investigated O
in O
human O
monocytic O
leukemia O
cell O
lines O
. O

The O
level O
of O
MRP14 B
in O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
was O
two O
- O
fold O
higher O
than O
that O
in O
THP O
- O
1 O
cells O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

B O
- O
LCL O
, O
but O
not O
T O
and O
B O
cells O
, O
expressed O
CYP11B B
. O

There O
was O
minimal O
expression O
of O
HSD3B1 B
and O
HSD3B2 B
( O
3beta B
- I
hydroxysteroid I
dehydrogenase I
I I
and I
II I
) O
in O
B O
- O
LCL O
and O
T O
cells O
. O

There O
was O
minimal O
expression O
of O
HSD3B1 B
and O
HSD3B2 B
( O
3beta B
- I
hydroxysteroid I
dehydrogenase I
I I
and I
II I
) O
in O
B O
- O
LCL O
and O
T O
cells O
. O

Transcripts O
for O
CYP19 B
and O
HSD11K B
were O
not O
detected O
. O

Transcripts O
for O
CYP19 B
and O
HSD11K B
were O
not O
detected O
. O

Human O
white O
blood O
cells O
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA B
for O
the O
pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
for O
mutation O
detection O
. O

Human O
white O
blood O
cells O
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA B
for O
the O
pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
for O
mutation O
detection O
. O

Pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
( O
PCD B
/ I
DCoH I
) O
is O
a O
protein O
that O
has O
a O
dual O
function O
. O

In O
addition O
, O
it O
is O
the O
dimerization O
cofactor O
of O
HNF1 B
that O
is O
able O
to O
activate O
the O
transcriptional O
activity O
of O
HNF1 B
. O

In O
addition O
, O
it O
is O
the O
dimerization O
cofactor O
of O
HNF1 B
that O
is O
able O
to O
activate O
the O
transcriptional O
activity O
of O
HNF1 B
. O

Recombination O
of O
the O
MPC11 B
plasma I
B I
- I
cell I
derived I
NF I
- I
Y I
A I
: I
B I
: I
C I
complex I
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF B
- I
Y I
- I
associated I
factors I
( O
YAFs B
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF B
- I
Y I
as O
an O
intact B
trimeric I
complex I
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

These O
results O
suggest O
that O
in O
class O
II O
+ O
mature O
B O
- O
cells O
NF B
- I
Y I
is O
associated O
with O
the O
protein O
cofactor O
, O
PC4 B
, O
which O
may O
play O
an O
important O
role O
in O
NF O
- O
Y O
- O
mediated O
transcriptional O
control O
of O
class B
II I
genes I
. O

Despite O
extensive O
research O
, O
the O
role O
of O
CD40 B
signaling O
in O
B O
cell O
terminal O
differentiation O
remains O
controversial O
. O

Here O
we O
show O
that O
CD40 B
engagement O
arrests O
B O
cell O
differentiation O
prior O
to O
plasma O
cell O
formation O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 B
interaction O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 B
interaction O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 B
interaction O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 B
interaction O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 B
interaction O
. O

At O
150 O
microM O
LA O
- O
Plus O
, O
but O
not O
LA O
, O
inhibited O
TNFalpha B
induced O
NF B
- I
kappaB I
activation O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

Sera O
from O
diabetic O
patients O
significantly O
( O
P O
< O
0 O
. O
01 O
) O
enhanced O
leukocyte O
adhesion O
as O
compared O
with O
controls O
, O
despite O
normal O
levels O
of O
IL B
- I
1beta I
and O
TNFalpha B
in O
these O
sera O
. O

Ikaros B
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O

Here O
we O
review O
the O
role O
of O
Ikaros B
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B
finger I
transcription I
factors I
in O
this O
developmental O
process O
. O

Studies O
on O
an O
Ikaros B
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor O
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O

Induction O
of O
early B
B I
cell I
factor I
( O
EBF B
) O
and O
multiple B
B I
lineage I
genes I
by O
the O
basic B
helix I
- I
loop I
- I
helix I
transcription I
factor I
E12 B
. O

Induction O
of O
early B
B I
cell I
factor I
( O
EBF B
) O
and O
multiple B
B I
lineage I
genes I
by O
the O
basic B
helix I
- I
loop I
- I
helix I
transcription I
factor I
E12 B
. O

The O
transcription B
factors I
encoded O
by O
the O
E2A B
and O
early B
B I
cell I
factor I
( O
EBF B
) O
genes O
are O
required O
for O
the O
proper O
development O
of O
B O
lymphocytes O
. O

The O
transcription B
factors I
encoded O
by O
the O
E2A B
and O
early B
B I
cell I
factor I
( O
EBF B
) O
genes O
are O
required O
for O
the O
proper O
development O
of O
B O
lymphocytes O
. O

We O
report O
the O
identification O
of O
a O
novel O
model O
system O
in O
which O
the O
role O
of O
E2A B
and O
EBF B
in O
the O
regulation O
of O
multiple O
B O
lineage O
traits O
can O
be O
studied O
. O

We O
report O
the O
identification O
of O
a O
novel O
model O
system O
in O
which O
the O
role O
of O
E2A B
and O
EBF B
in O
the O
regulation O
of O
multiple O
B O
lineage O
traits O
can O
be O
studied O
. O

We O
found O
that O
the O
conversion O
of O
70Z O
/ O
3 O
pre O
- O
B O
lymphocytes O
to O
cells O
with O
a O
macrophage O
- O
like O
phenotype O
is O
associated O
with O
the O
loss O
of O
E2A B
and O
EBF B
. O

We O
found O
that O
the O
conversion O
of O
70Z O
/ O
3 O
pre O
- O
B O
lymphocytes O
to O
cells O
with O
a O
macrophage O
- O
like O
phenotype O
is O
associated O
with O
the O
loss O
of O
E2A B
and O
EBF B
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Activation O
of O
EBF B
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B
- O
inducible O
traits O
. O

Activation O
of O
EBF B
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B
- O
inducible O
traits O
. O

Activation O
of O
EBF B
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B
- O
inducible O
traits O
. O

Activation O
of O
EBF B
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B
- O
inducible O
traits O
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B
induces O
expression O
of O
EBF B
and O
together O
these O
transcription B
factors I
coordinately O
regulate O
numerous O
B B
lineage I
- I
associated I
genes I
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B
induces O
expression O
of O
EBF B
and O
together O
these O
transcription B
factors I
coordinately O
regulate O
numerous O
B B
lineage I
- I
associated I
genes I
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 B
' I
end I
of O
this O
RNA B
as O
human B
retinoid I
receptor I
RXRalpha I
mRNA I
. O

Activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha B
protein O
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation O
- O
induced O
loss O
of O
RXRalpha B
mRNA I
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O

We O
present O
evidence O
that O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
results O
in O
the O
down O
- O
regulation O
of O
RXRalpha B
expression O
and O
that O
cell O
cycle O
inhibitors O
, O
which O
block O
the O
cells O
in O
G1 O
phase O
, O
prevent O
this O
down O
- O
regulation O
. O

These O
observations O
indicate O
that O
the O
levels O
of O
RXRalpha B
expression O
in O
T O
lymphocytes O
are O
coupled O
to O
cell O
cycle O
progression O
, O
and O
there O
is O
tight O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
. O

These O
observations O
indicate O
that O
the O
levels O
of O
RXRalpha B
expression O
in O
T O
lymphocytes O
are O
coupled O
to O
cell O
cycle O
progression O
, O
and O
there O
is O
tight O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
. O

Important O
in O
the O
development O
of O
HIV O
- O
associated O
NHL O
are O
cytokines B
and O
other O
factors O
that O
induce O
B O
- O
cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c B
- I
myc I
, O
bcl B
- I
6 I
, O
and O
other O
tumor B
- I
suppressor I
genes I
with O
carcinogenic O
potential O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
s O
( O
MMPs B
) O
are O
a O
group O
of O
enzymes O
thought O
to O
be O
responsible O
for O
both O
normal O
connective O
tissue O
matrix O
remodelling O
and O
accelerated O
breakdown O
associated O
with O
tumour O
development O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

Stromelysin B
- I
1 I
( O
ST1 B
) O
was O
observed O
in O
about O
10 O
% O
of O
epithelial O
cells O
in O
the O
control O
groups O
( O
cases O
of O
fibrocystic O
and O
benign O
proliferative O
breast O
disease O
) O
, O
while O
expression O
( O
> O
10 O
% O
of O
expression O
) O
was O
detected O
in O
89 O
. O
7 O
% O
of O
tumours O
. O

The O
expression O
of O
ST1 B
in O
carcinoma O
cells O
was O
strongly O
associated O
with O
its O
presence O
in O
the O
stroma O
( O
p O
< O
0 O
. O
001 O
) O
. O

A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 B
expression O
, O
and O
p53 B
tumour O
suppressor O
gene O
product O
( O
p O
= O
0 O
. O
004 O
) O
, O
and O
a O
relationship O
with O
c B
- I
erbB I
- I
2 I
protein O
and O
progesterone O
receptor O
status O
was O
also O
indicated O
. O

A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 B
expression O
, O
and O
p53 B
tumour O
suppressor O
gene O
product O
( O
p O
= O
0 O
. O
004 O
) O
, O
and O
a O
relationship O
with O
c B
- I
erbB I
- I
2 I
protein O
and O
progesterone O
receptor O
status O
was O
also O
indicated O
. O

These O
findings O
suggest O
that O
ST1 B
expression O
in O
breast O
cancer O
tissue O
is O
irrespective O
of O
the O
expression O
of O
the O
extracellular O
matrix O
component O
, O
the O
proteolytic B
enzyme I
cathepsin B
D I
and O
the O
growth O
fraction O
of O
the O
tumour O
, O
and O
that O
it O
could O
be O
a O
potential O
new O
prognostic O
marker O
in O
breast O
cancer O
. O

There O
is O
increased O
activity O
of O
the O
proinflammatory B
cytokine I
, O
tumor B
necrosis I
factor I
( O
TNF B
) O
in O
alcoholic O
liver O
disease O
( O
ALD O
) O
. O

TNF B
can O
induce O
cellular O
oxidative O
injury O
directly O
, O
and O
indirectly O
by O
inducing O
neutrophil O
chemotactic O
factor O
( O
IL B
- I
8 I
) O
production O
by O
hepatocytes O
. O

Manganous B
superoxide I
dismutase I
( O
MnSOD B
) O
is O
an O
antioxidant B
protective I
factor I
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B
factor I
( O
IL B
- I
8 I
) O
and O
a O
protective B
factor I
( O
MnSOD B
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

This O
system O
may O
be O
useful O
to O
assess O
the O
effects O
of O
ethanol O
on O
TNF B
- O
induced O
hepatocyte O
IL B
- I
8 I
production O
. O

Both O
TNF B
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD B
activity O
in O
short O
- O
term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

Both O
TNF B
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD B
activity O
in O
short O
- O
term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

However O
, O
after O
long O
- O
term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B
in O
response O
to O
TNF B
. O

However O
, O
after O
long O
- O
term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B
in O
response O
to O
TNF B
. O

However O
, O
after O
long O
- O
term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B
in O
response O
to O
TNF B
. O

Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
this O
diminished O
induction O
of O
MnSOD B
with O
chronic O
ethanol O
culture O
on O
HepG2 O
cell O
susceptibility O
to O
TNF O
cytotoxicity O
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin B
deposition O
is O
a O
result O
of O
expression O
of O
tissue B
factor I
, O
especially O
in O
oxygen B
- I
deprived I
mononuclear I
phagocytes I
( O
MPs B
) O
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin B
deposition O
is O
a O
result O
of O
expression O
of O
tissue B
factor I
, O
especially O
in O
oxygen B
- I
deprived I
mononuclear I
phagocytes I
( O
MPs B
) O
. O

MPs B
and O
HeLa O
cells O
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue B
factor I
transcripts I
( O
approximately O
18 O
- O
fold O
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15 O
- O
fold O
) O
, O
based O
on O
nuclear O
run O
- O
on O
analysis O
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

These O
data O
delineate O
a O
novel O
biology O
for O
hypoxia O
- O
induced O
fibrin B
deposition O
, O
in O
which O
oxygen O
deprivation O
- O
induced O
activation O
of O
Egr B
- I
1 I
, O
resulting O
in O
expression O
of O
tissue B
factor I
, O
has O
an O
unexpected O
and O
central O
role O
. O

Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral O
blood O
- O
derived O
T O
lymphoblasts O
stimulated O
with O
anti B
- I
CD3 I
antibodies I
or O
Lens B
culinaris I
lectin I
( O
LCL B
) O
. O

In O
conclusion O
, O
the O
cytokines B
synthesized O
by O
IL O
- O
2 O
- O
dependent O
T O
cells O
were O
predominantly O
IL B
- I
2 I
, O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
. O

Within O
6 O
hours O
, O
an O
accumulation O
of O
apolipoprotein O
B O
and O
epitopes B
present O
on O
oxLDL O
are O
detected O
in O
the O
arterial O
endothelium O
and O
media O
. O

gp34 B
is O
a O
type B
II I
transmembrane I
molecule I
belonging O
to O
the O
tumor O
necrosis O
factor O
family O
and O
is O
constitutively O
expressed O
on O
HTLV O
- O
I O
- O
producing O
cells O
but O
not O
normal O
resting O
T O
cells O
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 B
gene I
was O
activated O
by O
HTLV O
- O
I O
Tax B
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 B
is O
induced O
by O
Tax B
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 B
gene I
was O
activated O
by O
HTLV O
- O
I O
Tax B
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 B
is O
induced O
by O
Tax B
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 B
gene I
was O
activated O
by O
HTLV O
- O
I O
Tax B
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 B
is O
induced O
by O
Tax B
. O

Both O
NF B
- I
kappaB I
- I
like I
elements I
were O
able O
to O
bind O
to O
NF B
- I
kappaB I
or O
its O
related O
factor O
( O
s O
) O
in O
a O
Tax B
- O
dependent O
manner O
. O

Chloramphenicol B
acetyltransferase I
assays O
indicated O
that O
NF B
- I
kappaB I
- I
like I
element I
1 I
was O
Tax B
- O
responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native B
promoter I
. O

Unlike O
typical O
NF B
- I
kappaB I
elements I
, O
the O
NF B
- I
kappaB I
- I
like I
elements I
in O
gp34 B
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF B
- I
kappaB I
- O
like O
binding O
activity O
. O

Our O
results O
imply O
complex O
regulation O
of O
expression O
of O
the O
gp34 B
gene I
and O
suggest O
implication O
of O
gp34 B
in O
proliferation O
of O
HTLV O
- O
I O
infected O
T O
cells O
. O

Fibrillar B
forms I
of O
beta B
- I
amyloid I
( O
Abeta B
) O
, O
which O
are O
the O
primary O
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate O
tyrosine O
kinase O
- O
dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O

However O
, O
the O
downstream O
signaling O
pathways O
mediating O
Abeta B
- O
induced O
inflammatory O
events O
are O
not O
well O
characterized O
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Importantly O
, O
the O
stress B
- I
activated I
protein I
kinases I
( O
SAPKs B
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta B
. O

Importantly O
, O
the O
stress B
- I
activated I
protein I
kinases I
( O
SAPKs B
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta B
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B
kinases I
, O
such O
as O
RSK1 B
and O
RSK2 B
, O
as O
well O
as O
transcription B
factors I
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B
kinases I
, O
such O
as O
RSK1 B
and O
RSK2 B
, O
as O
well O
as O
transcription B
factors I
. O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

Cellular B
retinoic I
acid I
binding I
proteins I
( O
CRABP B
) O
are O
low B
molecular I
weight I
proteins I
whose O
precise O
function O
remains O
unknown O
. O

As O
MO O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP B
II I
in O
MO O
- O
derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS B
, O
IL B
- I
4 I
, O
and O
GM B
- I
CSF I
. O

Transcription B
factor I
B I
- I
cell I
- I
specific I
activator I
protein I
( O
BSAP B
) O
is O
differentially O
expressed O
in O
B O
cells O
and O
in O
subsets O
of O
B O
- O
cell O
lymphomas O
. O

The O
paired B
box I
containing I
gene I
PAX B
- I
5 I
encodes O
the O
transcription B
factor I
BSAP B
( O
B B
- I
cell I
- I
specific I
activator I
protein I
) O
, O
which O
plays O
a O
key O
role O
in O
B O
- O
lymphocyte O
development O
. O

Despite O
its O
known O
involvement O
in O
a O
rare O
subtype O
of O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL O
) O
, O
a O
detailed O
examination O
of O
BSAP B
expression O
in O
NHL O
has O
not O
been O
previously O
reported O
. O

Normal O
lymphoid O
tissues O
showed O
strong O
nuclear O
BSAP B
expression O
in O
mantle O
zone O
B O
cells O
, O
less O
intense O
reactivity O
in O
follicular O
center O
B O
cells O
, O
and O
no O
expression O
in O
cells O
of O
the O
T O
- O
cell O
- O
rich O
zones O
. O

Of O
the O
102 O
B O
- O
cell O
NHLs O
, O
83 O
( O
81 O
% O
) O
demonstrated O
BSAP B
expression O
. O

Eight O
of O
12 O
( O
67 O
% O
) O
marginal O
zone O
lymphoma O
cases O
showed O
negative O
or O
low O
BSAP B
levels O
, O
and O
17 O
of O
24 O
( O
71 O
% O
) O
large O
B O
- O
cell O
lymphomas O
displayed O
moderate O
to O
strong O
expression O
. O

None O
of O
the O
23 O
T O
- O
and O
null O
- O
cell O
lymphomas O
reacted O
with O
the O
BSAP B
antisera O
, O
whereas O
in O
Hodgkin O
' O
s O
disease O
, O
2 O
of O
4 O
( O
50 O
% O
) O
nodular O
lymphocytic O
predominance O
and O
5 O
of O
14 O
( O
36 O
% O
) O
classical O
cases O
showed O
weak O
nuclear O
or O
nucleolar O
BSAP B
reactions O
in O
a O
fraction O
of O
the O
tumor O
cells O
. O

None O
of O
the O
23 O
T O
- O
and O
null O
- O
cell O
lymphomas O
reacted O
with O
the O
BSAP B
antisera O
, O
whereas O
in O
Hodgkin O
' O
s O
disease O
, O
2 O
of O
4 O
( O
50 O
% O
) O
nodular O
lymphocytic O
predominance O
and O
5 O
of O
14 O
( O
36 O
% O
) O
classical O
cases O
showed O
weak O
nuclear O
or O
nucleolar O
BSAP B
reactions O
in O
a O
fraction O
of O
the O
tumor O
cells O
. O

Western O
blot O
analysis O
showed O
a O
52 O
- O
kD O
BSAP B
band O
in O
B O
- O
cell O
lines O
, O
but O
not O
in O
non O
- O
B O
- O
cell O
or O
plasma O
cell O
lines O
. O

We O
conclude O
that O
BSAP B
expression O
is O
largely O
restricted O
to O
lymphomas O
of O
B O
- O
cell O
lineage O
and O
that O
BSAP B
expression O
varies O
in O
B O
- O
cell O
subsets O
and O
subtypes O
of O
B O
- O
cell O
NHL O
. O

We O
conclude O
that O
BSAP B
expression O
is O
largely O
restricted O
to O
lymphomas O
of O
B O
- O
cell O
lineage O
and O
that O
BSAP B
expression O
varies O
in O
B O
- O
cell O
subsets O
and O
subtypes O
of O
B O
- O
cell O
NHL O
. O

The O
high O
levels O
of O
BSAP B
, O
especially O
those O
found O
in O
large O
- O
cell O
lymphomas O
and O
in O
some O
follicular O
lymphomas O
, O
may O
be O
a O
consequence O
of O
deregulated O
gene O
expression O
and O
suggest O
a O
possible O
involvement O
of O
PAX B
- I
5 I
in O
certain O
B O
- O
cell O
malignancies O
. O

In O
driving O
T O
cell O
proliferation O
, O
IL B
- I
2 I
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B
cell I
nuclear I
antigen I
( O
PCNA B
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B
polymerase I
delta I
. O

PCNA B
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE B
sequences I
in O
the O
promoter B
and I
CRE I
binding I
proteins I
; O
IL B
- I
2 I
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

However O
, O
phosphorylation O
of O
CREB B
alone O
is O
not O
sufficient O
to O
drive O
PCNA B
expression O
and O
L2 O
cell O
proliferation O
in O
the O
absence O
of O
IL B
- I
2 I
. O

However O
, O
phosphorylation O
of O
CREB B
alone O
is O
not O
sufficient O
to O
drive O
PCNA B
expression O
and O
L2 O
cell O
proliferation O
in O
the O
absence O
of O
IL B
- I
2 I
. O

CS O
at O
50 O
- O
200 O
microM O
reduced O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
and O
IL B
- I
6 I
activities O
in O
the O
culture O
supernatants O
from O
LPS O
- O
stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

Analysis O
of O
the O
cytoplasmic B
inhibitor I
IkappaBalpha B
indicated O
that O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
induced O
a O
long O
- O
lasting O
degradation O
in O
CD45RA O
+ O
cells O
but O
in O
CD45RO O
+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Because O
the O
CD28 B
costimulus O
is O
known O
to O
induce O
the O
production O
of O
reactive O
oxygen O
intermediates O
( O
ROIs O
) O
, O
the O
intracellular O
ROI O
levels O
in O
CD45RA O
+ O
and O
CD45RO O
+ O
cells O
were O
compared O
by O
flow O
cytometry O
. O

In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP B
- I
1 I
and O
MNP B
- I
2 I
are O
distinct O
but O
related O
factors O
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP B
- I
1 I
acts O
as O
a O
heterodimer B
. O

Bcl B
- I
3 I
expression O
and O
nuclear O
translocation O
are O
induced O
by O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
erythropoietin B
in O
proliferating O
human O
erythroid O
precursors O
. O

In O
TF O
- O
1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
and O
erythropoietin B
( O
Epo B
) O
greatly O
enhanced O
Bcl B
- I
3 I
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

In O
TF O
- O
1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
and O
erythropoietin B
( O
Epo B
) O
greatly O
enhanced O
Bcl B
- I
3 I
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

GM B
- I
CSF I
and O
Epo B
modulated O
the O
subcellular O
localization O
of O
Bcl B
- I
3 I
. O

Upon O
stimulation O
of O
TF O
- O
1 O
cells O
with O
GM B
- I
CSF I
or O
Epo B
, O
the O
nuclear O
translocation O
of O
Bcl B
- I
3 I
was O
dramatically O
enhanced O
. O

Furthermore O
, O
cotransfection O
of O
Bcl B
- I
3 I
with O
p52 B
or O
p50 B
in O
TF O
- O
1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c B
- I
myb I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
. O

Furthermore O
, O
cotransfection O
of O
Bcl B
- I
3 I
with O
p52 B
or O
p50 B
in O
TF O
- O
1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c B
- I
myb I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
. O

Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax B
transactivation O
of O
the O
TR3 B
/ I
nur77 I
promoter O
but O
not O
the O
NOR B
- I
1 I
promoter I
in O
different O
cell O
types O
. O

Furthermore O
, O
expression O
of O
a O
luciferase B
reporter I
gene I
driven O
by O
the O
NGFI B
- I
B I
( I
rat I
homolog I
of I
TR3 I
/ I
Nur77 I
) I
response I
element I
( O
NBRE B
) O
provided O
evidence O
that O
Tax B
- O
mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

Furthermore O
, O
expression O
of O
a O
luciferase B
reporter I
gene I
driven O
by O
the O
NGFI B
- I
B I
( I
rat I
homolog I
of I
TR3 I
/ I
Nur77 I
) I
response I
element I
( O
NBRE B
) O
provided O
evidence O
that O
Tax B
- O
mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

Negative O
regulation O
of O
the O
heat O
shock O
transcriptional O
response O
by O
HSBP1 B
. O

In O
response O
to O
stress O
, O
heat B
shock I
factor I
1 I
( O
HSF1 B
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non B
- I
DNA I
- I
binding I
monomer I
to O
active O
functional O
trimers O
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

HSBP1 B
is O
nuclear O
- O
localized O
and O
interacts O
in O
vivo O
with O
the O
active O
trimeric O
state O
of O
HSF1 B
that O
appears O
during O
heat O
shock O
. O

HSBP1 B
is O
nuclear O
- O
localized O
and O
interacts O
in O
vivo O
with O
the O
active O
trimeric O
state O
of O
HSF1 B
that O
appears O
during O
heat O
shock O
. O

During O
attenuation O
of O
HSF1 B
to O
the O
inert O
monomer O
, O
HSBP1 B
associates O
with O
Hsp70 O
. O

During O
attenuation O
of O
HSF1 B
to O
the O
inert O
monomer O
, O
HSBP1 B
associates O
with O
Hsp70 O
. O

HSBP1 B
negatively O
affects O
HSF1 B
DNA O
- O
binding O
activity O
, O
and O
overexpression O
of O
HSBP1 B
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 B
. O

HSBP1 B
negatively O
affects O
HSF1 B
DNA O
- O
binding O
activity O
, O
and O
overexpression O
of O
HSBP1 B
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 B
. O

HSBP1 B
negatively O
affects O
HSF1 B
DNA O
- O
binding O
activity O
, O
and O
overexpression O
of O
HSBP1 B
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 B
. O

HSBP1 B
negatively O
affects O
HSF1 B
DNA O
- O
binding O
activity O
, O
and O
overexpression O
of O
HSBP1 B
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 B
. O

To O
establish O
a O
biological O
role O
for O
HSBP1 B
, O
the O
homologous O
Caenorhabditis B
elegans I
protein I
was O
overexpressed O
in O
body O
wall O
muscle O
cells O
and O
was O
shown O
to O
block O
activation O
of O
the O
heat O
shock O
response O
from O
a O
heat B
shock I
promoter I
- I
reporter I
construct I
. O

Alteration O
in O
the O
level O
of O
HSBP1 B
expression O
in O
C O
. O
elegans O
has O
severe O
effects O
on O
survival O
of O
the O
animals O
after O
thermal O
and O
chemical O
stress O
, O
consistent O
with O
a O
role O
for O
HSBP1 B
as O
a O
negative O
regulator O
of O
the O
heat O
shock O
response O
. O

Alteration O
in O
the O
level O
of O
HSBP1 B
expression O
in O
C O
. O
elegans O
has O
severe O
effects O
on O
survival O
of O
the O
animals O
after O
thermal O
and O
chemical O
stress O
, O
consistent O
with O
a O
role O
for O
HSBP1 B
as O
a O
negative O
regulator O
of O
the O
heat O
shock O
response O
. O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
, O
a O
nuclear B
enzyme I
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB B
) O
. O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
, O
a O
nuclear B
enzyme I
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB B
) O
. O

However O
, O
inactivation O
of O
CaMKIV B
occurs O
despite O
the O
sustained O
increase O
in O
[ O
Ca2 O
+ O
] O
i O
that O
is O
required O
for O
T O
cell O
activation O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

In O
Jurkat O
T O
cells O
, O
inhibition O
of O
PP2A B
activity O
by O
small O
t O
antigen O
enhanced O
activation O
of O
CREB B
- O
mediated O
transcription O
by O
CaMKIV B
. O

In O
Jurkat O
T O
cells O
, O
inhibition O
of O
PP2A B
activity O
by O
small O
t O
antigen O
enhanced O
activation O
of O
CREB B
- O
mediated O
transcription O
by O
CaMKIV B
. O

In O
Jurkat O
T O
cells O
, O
inhibition O
of O
PP2A B
activity O
by O
small O
t O
antigen O
enhanced O
activation O
of O
CREB B
- O
mediated O
transcription O
by O
CaMKIV B
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein B
serine I
- I
threonine I
kinase I
( O
CaMKIV B
) O
is O
regulated O
by O
a O
tightly O
associated O
protein B
serine I
- I
threonine I
phosphatase I
( O
PP2A B
) O
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein B
serine I
- I
threonine I
kinase I
( O
CaMKIV B
) O
is O
regulated O
by O
a O
tightly O
associated O
protein B
serine I
- I
threonine I
phosphatase I
( O
PP2A B
) O
. O

RESULTS O
: O
Nuclear O
levels O
of O
NF B
kappa I
B I
p65 B
are O
increased O
in O
lamina O
propria O
biopsy O
specimens O
from O
patients O
with O
Crohn O
' O
s O
disease O
in O
comparison O
with O
patients O
with O
ulcerative O
colitis O
and O
controls O
. O

Synergistic O
activation O
of O
MAP B
kinase I
( O
ERK1 B
/ I
2 I
) O
by O
erythropoietin B
and O
stem B
cell I
factor I
is O
essential O
for O
expanded O
erythropoiesis O
. O

Stem B
cell I
factor I
( O
SCF B
) O
and O
erythropoietin B
( O
EPO B
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O

Stem B
cell I
factor I
( O
SCF B
) O
and O
erythropoietin B
( O
EPO B
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O

Stem B
cell I
factor I
( O
SCF B
) O
and O
erythropoietin B
( O
EPO B
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O

By O
using O
purified O
human O
erythroid O
colony O
- O
forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B
and O
EPO B
synergistically O
activate O
MAP B
kinase I
( O
MAPK B
, O
ERK1 B
/ I
2 I
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

By O
using O
purified O
human O
erythroid O
colony O
- O
forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B
and O
EPO B
synergistically O
activate O
MAP B
kinase I
( O
MAPK B
, O
ERK1 B
/ I
2 I
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

By O
using O
purified O
human O
erythroid O
colony O
- O
forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B
and O
EPO B
synergistically O
activate O
MAP B
kinase I
( O
MAPK B
, O
ERK1 B
/ I
2 I
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

Treatment O
of O
the O
cells O
with O
PD98059 O
and O
wortmannin O
, O
inhibitors O
of O
MEK B
and O
PI B
- I
3 I
kinase I
, O
respectively O
, O
inhibited O
the O
synergistic O
activation O
of O
MAPK B
and O
also O
the O
cell O
growth O
, O
further O
supporting O
this O
conclusion O
. O

Treatment O
of O
the O
cells O
with O
PD98059 O
and O
wortmannin O
, O
inhibitors O
of O
MEK B
and O
PI B
- I
3 I
kinase I
, O
respectively O
, O
inhibited O
the O
synergistic O
activation O
of O
MAPK B
and O
also O
the O
cell O
growth O
, O
further O
supporting O
this O
conclusion O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Together O
, O
the O
data O
suggest O
that O
synergistic O
activation O
of O
MAPK B
by O
SCF B
and O
EPO B
is O
essential O
for O
expanded O
erythropoiesis O
. O

Together O
, O
the O
data O
suggest O
that O
synergistic O
activation O
of O
MAPK B
by O
SCF B
and O
EPO B
is O
essential O
for O
expanded O
erythropoiesis O
. O

Together O
, O
the O
data O
suggest O
that O
synergistic O
activation O
of O
MAPK B
by O
SCF B
and O
EPO B
is O
essential O
for O
expanded O
erythropoiesis O
. O

Protein B
kinase I
C I
( O
PKC B
) O
has O
been O
suggested O
to O
regulate O
PMA O
- O
induced O
adhesion O
molecule O
expression O
by O
post O
- O
transcriptional O
stabilization O
of O
adhesion B
molecule I
mRNA I
. O

Alpha O
- O
lipoate O
pretreatment O
did O
not O
influence O
the O
response O
of O
PKC B
activity O
to O
PMA O
. O

Binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
to O
CD4 B
and I
CXCR4 I
receptors I
differentially O
regulates O
expression O
of O
inflammatory B
genes I
and O
activates O
the O
MEK B
/ O
ERK O
signaling O
pathway O
. O

We O
have O
previously O
shown O
that O
binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
virions O
to O
CD4 B
receptors I
stimulates O
association O
of O
Lck B
with O
Raf B
- I
1 I
and O
results O
in O
the O
activation O
of O
Raf B
- I
1 I
kinase O
in O
a O
Ras O
- O
independent O
manner O
. O

The O
activation O
of O
this O
signaling O
pathway O
requires O
functional O
CD4 B
receptors I
and O
is O
independent O
of O
binding O
to O
CXCR4 B
. O

Binding O
of O
the O
natural O
ligand O
stromal B
cell I
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
to O
CXCR4 B
, O
which O
inhibits O
entry O
of O
T O
- O
cell O
- O
tropic O
HIV O
- O
1 O
, O
activates O
also O
the O
ERK O
/ O
MAP B
kinase I
pathway O
. O

Here O
we O
show O
that O
antigen O
receptor O
activation O
leads O
to O
BCL B
- I
6 I
phosphorylation O
by O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
. O

Phosphorylation O
, O
in O
turn O
, O
targets O
BCL B
- I
6 I
for O
rapid O
degradation O
by O
the O
ubiquitin B
/ O
proteasome B
pathway O
. O

Phosphorylation O
, O
in O
turn O
, O
targets O
BCL B
- I
6 I
for O
rapid O
degradation O
by O
the O
ubiquitin B
/ O
proteasome B
pathway O
. O

These O
findings O
indicate O
that O
BCL B
- I
6 I
expression O
is O
directly O
controlled O
by O
the O
antigen O
receptor O
via O
MAPK B
activation O
. O

Cytosolic B
glucocorticoid I
receptor I
( O
GR B
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR B
protein I
than O
the O
spleen O
. O

High O
levels O
of O
GR B
are O
consistent O
with O
the O
exquisite O
sensitivity O
of O
the O
thymus O
to O
glucocorticoid O
exposure O
. O

Nevertheless O
, O
whole O
cell O
binding O
studies O
reveal O
similar O
levels O
of O
GR B
in O
immature O
thymic O
T O
lymphocytes O
and O
more O
mature O
, O
splenic O
T O
lymphocytes O
. O

Moreover O
, O
whole O
cell O
binding O
techniques O
indicate O
that O
neutrophils O
( O
which O
represent O
roughly O
30 O
% O
of O
splenic O
leukocytes O
) O
exhibit O
higher O
GR B
than O
both O
T O
and O
B O
lymphocytes O
, O
further O
contradicting O
results O
from O
cytosolic O
binding O
studies O
. O

Consistent O
with O
previous O
cytosolic O
receptor O
binding O
studies O
on O
immune O
tissue O
homogenates O
, O
thymic O
T O
cells O
were O
found O
to O
have O
higher O
levels O
of O
GR B
than O
T O
cells O
isolated O
from O
the O
spleen O
. O

In O
addition O
, O
neutrophils O
were O
found O
to O
have O
fewer O
GR B
than O
lymphocytes O
and O
monocytes O
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene B
products I
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B
, O
but O
not O
HEB B
or O
E2 B
- I
2 I
, O
leads O
to O
a O
complete O
arrest O
in O
B O
- O
lymphocyte O
development O
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene B
products I
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B
, O
but O
not O
HEB B
or O
E2 B
- I
2 I
, O
leads O
to O
a O
complete O
arrest O
in O
B O
- O
lymphocyte O
development O
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

Further O
, O
we O
find O
that O
HEB B
driven O
by O
the O
endogenous B
E2A I
promoter I
can O
functionally O
replace O
E2A B
in O
supporting O
B O
- O
cell O
commitment O
and O
differentiation O
toward O
completion O
. O

Further O
, O
we O
find O
that O
HEB B
driven O
by O
the O
endogenous B
E2A I
promoter I
can O
functionally O
replace O
E2A B
in O
supporting O
B O
- O
cell O
commitment O
and O
differentiation O
toward O
completion O
. O

Finally O
, O
the O
postnatal O
lethality O
associated O
with O
E2A B
disruption O
is O
fully O
rescued O
by O
the O
addition O
of O
HEB B
. O

Finally O
, O
the O
postnatal O
lethality O
associated O
with O
E2A B
disruption O
is O
fully O
rescued O
by O
the O
addition O
of O
HEB B
. O

This O
study O
suggests O
that O
the O
functional O
divergence O
among O
E12 B
, O
E47 B
, O
and O
HEB B
in O
different O
cell O
types O
is O
partially O
defined O
by O
the O
context O
of O
gene O
expression O
. O

This O
study O
suggests O
that O
the O
functional O
divergence O
among O
E12 B
, O
E47 B
, O
and O
HEB B
in O
different O
cell O
types O
is O
partially O
defined O
by O
the O
context O
of O
gene O
expression O
. O

This O
study O
suggests O
that O
the O
functional O
divergence O
among O
E12 B
, O
E47 B
, O
and O
HEB B
in O
different O
cell O
types O
is O
partially O
defined O
by O
the O
context O
of O
gene O
expression O
. O

Biased O
dependency O
of O
CD80 B
versus O
CD86 B
in O
the O
induction O
of O
transcription B
factors I
regulating O
the O
human B
IL I
- I
2 I
promoter I
. O

Biased O
dependency O
of O
CD80 B
versus O
CD86 B
in O
the O
induction O
of O
transcription B
factors I
regulating O
the O
human B
IL I
- I
2 I
promoter I
. O

One O
such O
co O
- O
stimulatory O
signal O
is O
delivered O
when O
CD28 B
on O
T O
cells O
binds O
to O
CD80 B
or O
CD86 B
on O
antigen O
- O
presenting O
cells O
( O
APC O
) O
. O

One O
such O
co O
- O
stimulatory O
signal O
is O
delivered O
when O
CD28 B
on O
T O
cells O
binds O
to O
CD80 B
or O
CD86 B
on O
antigen O
- O
presenting O
cells O
( O
APC O
) O
. O

One O
such O
co O
- O
stimulatory O
signal O
is O
delivered O
when O
CD28 B
on O
T O
cells O
binds O
to O
CD80 B
or O
CD86 B
on O
antigen O
- O
presenting O
cells O
( O
APC O
) O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
ability O
of O
CD80 B
and O
CD86 B
to O
co O
- O
stimulate O
human O
T O
cells O
activated O
by O
superantigen O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
ability O
of O
CD80 B
and O
CD86 B
to O
co O
- O
stimulate O
human O
T O
cells O
activated O
by O
superantigen O
. O

Using O
the O
Raji O
B O
cell O
lymphoma O
, O
which O
express O
similar O
levels O
of O
CD80 B
and O
CD86 B
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co O
- O
stimulated O
by O
CD80 B
. O

Using O
the O
Raji O
B O
cell O
lymphoma O
, O
which O
express O
similar O
levels O
of O
CD80 B
and O
CD86 B
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co O
- O
stimulated O
by O
CD80 B
. O

Using O
the O
Raji O
B O
cell O
lymphoma O
, O
which O
express O
similar O
levels O
of O
CD80 B
and O
CD86 B
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co O
- O
stimulated O
by O
CD80 B
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human B
MHC I
class I
II I
together O
with O
CD80 B
, O
CD86 B
or O
CD80 B
and O
CD86 B
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human B
MHC I
class I
II I
together O
with O
CD80 B
, O
CD86 B
or O
CD80 B
and O
CD86 B
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human B
MHC I
class I
II I
together O
with O
CD80 B
, O
CD86 B
or O
CD80 B
and O
CD86 B
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human B
MHC I
class I
II I
together O
with O
CD80 B
, O
CD86 B
or O
CD80 B
and O
CD86 B
. O

Proliferation O
of O
freshly O
prepared O
CD4 O
+ O
T O
cells O
required O
the O
presence O
of O
either O
CD80 B
or O
CD86 B
. O

Proliferation O
of O
freshly O
prepared O
CD4 O
+ O
T O
cells O
required O
the O
presence O
of O
either O
CD80 B
or O
CD86 B
. O

However O
, O
IL B
- I
2 I
production O
reached O
only O
suboptimal O
levels O
in O
the O
presence O
of O
CD86 B
but O
optimal O
levels O
with O
CD80 B
. O

However O
, O
IL B
- I
2 I
production O
reached O
only O
suboptimal O
levels O
in O
the O
presence O
of O
CD86 B
but O
optimal O
levels O
with O
CD80 B
. O

To O
analyze O
IL B
- I
2 I
transcriptional O
activity O
in O
CD80 B
and O
CD86 B
co O
- O
stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase B
reporter I
gene I
constructs I
. O

To O
analyze O
IL B
- I
2 I
transcriptional O
activity O
in O
CD80 B
and O
CD86 B
co O
- O
stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase B
reporter I
gene I
constructs I
. O

CD80 B
induced O
higher O
levels O
of O
IL B
- I
2 I
promoter I
- O
enhancer O
activity O
compared O
to O
CD86 B
. O

CD80 B
induced O
higher O
levels O
of O
IL B
- I
2 I
promoter I
- O
enhancer O
activity O
compared O
to O
CD86 B
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Our O
results O
suggest O
that O
the O
eventual O
appearance O
of O
CD80 B
on O
recently O
activated O
CD86 O
+ O
APC O
is O
important O
for O
the O
superinduction O
of O
IL B
- I
2 I
production O
and O
to O
support O
vigorous O
T O
cell O
proliferation O
. O

DR3 B
is O
capable O
of O
inducing O
both O
NF B
- I
kappa I
B I
activation O
and O
apoptosis O
when O
overexpressed O
in O
mammalian O
cells O
, O
although O
its O
ligand O
has O
not O
yet O
been O
identified O
. O

In O
most O
NB O
cell O
lines O
, O
both O
the O
DR3 B
and I
the I
DR3L I
sequences I
are O
simultaneously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome B
. O

Glucocorticoid B
receptor I
( O
GR B
) O
levels O
were O
quantified O
in O
leukemic O
blasts O
from O
peripheral O
blood O
of O
86 O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

In O
16 O
out O
of O
20 O
ALL O
patients O
studied O
exposure O
of O
the O
cells O
to O
physiological O
concentrations O
of O
dexamethasone O
in O
vitro O
increased O
enzyme B
activity O
above O
the O
control O
levels O
. O

Moreover O
, O
the O
basal O
levels O
of O
the O
enzyme B
measured O
in O
cells O
prior O
to O
exposure O
to O
dexamethasone O
correlated O
negatively O
with O
receptor O
density O
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T B
- I
cell I
mitogens I
concanavalin B
A I
and O
phytohaemagglutinin B
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed O
mitogen O
- O
stimulated O
cultures O
. O

Human O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
cells O
like O
prothymocytes O
and O
immunoactivated O
T O
- O
lymphocytes O
are O
readily O
lysed O
in O
vitro O
by O
pharmacological O
concentrations O
of O
glucocorticoids O
such O
as O
cortisol O
, O
whereas O
peripheral O
blood O
lymphocytes O
and O
thymocytes O
are O
unaffected O
by O
the O
hormone B
. O

However O
, O
30 O
min O
of O
incubation O
with O
cortisol O
at O
either O
37 O
degrees O
or O
4 O
degrees O
followed O
by O
the O
removal O
of O
the O
hormone B
was O
still O
sufficient O
to O
induce O
the O
lytic O
process O
. O

The O
large O
holes O
in O
the O
membrane O
appearing O
after O
6 O
hr O
of O
incubation O
with O
the O
hormone B
may O
be O
the O
cause O
for O
the O
penetration O
of O
the O
viable O
stain O
into O
the O
dead O
cells O
, O
as O
seen O
by O
light O
microscopy O
. O

The O
resulting O
complex O
appears O
to O
activate O
specific O
gene B
( O
s O
) O
the O
products O
of O
which O
eventually O
cause O
cytolysis O
. O

Both O
cell O
types O
secrete O
a O
urokinase B
( I
UK I
) I
- I
like I
plasminogen I
activator I
( O
PA B
) O
. O

Treatment O
of O
both O
HMy2 O
and O
GM4672A O
cells O
with O
Dex O
for O
1 O
- O
4 O
days O
inhibits O
extracellular O
PA B
activity O
in O
a O
concentration O
- O
dependent O
manner O
, O
being O
half O
- O
maximal O
at O
approximately O
1 O
X O
10 O
( O
- O
9 O
) O
M O
. O

Inhibition O
of O
PA B
in O
both O
cell O
types O
is O
specific O
for O
active O
glucocorticoids O
, O
and O
this O
specificity O
parallels O
the O
ability O
of O
various O
steroids O
to O
bind O
to O
glucocorticoid B
receptors I
. O

HMy2 O
cell O
PA B
is O
fully O
suppressible O
by O
Dex O
, O
whereas O
up O
to O
one O
third O
of O
the O
activator O
expressed O
by O
GM4672A O
cells O
is O
resistant O
to O
glucocorticoid O
inhibition O
. O

Mixing O
experiments O
using O
a O
UK O
standard O
and O
conditioned O
media O
from O
Dex O
- O
treated O
cells O
suggest O
an O
absence O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
UK B
or O
plasmin B
in O
both O
cell O
types O
. O

Mixing O
experiments O
using O
a O
UK O
standard O
and O
conditioned O
media O
from O
Dex O
- O
treated O
cells O
suggest O
an O
absence O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
UK B
or O
plasmin B
in O
both O
cell O
types O
. O

Estrogens O
stimulate O
some O
aspects O
of O
macrophage O
activity O
and O
, O
depending O
on O
dose O
and O
mitogen B
, O
inhibit O
or O
stimulate O
lymphocyte O
proliferative O
response O
in O
vitro O
. O

Lymphocytes O
from O
adult O
, O
neonatally O
DES O
- O
treated O
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA B
and O
LPS B
( O
T B
and I
B I
cell I
mitogen I
) O
and O
the O
delayed O
type O
hypersensitivity O
response O
is O
depressed O
. O

Lymphocytes O
from O
adult O
, O
neonatally O
DES O
- O
treated O
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA B
and O
LPS B
( O
T B
and I
B I
cell I
mitogen I
) O
and O
the O
delayed O
type O
hypersensitivity O
response O
is O
depressed O
. O

This O
alteration O
was O
scarcely O
modified O
by O
incubation O
with O
theophylline B
, O
which O
increases O
cellular O
concentration O
of O
cAMP O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

Serum O
estradiol O
and O
progesterone O
concentrations O
were O
significantly O
decreased O
during O
the O
treatment O
cycle O
, O
suggesting O
that O
interferon B
interacts O
in O
vivo O
with O
the O
function O
of O
both O
FSH O
and O
LH O
. O

No O
significant O
changes O
were O
observed O
in O
the O
serum O
peptide O
hormone O
concentrations O
measured O
( O
FSH O
, O
LH O
, O
prolactin O
, O
insulin O
, O
growth O
hormone O
and O
TSH O
) O
; O
neither O
were O
the O
levels O
of O
endometrial B
ERC I
, I
ERN I
, I
PRC I
and I
PRN I
affected O
by O
interferon B
administration O
. O

As O
expected O
, O
interferon B
administration O
resulted O
in O
decreased O
leukocyte O
counts O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum B
alkaline I
phosphatase I
and O
gamma B
- I
glutamyltransferase I
during O
the O
interferon B
therapy O
shows O
that O
interferon B
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum B
alkaline I
phosphatase I
and O
gamma B
- I
glutamyltransferase I
during O
the O
interferon B
therapy O
shows O
that O
interferon B
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

These O
results O
suggest O
that O
one O
of O
the O
mechanisms O
by O
which O
interferon B
treatment O
may O
affect O
the O
growth O
of O
hormone O
- O
dependent O
neoplasms O
could O
be O
the O
interaction O
with O
production O
and O
/ O
or O
function O
of O
circulating O
hormonal O
compounds O
. O

The O
lymphokine B
enhanced O
the O
antimicrobial O
activity O
of O
dexamethasone O
- O
treated O
macrophages O
against O
Listeria O
and O
Salmonella O
but O
not O
against O
Aspergillus O
or O
Nocardia O
. O

Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
is O
a O
lymphokine B
synthesized O
by O
some O
T O
- O
cells O
following O
activation O
. O

The O
transformed B
receptor I
then O
interacts O
with O
chromatin B
( O
state O
D O
) O
. O

The O
glucocorticoid B
receptor I
( O
GR B
) O
quantitation O
by O
a O
whole O
- O
cell O
assay O
and O
/ O
or O
cytosol O
technique O
and O
the O
in O
vitro O
sensitivity O
to O
steroids O
have O
been O
assessed O
in O
peripheral O
blood O
cells O
from O
normal O
donors O
and O
patients O
with O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
, O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphosarcoma O
cell O
leukemia O
( O
LSCL O
) O
, O
acute O
nonlymphatic O
leukemia O
( O
ANLL O
) O
, O
and O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

Within O
the O
lymphoproliferative O
diseases O
, O
ALL O
cells O
exhibited O
the O
highest O
GR B
concentration O
( O
regardless O
of O
the O
method O
used O
) O
and O
the O
highest O
in O
vitro O
inhibition O
of O
spontaneous O
[ O
3H O
] O
thymidine O
( O
[ O
3H O
] O
TdR O
) O
uptake O
by O
glucocorticoids O
. O

A O
significant O
relationship O
between O
GR B
concentration O
( O
whole O
- O
cell O
assay O
) O
and O
in O
vitro O
sensitivity O
to O
dexamethasone O
was O
also O
found O
. O

Concerning O
myeloid O
leukemia O
, O
ANLL O
patients O
had O
GR B
concentrations O
slightly O
higher O
than O
those O
found O
in O
the O
ALL O
group O
but O
exhibited O
the O
lowest O
degree O
of O
inhibition O
of O
spontaneous O
[ O
3H O
] O
TdR O
uptake O
by O
dexamethasone O
( O
stimulatory O
effects O
occurred O
in O
some O
cases O
) O
. O

The O
lymphocytes O
acquire O
specific O
receptors O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
upon O
activation O
by O
the O
lectins B
. O

Moreover O
, O
in O
contrast O
to O
normal O
lymphocytes O
, O
the O
mitogenic O
stimulation O
of O
these O
patients O
' O
lymphocytes O
by O
phytohemagglutinin B
and O
concanavalin O
A O
was O
not O
inhibited O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

The O
present O
study O
was O
performed O
to O
analyse O
glucocorticoid B
receptor I
( O
GR B
) O
binding O
in O
peripheral O
blood O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
39 O
myasthenia O
gravis O
( O
MG O
) O
patients O
( O
unoperated O
patients O
( O
n O
= O
13 O
) O
, O
thymectomized O
patients O
( O
n O
= O
14 O
) O
and O
patients O
receiving O
glucocorticoids O
: O
thymectomized O
( O
n O
= O
11 O
) O
and O
unoperated O
( O
n O
= O
6 O
] O
. O

GR B
mean O
values O
were O
significantly O
higher O
in O
the O
MNL O
of O
MG O
patients O
( O
thymectomized O
or O
not O
) O
not O
receiving O
glucocorticoid O
than O
in O
the O
MNL O
of O
healthy O
donors O
. O

In O
patients O
receiving O
prednisone O
( O
Pd O
) O
the O
GR B
values O
were O
significantly O
lower O
than O
in O
MG O
patients O
without O
Pd O
therapy O
, O
independent O
of O
Pd O
dose O
or O
time O
of O
administration O
. O

The O
inhibitory O
effect O
on O
B O
- O
cell O
function O
can O
be O
observed O
both O
as O
decreased O
serum O
levels O
of O
immunoglobulins B
and O
as O
impaired O
binding O
of O
antibodies B
and O
complement O
to O
the O
cellular O
surface O
. O

The O
inhibitory O
effect O
on O
B O
- O
cell O
function O
can O
be O
observed O
both O
as O
decreased O
serum O
levels O
of O
immunoglobulins B
and O
as O
impaired O
binding O
of O
antibodies B
and O
complement O
to O
the O
cellular O
surface O
. O

Reduced O
T O
- O
cell O
function O
indicated O
by O
impaired O
stimulation O
by O
PHA B
and O
porkweed B
as O
well O
as O
by O
impaired O
lymphokinin O
effects O
on O
leukocyte O
migration O
inhibition O
has O
been O
reported O
. O

Reduced O
T O
- O
cell O
function O
indicated O
by O
impaired O
stimulation O
by O
PHA B
and O
porkweed B
as O
well O
as O
by O
impaired O
lymphokinin O
effects O
on O
leukocyte O
migration O
inhibition O
has O
been O
reported O
. O

These O
antibodies B
also O
recognized O
rat O
liver O
and O
murine B
S49 I
cell I
glucocorticoid I
receptors I
. O

After O
activation O
with O
phytohemagglutinin B
the O
T O
cells O
exhibit O
the O
receptor O
within O
24 O
h O
, O
and O
this O
expression O
is O
blocked O
by O
cycloheximide O
. O

A O
statistically O
significant O
association O
of O
IgA B
and O
IgM B
with O
benign O
lesions O
was O
contrasted O
to O
the O
association O
of O
IgG B
with O
malignant O
lesions O
. O

A O
statistically O
significant O
association O
of O
IgA B
and O
IgM B
with O
benign O
lesions O
was O
contrasted O
to O
the O
association O
of O
IgG B
with O
malignant O
lesions O
. O

A O
statistically O
significant O
association O
of O
IgA B
and O
IgM B
with O
benign O
lesions O
was O
contrasted O
to O
the O
association O
of O
IgG B
with O
malignant O
lesions O
. O

In O
both O
primary O
and O
metastatic O
lesions O
, O
IgG B
localization O
was O
associated O
with O
estrogen O
- O
receptor O
- O
poor O
primary O
cancers O
as O
compared O
with O
estrogen O
- O
receptor O
- O
rich O
primary O
cancers O
. O

Among O
primary O
breast O
cancer O
patients O
, O
IgG B
localization O
in O
the O
tumor O
correlated O
with O
relative O
lymphopenia O
. O

A O
shorter O
disease O
- O
free O
interval O
was O
noted O
in O
association O
with O
IgG B
localization O
among O
the O
metastatic O
breast O
lesions O
. O

A O
detailed O
histopathologic O
review O
of O
50 O
primary O
breast O
cancer O
tumors O
analyzed O
for O
estrogen B
receptor I
( O
ER B
) O
level O
was O
carried O
out O
and O
a O
variety O
of O
morphologic O
features O
correlated O
with O
ER B
results O
to O
identify O
any O
factors O
that O
will O
improve O
the O
management O
and O
prognosis O
for O
breast O
cancer O
. O

A O
detailed O
histopathologic O
review O
of O
50 O
primary O
breast O
cancer O
tumors O
analyzed O
for O
estrogen B
receptor I
( O
ER B
) O
level O
was O
carried O
out O
and O
a O
variety O
of O
morphologic O
features O
correlated O
with O
ER B
results O
to O
identify O
any O
factors O
that O
will O
improve O
the O
management O
and O
prognosis O
for O
breast O
cancer O
. O

Tumors O
binding O
more O
than O
5 O
fmol O
/ O
mg O
cytosol B
protein I
were O
classified O
as O
ER B
- O
positive O
. O

Progesterone B
receptor I
( O
PR B
) O
level O
was O
analyzed O
in O
some O
specimens O
with O
the O
use O
of O
a O
similar O
method O
. O

Results O
indicated O
that O
there O
was O
strong O
correlation O
between O
ER B
level O
, O
age O
, O
and O
histologic O
grade O
of O
the O
tumors O
. O

No O
correlation O
existed O
between O
absence O
or O
presence O
of O
lymph O
node O
metastases O
and O
ER B
. O

Although O
there O
was O
a O
trend O
for O
ER B
- O
positive O
tumors O
to O
have O
a O
low O
- O
grade O
lymphocytic O
infiltration O
, O
the O
difference O
was O
not O
statistically O
significant O
. O

The O
proliferative O
response O
of O
murine O
spleen O
and O
thymus O
cells O
to O
antigen B
but O
not O
to O
lectin B
was O
inhibited O
by O
the O
active O
metabolite O
of O
vitamin O
D3 O
, O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
. O

The O
proliferative O
response O
of O
murine O
spleen O
and O
thymus O
cells O
to O
antigen B
but O
not O
to O
lectin B
was O
inhibited O
by O
the O
active O
metabolite O
of O
vitamin O
D3 O
, O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
. O

1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
failed O
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T O
cell O
hybridomas O
by O
lectin B
or O
by O
an O
anti B
- I
Thy I
- I
1 I
antibody I
. O

Glucocorticoid B
receptor I
concentrations O
and O
terminal O
transferase B
activity O
as O
indicators O
of O
prognosis O
in O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT B
) O
, O
adenosine B
deaminase I
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Increased O
activity O
of O
TdT B
( O
greater O
than O
0 O
. O
1 O
unit O
/ O
microgram O
DNA O
) O
was O
found O
in O
11 O
patients O
. O

These O
results O
show O
that O
measurements O
of O
TdT B
activity O
and O
the O
glucocorticoid B
receptor I
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non O
- O
lymphocytic O
leukaemia O

Fragmentation O
of O
the O
oligomer B
and O
the O
subunit B
was O
evident O
in O
some O
cytosols O
. O

Fragmentation O
of O
the O
oligomer B
and O
the O
subunit B
was O
evident O
in O
some O
cytosols O
. O

High O
activities O
of O
peptidases B
of O
various O
specificities O
were O
detected O
in O
leukemic O
cell O
cytosols O
, O
as O
in O
other O
cytosols O
, O
by O
fluorometric O
assays O
with O
derivatives O
of O
7 O
- O
amino O
- O
4 O
- O
methylcoumarin O
. O

Lymphoid O
cells O
contain O
specific O
receptors B
for O
glucocorticoids O
. O

There O
were O
significant O
associations O
between O
epithelial O
cellularity O
, O
stromal O
fibrosis O
and O
the O
value O
of O
REc B
in O
those O
tumours O
in O
which O
the O
receptor O
was O
present O
. O

By O
contrast O
, O
neither O
the O
presence O
or O
absence O
nor O
the O
value O
of O
RPc B
could O
be O
related O
to O
cellularity O
or O
fibrosis O
. O

The O
value O
of O
REc B
and O
RPc B
analysis O
as O
an O
indicator O
of O
prognosis O
was O
examined O
in O
a O
sub O
- O
group O
of O
175 O
patients O
receiving O
no O
additional O
treatment O
following O
mastectomy O
. O

The O
value O
of O
REc B
and O
RPc B
analysis O
as O
an O
indicator O
of O
prognosis O
was O
examined O
in O
a O
sub O
- O
group O
of O
175 O
patients O
receiving O
no O
additional O
treatment O
following O
mastectomy O
. O

Overall O
relapse O
- O
free O
survival O
( O
RFS O
) O
was O
no O
different O
for O
those O
patients O
with O
receptors O
compared O
to O
those O
without O
them O
( O
REc B
P O
= O
0 O
. O
11 O
, O
RPc O
P O
= O
0 O
. O
7 O
) O
. O

CD28 B
- O
mediated O
activation O
in O
CD45RA O
+ O
and O
CD45RO O
+ O
T O
cells O
: O
enhanced O
levels O
of O
reactive O
oxygen O
intermediates O
and O
c B
- I
Rel I
nuclear O
translocation O
in O
CD45RA O
+ O
cells O
. O

Analysis O
of O
the O
cytoplasmic O
inhibitor O
IkappaBalpha B
indicated O
that O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
induced O
a O
long O
- O
lasting O
degradation O
in O
CD45RA O
+ O
cells O
but O
in O
CD45RO O
+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Ikaros B
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O

Here O
we O
review O
the O
role O
of O
Ikaros B
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B
finger I
transcription I
factors I
in O
this O
developmental O
process O
. O

Studies O
on O
an O
Ikaros B
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor O
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B
mutations O
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros B
in O
the O
production O
and O
differentiation O
of O
these O
populations O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B
mutations O
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros B
in O
the O
production O
and O
differentiation O
of O
these O
populations O
. O

Overexpression O
of O
p65 O
and O
c O
- O
Jun O
substitutes O
for O
B7 O
- O
1 O
costimulation O
by O
targeting O
the O
CD28RE B
within O
the O
IL B
- I
2 I
promoter I
. O

The O
role O
of O
Rel B
and O
activation B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
in O
IL B
- I
2 I
promoter I
activity O
in O
B7 O
- O
1 O
- O
and O
leukocyte O
function O
- O
associated O
Ag O
- O
3 O
( O
LFA O
. O
3 O
) O
- O
costimulated O
T O
cells O
has O
been O
evaluated O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter I
- I
and I
CD28RE I
- I
driven I
reporter I
constructs I
in O
both O
LFA O
- O
3 O
- O
and O
B7 O
- O
1 O
- O
costimulated O
Jurkat O
cells O
. O

Mutating O
the O
CD28RE B
but O
not O
the O
upstream B
nuclear I
factor I
kappabeta I
- I
binding I
site I
in O
the O
IL B
- I
2 I
promoter I
reduced O
B7 B
- I
1 I
- O
driven O
transcription O
> O
90 O
% O
. O

The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B
in O
the O
integration O
of O
p65 B
/ O
c B
- I
Jun I
- O
mediated O
transcription O
within O
the O
IL B
- I
2 I
promoter I
. O

The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B
in O
the O
integration O
of O
p65 B
/ O
c B
- I
Jun I
- O
mediated O
transcription O
within O
the O
IL B
- I
2 I
promoter I
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA B
- I
3 I
- O
driven O
immune O
response O
to O
a O
B7 O
- O
- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c B
- I
Jun I
and O
p65 B
, O
which O
target O
the O
CD28RE B
region O
of O
the O
IL B
- I
2 I
promoter I
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA B
- I
3 I
- O
driven O
immune O
response O
to O
a O
B7 O
- O
- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c B
- I
Jun I
and O
p65 B
, O
which O
target O
the O
CD28RE B
region O
of O
the O
IL B
- I
2 I
promoter I
. O

BACKGROUND O
: O
Antigen O
- O
receptor O
interactions O
on O
lymphocytes O
result O
in O
local O
clustering O
of O
actin B
, O
receptors O
and O
signaling O
molecules O
into O
an O
asymmetric O
membrane O
structure O
termed O
a O
cap O
. O

We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav B
( O
vav B
- O
/ O
- O
) O
, O
a O
gene O
that O
encodes O
a O
guanine B
- I
nucleotide I
exchange I
factor I
for O
the O
GTPase B
Rac I
. O

We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav B
( O
vav B
- O
/ O
- O
) O
, O
a O
gene O
that O
encodes O
a O
guanine B
- I
nucleotide I
exchange I
factor I
for O
the O
GTPase B
Rac I
. O

RESULTS O
: O
Lymphocytes O
from O
vav B
- O
/ O
- O
mice O
failed O
to O
form O
T O
- O
cell O
receptor O
caps O
following O
activation O
and O
had O
a O
defective O
actin O
cytoskeleton O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Despite O
the O
reduced O
Ca2 O
+ O
mobilization O
, O
translocation O
of O
cytoplasmic B
NF I
- I
ATc I
to O
the O
nucleus O
was O
normal O
, O
reflecting O
that O
the O
lower O
levels O
of O
Ca2 O
+ O
in O
vav O
- O
/ O
- O
cells O
were O
still O
sufficient O
to O
activate O
calcineurin B
. O

In O
transfection O
studies O
, O
either O
constitutively O
active O
Vav B
or O
Rac B
could O
complement O
constitutively O
active O
calcineurin B
to O
activate O
NF O
- O
AT O
- O
dependent O
transcription O
. O

In O
transfection O
studies O
, O
either O
constitutively O
active O
Vav B
or O
Rac B
could O
complement O
constitutively O
active O
calcineurin B
to O
activate O
NF O
- O
AT O
- O
dependent O
transcription O
. O

In O
transfection O
studies O
, O
either O
constitutively O
active O
Vav B
or O
Rac B
could O
complement O
constitutively O
active O
calcineurin B
to O
activate O
NF O
- O
AT O
- O
dependent O
transcription O
. O

CONCLUSIONS O
: O
These O
results O
indicate O
that O
Vav B
is O
required O
for O
cap O
formation O
in O
lymphocytes O
. O

CD14 B
- O
dependent O
activation O
of O
human O
endothelial O
cells O
by O
Bacteroides O
fragilis O
outer O
membrane O
. O

We O
conclude O
that O
the O
outer O
membrane O
component O
of O
the O
B O
. O
fragilis O
cell O
wall O
contains O
a O
proinflammatory O
factor O
( O
s O
) O
, O
that O
is O
not O
LPS O
, O
which O
induces O
human O
endothelial O
cell O
activation O
by O
a O
soluble O
CD14 B
- O
dependent O
mechanism O
. O

TNFalpha B
and O
cycloheximide O
caused O
infected O
cells O
to O
undergo O
apoptosis O
more O
rapidly O
than O
parental O
U937 O
and O
PLB O
- O
985 O
cells O
. O

Inhibition O
of O
TNFalpha B
- O
induced O
NF O
- O
kappaB O
activation O
using O
the O
antioxidant O
N O
- O
acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 O
and O
U9 O
- O
IIIB O
cells O
, O
while O
preactivation O
of O
NF B
- I
kappaB I
with O
the O
non B
- I
apoptotic I
inducer I
IL I
- I
1beta I
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

Cells O
underwent O
apoptosis O
in O
response O
to O
TNFalpha B
only O
when O
NF O
- O
kappaB O
activation O
was O
inhibited O
by O
TD B
- I
IkappaB I
expression O
. O

As O
was O
observed O
for O
the O
U9 O
- O
IIIB O
cells O
, O
TNFalpha B
treatment O
also O
induced O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
TD O
- O
IkappaB O
expressing O
cells O
. O

Ku B
is O
the O
DNA B
- I
targeting I
component I
of O
the O
large O
catalytic B
sub I
- I
unit I
of O
the O
DNA B
- I
dependent I
protein I
kinase I
complex I
( O
DNA B
- I
PK I
[ I
CS I
] I
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

Co O
- O
stimulation O
of O
human O
peripheral O
blood O
mononuclear O
cells O
with O
IL B
- I
2 I
and O
anti B
- I
CD3 I
monoclonal I
antibodies I
induces O
phosphorylation O
of O
CREB B
. O

Phosphorylation O
of O
the O
cAMP B
- I
response I
element I
binding I
protein I
CREB I
within O
1 O
h O
of O
CD2 B
but O
not O
CD3 B
cross O
- O
linking O
of O
human O
PBMC O
was O
recently O
demonstrated O
. O

Phosphorylation O
of O
the O
cAMP B
- I
response I
element I
binding I
protein I
CREB I
within O
1 O
h O
of O
CD2 B
but O
not O
CD3 B
cross O
- O
linking O
of O
human O
PBMC O
was O
recently O
demonstrated O
. O

The O
absence O
of O
P B
- I
CREB I
following O
CD3 O
cross O
- O
linking O
was O
unexpected O
, O
as O
other O
laboratories O
reported O
increased O
phosphorylation O
of O
CREB B
following O
CD3 O
cross O
- O
linking O
of O
the O
Jurkat O
lymphocyte O
cell O
line O
. O

Due O
to O
Jurkat O
T O
- O
cells O
being O
IL O
- O
2 O
- O
independent O
, O
it O
was O
postulated O
that O
IL B
- I
2 I
might O
provide O
a O
necessary O
co O
- O
stimulus O
for O
phosphorylation O
of O
CREB B
in O
primary O
lymphocytes O
. O

IL B
- I
2 I
did O
not O
further O
augment O
phosphorylation O
of O
CREB B
following O
CD2 O
cross O
- O
linking O
. O

However O
, O
while O
neither O
IL B
- I
2 I
nor O
CD3 O
cross O
- O
linking O
alone O
induced O
P B
- I
CREB I
, O
a O
4 O
. O
5 O
- O
fold O
increase O
in O
phosphorylation O
of O
CREB B
within O
1 O
h O
of O
IL O
- O
2 O
/ O
CD3 O
co O
- O
stimulation O
was O
observed O
. O

Consistent O
with O
signal O
transduction O
through O
p56lck B
or O
p59fyn B
, O
inhibition O
of O
PTK O
signaling O
reduced O
phosphorylation O
50 O
% O
. O

Consistent O
with O
signal O
transduction O
through O
p56lck B
or O
p59fyn B
, O
inhibition O
of O
PTK O
signaling O
reduced O
phosphorylation O
50 O
% O
. O

In O
contrast O
to O
previous O
studies O
performed O
in O
the O
absence O
of O
exogenous B
IL I
- I
2 I
, O
no O
increase O
in O
binding O
of O
CREB B
to O
a O
32P O
- O
labeled O
oligonucleotide O
probe O
was O
observed O
by O
electrophoretic O
mobility O
shift O
assay O
. O

These O
data O
suggest O
that O
the O
IL B
- I
2 I
and O
CD3 B
signaling O
pathways O
provide O
a O
necessary O
and O
co O
- O
operative O
stimulus O
promoting O
phosphorylation O
of O
CREB B
following O
receptor O
cross O
- O
linking O
. O

These O
data O
suggest O
that O
the O
IL B
- I
2 I
and O
CD3 B
signaling O
pathways O
provide O
a O
necessary O
and O
co O
- O
operative O
stimulus O
promoting O
phosphorylation O
of O
CREB B
following O
receptor O
cross O
- O
linking O
. O

Loss O
of O
immune O
function O
in O
HIV O
patients O
is O
usually O
associated O
with O
a O
profound O
dysregulation O
of O
cytokine B
production O
. O

To O
investigate O
whether O
cytokine B
signaling O
defects O
occur O
during O
HIV O
infection O
, O
PHA O
blasts O
from O
healthy O
human O
donors O
were O
infected O
with O
two O
strains O
of O
HIV O
- O
1 O
and O
screened O
for O
the O
expression O
of O
STAT B
proteins I
used O
in O
cytokine B
signaling O
. O

To O
investigate O
whether O
cytokine B
signaling O
defects O
occur O
during O
HIV O
infection O
, O
PHA O
blasts O
from O
healthy O
human O
donors O
were O
infected O
with O
two O
strains O
of O
HIV O
- O
1 O
and O
screened O
for O
the O
expression O
of O
STAT B
proteins I
used O
in O
cytokine B
signaling O
. O

A O
selective O
decrease O
in O
STAT5B B
was O
seen O
8 O
days O
after O
infection O
with O
the O
BZ167 O
dual O
- O
tropic O
HIV O
isolate O
, O
but O
not O
with O
the O
Ba O
- O
L O
, O
M O
- O
tropic O
strain O
. O

Based O
on O
these O
findings O
, O
purified O
T O
cells O
from O
HIV O
- O
infected O
patients O
in O
different O
stages O
of O
disease O
were O
also O
tested O
for O
STAT O
expression O
; O
decreases O
in O
STAT5A B
, O
STAT5B B
, O
and O
STAT1alpha B
were O
observed O
in O
all O
patients O
. O

Based O
on O
these O
findings O
, O
purified O
T O
cells O
from O
HIV O
- O
infected O
patients O
in O
different O
stages O
of O
disease O
were O
also O
tested O
for O
STAT O
expression O
; O
decreases O
in O
STAT5A B
, O
STAT5B B
, O
and O
STAT1alpha B
were O
observed O
in O
all O
patients O
. O

Based O
on O
these O
findings O
, O
purified O
T O
cells O
from O
HIV O
- O
infected O
patients O
in O
different O
stages O
of O
disease O
were O
also O
tested O
for O
STAT O
expression O
; O
decreases O
in O
STAT5A B
, O
STAT5B B
, O
and O
STAT1alpha B
were O
observed O
in O
all O
patients O
. O

The O
reduction O
in O
STATs B
seen O
in O
vivo O
and O
in O
vitro O
after O
HIV O
infection O
may O
contribute O
to O
the O
loss O
of O
T O
cell O
function O
in O
HIV O
disease O
. O

Here O
we O
show O
that O
forced O
expression O
of O
the O
lung B
Kruppel I
- I
like I
transcription I
factor I
( O
LKLF B
) O
in O
Jurkat O
T O
cells O
is O
sufficient O
to O
program O
a O
quiescent O
phenotype O
characterized O
by O
decreased O
proliferation O
, O
reduced O
cell O
size O
and O
protein O
synthesis O
and O
decreased O
surface O
expression O
of O
activation O
markers O
. O

LKLF B
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto B
- I
oncogene I
encoding O
c B
- I
Myc I
. O

Forced O
expression O
of O
LKLF B
was O
associated O
with O
markedly O
decreased O
c B
- I
Myc I
expression O
. O

In O
addition O
, O
many O
effects O
of O
LKLF B
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant B
- I
negative I
MadMyc I
protein I
and O
rescued O
by O
overexpression O
of O
c B
- I
Myc I
. O

Thus O
, O
LKLF B
is O
both O
necessary O
and O
sufficient O
to O
program O
quiescence O
in O
T O
cells O
and O
functions O
, O
in O
part O
, O
by O
negatively O
regulating O
a O
c O
- O
Myc O
- O
- O
dependent O
pathway O
. O

Although O
p12 B
( I
I I
) I
contains O
4 O
minimal O
proline O
- O
rich O
, O
src B
homology I
3 I
- I
binding I
motifs I
( O
PXXP B
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins O
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 B
( I
I I
) I
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B
( I
I I
) I
increases O
signal B
transducers I
and I
activators I
of I
transcription I
5 I
( O
STAT5 B
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL B
- I
2R I
beta I
and I
gamma I
( I
c I
) I
chains I
and O
Jak3 B
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B
( I
I I
) I
increases O
signal B
transducers I
and I
activators I
of I
transcription I
5 I
( O
STAT5 B
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL B
- I
2R I
beta I
and I
gamma I
( I
c I
) I
chains I
and O
Jak3 B
. O

Transduction O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
a O
human B
immunodeficiency I
virus I
type I
1 I
- I
based I
retroviral I
vector I
expressing O
p12 B
( I
I I
) I
also O
resulted O
in O
increased O
STAT5 B
phosphorylation O
and O
DNA O
binding O
. O

METHODS O
: O
Flow O
cytometry O
, O
cell O
proliferation O
assays O
, O
and O
microscopy O
were O
used O
to O
track O
antigen B
following O
a O
single O
, O
intranasal O
dose O
of O
Alexa B
- I
488 I
labelled I
retinal I
antigen I
. O

RESULTS O
: O
A O
rapid O
accumulation O
of O
antigen B
within O
both O
superficial O
cervical O
lymph O
nodes O
( O
SCLN O
) O
and O
spleen O
was O
observed O
after O
30 O
minutes O
. O

Cell O
activation O
was O
further O
confirmed O
by O
immunoprecipitation O
studies O
, O
which O
demonstrated O
phosphorylation O
of O
STAT4 B
but O
not O
STAT6 B
in O
both O
lymph O
nodes O
and O
spleen O
. O

Cell O
activation O
was O
further O
confirmed O
by O
immunoprecipitation O
studies O
, O
which O
demonstrated O
phosphorylation O
of O
STAT4 B
but O
not O
STAT6 B
in O
both O
lymph O
nodes O
and O
spleen O
. O

CONCLUSIONS O
: O
The O
results O
provide O
novel O
evidence O
that O
following O
a O
single O
intranasal O
application O
rapid O
transfer O
of O
antigen B
occurs O
. O

To O
determine O
the O
mechanisms O
by O
which O
IL B
- I
18 I
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines B
in O
the O
regulation O
of O
IL B
- I
18 I
receptor I
alpha I
chain I
( O
IL B
- I
18Ralpha I
) O
expression O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL B
- I
18Ralpha I
by O
the O
major O
inductive O
cytokines B
( O
IL B
- I
12 I
and O
IL B
- I
4 I
) O
determines O
the O
capacity O
of O
IL B
- I
18 I
to O
polarize O
an O
immune O
response O
. O

They O
act O
by O
binding O
to O
a O
specific O
receptor O
( O
GR B
) O
that O
, O
upon O
activation O
, O
translocates O
to O
the O
nucleus O
and O
either O
increases O
( O
transactivates O
) O
or O
decreases O
( O
transrepresses O
) O
gene O
expression O
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

Acetylation O
of O
histones B
allows O
unwinding O
of O
the O
local B
DNA I
structure I
and O
enables O
RNA B
polymerase I
II I
to O
enhance O
gene O
transcription O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone B
acetyltransferases I
( O
HATs B
) O
and O
histone B
deacetylases I
( O
HDACs B
) O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone B
acetyltransferases I
( O
HATs B
) O
and O
histone B
deacetylases I
( O
HDACs B
) O
. O

GR B
acts O
as O
a O
direct O
inhibitor O
of O
NF O
- O
kappa O
B O
- O
induced O
HAT O
activity O
and O
also O
by O
recruiting O
HDAC2 B
to O
the O
NF B
- I
kappa I
B I
/ I
HAT I
complex I
. O

GR B
acts O
as O
a O
direct O
inhibitor O
of O
NF O
- O
kappa O
B O
- O
induced O
HAT O
activity O
and O
also O
by O
recruiting O
HDAC2 B
to O
the O
NF B
- I
kappa I
B I
/ I
HAT I
complex I
. O

Identification O
of O
the O
precise O
mechanism O
by O
which O
activated B
GR I
recruits O
HDAC2 B
may O
reveal O
new O
targets O
for O
the O
development O
of O
drugs O
that O
may O
dissociate O
the O
antiinflammatory O
actions O
of O
glucocorticoids O
from O
their O
side O
effects O
that O
are O
largely O
due O
to O
gene O
induction O
. O

We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B
A I
scavenger I
receptor I
( O
SRA B
) O
, O
an O
important O
lipoprotein B
receptor I
in O
atherogenesis O
. O

METHODS O
AND O
RESULTS O
: O
Human O
monocyte O
/ O
macrophages O
or O
THP O
- O
1 O
cells O
were O
cultured O
in O
a O
device O
that O
imposes O
uniform O
biaxial O
cyclic O
1 O
- O
Hz O
strains O
of O
0 O
% O
, O
1 O
% O
, O
2 O
% O
, O
or O
3 O
% O
, O
and O
SRA B
expression O
was O
analyzed O
. O

Immunohistochemistry O
revealed O
that O
among O
macrophages O
in O
atherosclerotic O
lesions O
of O
the O
aorta O
, O
the O
proportion O
of O
macrophages O
with O
SRA B
expression O
was O
highest O
in O
hypertensive O
animals O
on O
a O
high O
- O
cholesterol O
diet O
( O
43 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
% O
, O
versus O
12 O
. O
0 O
+ O
/ O
- O
2 O
. O
0 O
% O
for O
normotensive O
animals O
on O
a O
high O
- O
cholesterol O
diet O
and O
4 O
. O
7 O
+ O
/ O
- O
4 O
. O
7 O
% O
for O
animals O
on O
standard O
chow O
; O
P O
< O
0 O
. O
001 O
) O
. O

CONCLUSIONS O
: O
Biomechanical O
strain O
induces O
SRA B
expression O
by O
monocyte O
/ O
macrophages O
, O
suggesting O
a O
novel O
mechanism O
for O
promotion O
of O
atherosclerosis O
in O
hypertensive O
patients O
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B
and O
CD86 B
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B
receptor I
, O
and O
the O
adhesion B
molecule I
CD54 B
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B
and O
CD86 B
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B
receptor I
, O
and O
the O
adhesion B
molecule I
CD54 B
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B
and O
CD86 B
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B
receptor I
, O
and O
the O
adhesion B
molecule I
CD54 B
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti B
- I
CD54 I
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti B
- I
CD54 I
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti B
- I
CD54 I
. O

The O
principal O
downstream O
component O
contributed O
by O
BCR B
signaling O
, O
toward O
both O
CD80 B
and O
CD86 B
induction O
, O
was O
the O
elevated O
concentration O
of O
free O
cytoplasmic O
Ca O
( O
2 O
+ O
) O
, O
recruited O
by O
way O
of O
capacitative O
influx O
. O

The O
principal O
downstream O
component O
contributed O
by O
BCR B
signaling O
, O
toward O
both O
CD80 B
and O
CD86 B
induction O
, O
was O
the O
elevated O
concentration O
of O
free O
cytoplasmic O
Ca O
( O
2 O
+ O
) O
, O
recruited O
by O
way O
of O
capacitative O
influx O
. O

The O
principal O
downstream O
component O
contributed O
by O
BCR B
signaling O
, O
toward O
both O
CD80 B
and O
CD86 B
induction O
, O
was O
the O
elevated O
concentration O
of O
free O
cytoplasmic O
Ca O
( O
2 O
+ O
) O
, O
recruited O
by O
way O
of O
capacitative O
influx O
. O

This O
alone O
was O
sufficient O
to O
generate O
an O
increase O
in O
CD86 B
levels O
. O

However O
, O
CD80 B
enhancement O
required O
the O
concerted O
action O
of O
both O
intracellular O
Ca O
( O
2 O
+ O
) O
concentration O
and O
CD54 O
- O
initiated O
pathways O
. O

The O
nexus O
between O
anti O
- O
IgM O
and O
anti O
- O
CD54 O
stimulation O
, O
in O
the O
context O
of O
CD80 B
regulation O
, O
was O
identified O
to O
involve O
a O
self O
- O
propagating O
process O
of O
sequential O
synergy O
. O

The O
first O
step O
involved O
amplified O
accumulation O
of O
intracellular O
cAMP O
, O
as O
a O
result O
of O
cross O
- O
talk O
between O
BCR B
- O
mobilized O
Ca O
( O
2 O
+ O
) O
and O
CD54 O
- O
derived O
signals O
. O

This O
then O
facilitated O
a O
second O
synergistic O
interaction O
between O
Ca O
( O
2 O
+ O
) O
and O
cAMP O
, O
culminating O
in O
CD80 B
expression O
. O

LMP1 B
acts O
like O
a O
constitutively B
activated I
receptor I
of O
the O
tumor B
necrosis I
factor I
receptor I
family I
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor B
necrosis I
factor I
receptor I
- I
associated I
factor I
( I
TRAF I
) I
family I
. O

TRAF2 B
- O
mediated O
NF B
- I
kappaB I
activation O
, O
AP B
- I
1 I
induction O
and O
JAK3 B
/ O
STAT B
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

TRAF2 B
- O
mediated O
NF B
- I
kappaB I
activation O
, O
AP B
- I
1 I
induction O
and O
JAK3 B
/ O
STAT B
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

TRAF2 B
- O
mediated O
NF B
- I
kappaB I
activation O
, O
AP B
- I
1 I
induction O
and O
JAK3 B
/ O
STAT B
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

The O
ability O
of O
LMP1 B
to O
suppress O
germinal O
center O
formation O
and O
its O
capacity O
to O
mediate O
its O
own O
transcriptional O
activation O
shed O
new O
light O
on O
the O
pathogenesis O
of O
EBV O
- O
associated O
latency O
type O
II O
lymphoproliferations O
like O
Hodgkin O
' O
s O
disease O
and O
angioimmunoblastic O
lymphadenopathy O
. O

The O
carboxy B
terminus I
of O
LMP1 B
is O
also O
a O
reliable O
marker O
for O
individual O
EBV O
strain O
identification O
and O
thus O
offers O
new O
possibilities O
in O
tracing O
the O
molecular O
events O
leading O
to O
posttransplant O
lymphoproliferative O
disorders O
( O
PTLDs O
) O
. O

This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 B
, O
STAT3 B
, O
and O
Fyn B
, I
a I
Src I
homology I
tyrosine I
kinase I
, O
which O
interacts O
with O
both O
TCR O
and O
IFN O
- O
alpha O
signal O
components O
. O

This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 B
, O
STAT3 B
, O
and O
Fyn B
, I
a I
Src I
homology I
tyrosine I
kinase I
, O
which O
interacts O
with O
both O
TCR O
and O
IFN O
- O
alpha O
signal O
components O
. O

Cytokine B
( O
TNF B
- I
alpha I
and O
IL B
- I
10 I
) O
release O
was O
measured O
by O
immunoassay O
. O

Neutralization O
of O
IL B
- I
10 I
with O
a O
specific O
antibody B
did O
not O
attenuate O
the O
effect O
of O
cAMP O
- O
elevating O
agents O
on O
TNF B
- I
alpha I
production O
. O

BMPs B
exert O
a O
negative O
growth O
effect O
on O
various O
types O
of O
cells O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29 B
- I
b I
region I
was O
found O
to O
be O
associated O
with O
Smad4 B
and O
phosphorylated B
Smad1 I
in O
the O
nuclear O
extract O
of O
BMP B
- I
2 I
- O
stimulated O
HS O
- O
72 O
cells O
. O

These O
results O
suggested O
that O
BMP B
- I
2 I
might O
activate O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 B
and O
Smad1 B
to O
the O
29 B
- I
b I
region I
in O
HS O
- O
72 O
cells O
. O

These O
results O
suggested O
that O
BMP B
- I
2 I
might O
activate O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 B
and O
Smad1 B
to O
the O
29 B
- I
b I
region I
in O
HS O
- O
72 O
cells O
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
, O
C B
/ I
EBPbeta I
and O
STAT1 B
: O
role O
of O
CD14 B
and O
Toll B
- I
like I
receptors I
2 I
and I
4 I
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
, O
C B
/ I
EBPbeta I
and O
STAT1 B
: O
role O
of O
CD14 B
and O
Toll B
- I
like I
receptors I
2 I
and I
4 I
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
( I
Erk I
) I
1 I
/ I
2 I
, O
in O
the O
absence O
of O
detectable O
Jun B
N I
- I
terminal I
kinase I
( O
JNK B
) O
or O
p38 B
mitogen I
- I
activated I
kinase I
activation O
. O

Furthermore O
, O
STAT1 B
activation O
but O
weak O
or O
no O
activation O
of O
STAT3 B
or O
STAT5 B
respectively O
, O
could O
be O
detected O
in O
MB O
- O
stimulated O
MDM O
. O

Furthermore O
, O
STAT1 B
activation O
but O
weak O
or O
no O
activation O
of O
STAT3 B
or O
STAT5 B
respectively O
, O
could O
be O
detected O
in O
MB O
- O
stimulated O
MDM O
. O

Furthermore O
, O
STAT1 B
activation O
but O
weak O
or O
no O
activation O
of O
STAT3 B
or O
STAT5 B
respectively O
, O
could O
be O
detected O
in O
MB O
- O
stimulated O
MDM O
. O

Surprisingly O
, O
neither O
MB O
nor O
MDP O
were O
able O
to O
transduce O
signals O
via O
CD14 B
and O
TLR2 B
or I
4 I
. O

These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co B
- I
receptors I
other O
than O
TLR2 B
and O
TLR4 B
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O

These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co B
- I
receptors I
other O
than O
TLR2 B
and O
TLR4 B
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O

In O
this O
study O
, O
we O
examined O
the O
possible O
role O
of O
PPARs B
in O
macrophage O
attraction O
into O
the O
peritoneal O
cavity O
of O
patients O
with O
endometriosis O
. O

Keywords O
included O
reperfusion O
injury O
, O
transplantation O
, O
liver O
resection O
, O
nitric O
oxide O
, O
endothelin O
, O
cytokines B
, O
Kupffer O
cells O
, O
ischemic O
/ O
ischaemic O
preconditioning O
, O
and O
nuclear B
factor I
- I
kappa I
B I
. O

The O
Drosophila B
FOG I
homologue I
U I
- I
shaped I
( O
Ush B
) O
is O
expressed O
similarly O
in O
the O
blood O
cell O
anlage O
during O
embryogenesis O
. O

In O
this O
report O
, O
we O
show O
that O
Ush B
is O
expressed O
in O
hemocyte O
precursors O
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA B
factor I
Serpent I
is O
essential O
for O
Ush B
embryonic O
expression O
. O

In O
this O
report O
, O
we O
show O
that O
Ush B
is O
expressed O
in O
hemocyte O
precursors O
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA B
factor I
Serpent I
is O
essential O
for O
Ush B
embryonic O
expression O
. O

Furthermore O
, O
loss O
of O
ush O
function O
results O
in O
an O
overproduction O
of O
crystal O
cells O
, O
whereas O
forced O
expression O
of O
Ush B
reduces O
this O
cell O
population O
. O

The O
GATA B
factor I
Pannier I
( O
Pnr B
) O
is O
required O
for O
eye O
and O
heart O
development O
in O
Drosophila O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

The O
association O
of O
trans B
- I
acting I
T I
cell I
factors I
( O
TCFs B
) O
or O
lymphoid B
enhancer I
factor I
1 I
( O
LEF B
- I
1 I
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

Thus O
, O
TCF B
- I
1 I
, O
upon O
association O
with O
beta O
- O
catenin O
, O
transiently O
ensures O
the O
survival O
of O
immature O
T O
cells O
, O
which O
enables O
them O
to O
generate O
and O
edit O
T B
cell I
receptor I
( I
TCR I
) I
alpha I
chains I
and O
attempt O
TCR B
- O
mediated O
positive O
selection O
. O

The O
anti O
- O
MM O
activity O
of O
TRAIL B
/ I
Apo2L I
was O
confirmed O
in O
nu O
/ O
xid O
/ O
bg O
mice O
xenografted O
with O
human O
MM O
cells O
; O
TRAIL B
( O
500 O
microg O
intraperitoneally O
daily O
for O
14 O
days O
) O
was O
well O
tolerated O
and O
significantly O
suppressed O
the O
growth O
of O
plasmacytomas O
. O

Dox O
up O
- O
regulated O
the O
expression O
of O
the O
TRAIL B
receptor I
death B
receptor I
5 I
( O
DR5 B
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL B
not O
only O
against O
MM O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex O
- O
or O
Dox O
- O
induced O
apoptosis O
. O

Dox O
up O
- O
regulated O
the O
expression O
of O
the O
TRAIL B
receptor I
death B
receptor I
5 I
( O
DR5 B
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL B
not O
only O
against O
MM O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex O
- O
or O
Dox O
- O
induced O
apoptosis O
. O

Importantly O
, O
normal O
B O
lymphocytes O
were O
not O
sensitized O
to O
TRAIL B
by O
either O
Dox O
, O
SN50 O
, O
or O
PS O
- O
341 O
. O

These O
preclinical O
studies O
suggest O
that O
TRAIL B
/ I
Apo2L I
can O
overcome O
conventional O
drug O
resistance O
and O
provide O
the O
basis O
for O
clinical O
trials O
of O
TRAIL B
- O
based O
treatment O
regimens O
to O
improve O
outcome O
in O
patients O
with O
MM O
. O

CD28 B
costimulation O
is O
required O
not O
only O
to O
induce O
IL B
- I
12 I
receptor I
but O
also O
to O
render O
janus B
kinases I
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
in O
TCR O
- O
triggered O
T O
cells O
. O

Here O
, O
we O
investigated O
how O
CD28 O
costimulation O
functions O
to O
allow O
TCR B
- O
triggered O
resting O
T O
cells O
to O
acquire O
IL B
- I
12 I
responsiveness O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

Role O
of O
Mcl B
- I
1 I
, O
independent O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
, O
Bad B
, O
or O
caspase O
activation O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Akt B
- I
1 I
was O
constitutively O
activated O
in O
human O
macrophages O
and O
addition O
of O
the O
PI3K B
inhibitor O
, O
LY294002 O
, O
suppressed O
the O
activation O
of O
Akt B
- I
1 I
and O
induced O
cell O
death O
. O

Furthermore O
, O
suppression O
of O
Akt B
- I
1 I
by O
inhibition O
of O
PI3K B
or O
a O
dominant B
negative I
( I
DN I
) I
Akt I
- I
1 I
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases B
- I
9 I
and I
- I
3 I
, O
and O
DNA O
fragmentation O
. O

The O
effects O
of O
PI3K B
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt B
- I
1 I
or O
Bcl B
- I
x I
( I
L I
) I
. O

Inhibition O
of O
PI3K B
/ O
Akt O
- O
1 O
pathway O
either O
by O
LY294002 O
or O
DN B
Akt I
- I
1 I
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
in O
human O
macrophages O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt B
- I
1 I
regulates O
macrophage O
survival O
through O
Mcl B
- I
1 I
, O
which O
is O
independent O
of O
caspases B
, O
NF B
- I
kappaB I
, O
or O
Bad B
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt B
- I
1 I
regulates O
macrophage O
survival O
through O
Mcl B
- I
1 I
, O
which O
is O
independent O
of O
caspases B
, O
NF B
- I
kappaB I
, O
or O
Bad B
. O

Recent O
evidence O
suggests O
that O
overexpression O
of O
the O
glucocorticoid B
receptor I
splice I
variant I
GRbeta B
in O
inflammatory O
cells O
might O
contribute O
to O
steroid O
insensitivity O
in O
diseases O
such O
as O
asthma O
. O

OBJECTIVE O
: O
The O
purposes O
of O
this O
investigation O
were O
to O
determine O
whether O
nasal O
polyp O
( O
NP O
) O
inflammatory O
cells O
overexpress O
GRbeta B
and O
to O
examine O
whether O
GRbeta B
overexpression O
is O
associated O
with O
insensitivity O
to O
the O
potent O
topical O
steroid O
fluticasone O
propionate O
( O
FP O
) O
. O

OBJECTIVE O
: O
The O
purposes O
of O
this O
investigation O
were O
to O
determine O
whether O
nasal O
polyp O
( O
NP O
) O
inflammatory O
cells O
overexpress O
GRbeta B
and O
to O
examine O
whether O
GRbeta B
overexpression O
is O
associated O
with O
insensitivity O
to O
the O
potent O
topical O
steroid O
fluticasone O
propionate O
( O
FP O
) O
. O

Biopsies O
were O
immunostained O
for O
inflammatory O
cell O
markers O
as O
well O
as O
GRbeta B
and O
probed O
for O
various O
cytokine B
mRNA I
. O

The O
percentage O
of O
inflammatory O
cells O
expressing O
GRbeta B
was O
also O
increased O
( O
40 O
. O
5 O
% O
+ O
/ O
- O
19 O
. O
2 O
% O
vs O
16 O
. O
1 O
% O
+ O
/ O
- O
4 O
. O
0 O
% O
, O
P O
= O
. O
009 O
) O
. O

GRbeta B
expression O
in O
NPs O
was O
almost O
exclusive O
to O
T O
lymphocytes O
, O
eosinophils O
, O
and O
macrophages O
. O

An O
inverse O
correlation O
was O
observed O
between O
the O
baseline O
inflammatory O
cell O
GRbeta B
expression O
and O
the O
reduction O
after O
FP O
treatment O
in O
EG2 O
- O
positive O
eosinophils O
, O
CD4 O
- O
positive O
T O
lymphocytes O
, O
endothelial O
VCAM B
- I
1 I
expression O
, O
and O
IL O
- O
4 O
mRNA O
- O
positive O
cells O
. O

` O
` O
FP O
- O
insensitive O
' O
' O
NPs O
also O
demonstrated O
a O
higher O
percentage O
of O
IL O
- O
5 O
- O
positive O
inflammatory O
cells O
expressing O
GRbeta B
before O
and O
after O
FP O
treatment O
. O

CONCLUSION O
: O
GRbeta B
expression O
appears O
to O
be O
a O
marker O
of O
steroid O
insensitivity O
in O
NPs O
. O

Expression O
of O
GRbeta B
by O
NP O
inflammatory O
cells O
, O
particularly O
T O
cells O
and O
eosinophils O
, O
might O
render O
them O
resistant O
to O
suppression O
by O
topical O
steroids O
and O
thereby O
contribute O
to O
persistent O
NP O
inflammation O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B
factors I
Sp1 B
and O
Oct1 B
to O
the O
consensus B
GC I
box I
and O
the O
Oct B
site I
, O
respectively O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B
factors I
Sp1 B
and O
Oct1 B
to O
the O
consensus B
GC I
box I
and O
the O
Oct B
site I
, O
respectively O
. O

Adipophilin B
is O
a O
sensitive O
marker O
for O
lipid O
loading O
in O
human O
blood O
monocytes O
. O

Adipophilin B
, O
a O
marker O
of O
lipid O
accumulation O
initially O
described O
in O
adipocytes O
, O
was O
recently O
shown O
to O
be O
induced O
in O
macrophage O
foam O
cells O
. O

We O
found O
that O
even O
freshly O
isolated O
blood O
monocytes O
express O
adipophilin B
and O
that O
the O
amount O
of O
adipophilin B
protein I
is O
variable O
in O
monocytes O
from O
different O
healthy O
individuals O
. O

However O
, O
the O
physiological O
expression O
of O
adipophilin B
does O
not O
correlate O
with O
the O
levels O
of O
free O
fatty O
acids O
, O
cholesterylesters O
or O
free O
cholesterol O
. O

Enzymatically B
modified I
low I
- I
density I
lipoprotein I
( O
E B
- I
LDL I
) O
induces O
rapid O
foam O
cell O
formation O
in O
monocytes O
and O
upregulates O
adipophilin B
mRNA O
and O
protein O
within O
2 O
h O
of O
incubation O
. O

This O
rapid O
induction O
of O
adipophilin B
is O
accompanied O
by O
a O
significant O
increase O
of O
free O
fatty O
acids O
in O
monocytes O
incubated O
with O
E B
- I
LDL I
. O

Adipophilin B
facilitates O
the O
uptake O
of O
free O
fatty O
acids O
, O
and O
here O
we O
demonstrate O
that O
free O
fatty O
acids O
increase O
is O
related O
to O
the O
early O
upregulation O
of O
adipophilin O
expression O
in O
blood O
monocytes O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma B
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma B
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma B
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA B
- I
D I
genes I
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B
( I
class I
II I
transactivator I
) I
transcripts I
, O
CIITA B
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

Constitutive O
transcription O
of O
CIITA B
from O
promoter B
III I
having O
been O
observed O
in O
unrelated O
melanoma O
cell O
lines O
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma O
cells O

Caspase B
- O
mediated O
calcineurin O
activation O
contributes O
to O
IL B
- I
2 I
release O
during O
T O
cell O
activation O
. O

Calcineurin B
, O
a O
Ca B
( I
2 I
+ I
) I
/ I
calmodulin I
- I
dependent I
Ser I
/ I
Thr I
phosphatase I
( I
protein I
phosphatase I
2B I
) I
, O
plays O
a O
critical O
role O
in O
IL O
- O
2 O
production O
during O
T O
cell O
activation O
. O

In O
parallel O
, O
proteolytic O
activation O
of O
upstream O
caspases B
( O
caspase O
- O
8 O
and O
- O
9 O
) O
as O
well O
as O
effector B
caspase I
- I
3 I
was O
also O
observed O
. O

Cn B
A I
cleavage O
was O
also O
observed O
when O
purified O
calcineurin B
was O
digested O
in O
vitro O
with O
caspase B
- I
3 I
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I O
- O
activated O
Jurkat O
cells O
, O
dephosphorylation O
of O
calcineurin B
substrate O
NFATc B
( O
a O
transcription B
factor I
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL B
- I
2 I
gene I
) O
, O
was O
also O
suppressed O
by O
Z O
- O
D O
- O
DCB O
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I O
- O
activated O
Jurkat O
cells O
, O
dephosphorylation O
of O
calcineurin B
substrate O
NFATc B
( O
a O
transcription B
factor I
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL B
- I
2 I
gene I
) O
, O
was O
also O
suppressed O
by O
Z O
- O
D O
- O
DCB O
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B
and O
CD68 B
and O
downregulated O
the O
levels O
of O
CD40 B
, O
CD80 B
, O
and O
CD83 B
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B
and O
CD68 B
and O
downregulated O
the O
levels O
of O
CD40 B
, O
CD80 B
, O
and O
CD83 B
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B
and O
CD68 B
and O
downregulated O
the O
levels O
of O
CD40 B
, O
CD80 B
, O
and O
CD83 B
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B
and O
CD68 B
and O
downregulated O
the O
levels O
of O
CD40 B
, O
CD80 B
, O
and O
CD83 B
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B
and O
CD68 B
and O
downregulated O
the O
levels O
of O
CD40 B
, O
CD80 B
, O
and O
CD83 B
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

Defective O
function O
of O
the O
proteasome B
in O
autoimmunity O
: O
involvement O
of O
impaired O
NF O
- O
kappaB O
activation O
. O

Type O
1 O
diabetes O
( O
also O
known O
as O
insulin O
- O
dependent O
diabetes O
mellitus O
or O
juvenile O
- O
onset O
diabetes O
) O
is O
usually O
caused O
by O
T O
cell O
- O
mediated O
autoimmunity O
, O
with O
a O
prediabetic O
state O
characterized O
by O
the O
production O
of O
autoantibodies B
specific O
for O
proteins O
expressed O
by O
pancreatic O
beta O
cells O
. O

The O
nonobese O
patient O
with O
diabetes O
( O
NOD O
) O
mouse O
is O
a O
spontaneous O
model O
of O
type O
1 O
diabetes O
with O
a O
strong O
genetic O
component O
that O
maps O
to O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
region I
of O
the O
genome B
. O

A O
specific O
proteasome B
defect O
has O
been O
identified O
in O
NOD O
mouse O
in O
select O
lymphocytic O
and O
monocytic O
lineages O
that O
results O
from O
down O
- O
regulation O
of O
expression O
of O
the O
proteasome B
subunit I
LMP2 I
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC B
genomic I
region I
. O

The O
novel O
role O
of O
the O
proteasome B
in O
dysfunction O
in O
autoimmunity O
is O
presented O
and O
documented O
to O
be O
both O
tissue O
and O
developmental O
stage O
specific O
. O

We O
propose O
a O
role O
of O
the O
proteasome B
as O
a O
step O
in O
disease O
pathogenesis O
and O
tissue O
targeting O
. O

Ikaros B
is O
a O
unique O
regulator O
of O
lymphopoiesis O
that O
associates O
with O
pericentromeric B
heterochromatin I
and O
has O
been O
implicated O
in O
heritable O
gene O
inactivation O
. O

However O
, O
these O
mutations O
abolished O
down O
- O
regulation O
on O
differentiation O
, O
providing O
evidence O
that O
Ikaros B
plays O
a O
direct O
role O
in O
repression O
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros B
should O
be O
disrupted O
by O
a O
small O
isoform B
that O
retains O
the O
dimerization B
domain I
and O
lacks O
the O
DNA B
- I
binding I
domain I
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros B
should O
be O
disrupted O
by O
a O
small O
isoform B
that O
retains O
the O
dimerization B
domain I
and O
lacks O
the O
DNA B
- I
binding I
domain I
. O

Surprisingly O
, O
in O
the O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
, O
overexpression O
of O
a O
small B
Ikaros I
isoform I
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA O
- O
binding O
properties O
of O
Ikaros B
. O

Rather O
, O
the O
small O
isoform B
assembled O
into O
multimeric B
complexes I
with O
DNA B
- I
bound I
Ikaros I
at O
the O
pericentromeric O
foci O
. O

The O
ability O
of O
IFN B
- I
alpha I
/ I
beta I
to O
suppress O
IL O
- O
12 O
production O
while O
up O
- O
regulating O
IFN O
- O
gamma O
production O
suggests O
a O
possible O
mechanistic O
basis O
for O
the O
difficulties O
of O
employing O
these O
cytokines B
in O
diseases O
involving O
abnormalities O
of O
CMI O
. O

OX40 B
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
superfamily I
and O
known O
to O
be O
an O
important O
costimulatory B
molecule I
expressed O
on O
activated O
T O
cells O
. O

To O
investigate O
the O
role O
of O
costimulation O
of O
OX40 B
in O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
by O
its O
natural O
ligand O
, O
gp34 B
, O
the O
OX40 O
- O
transfected O
ACH O
- O
2 O
cell O
line O
, O
ACH O
- O
2 O
/ O
OX40 O
, O
chronically O
infected O
with O
HIV O
- O
1 O
, O
was O
cocultured O
with O
paraformaldehyde O
( O
PFA O
) O
- O
fixed O
gp34 O
- O
transfected O
mouse O
cell O
line O
, O
SV O
- O
T2 O
/ O
gp34 O
. O

To O
investigate O
the O
role O
of O
costimulation O
of O
OX40 B
in O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
by O
its O
natural O
ligand O
, O
gp34 B
, O
the O
OX40 O
- O
transfected O
ACH O
- O
2 O
cell O
line O
, O
ACH O
- O
2 O
/ O
OX40 O
, O
chronically O
infected O
with O
HIV O
- O
1 O
, O
was O
cocultured O
with O
paraformaldehyde O
( O
PFA O
) O
- O
fixed O
gp34 O
- O
transfected O
mouse O
cell O
line O
, O
SV O
- O
T2 O
/ O
gp34 O
. O

This O
was O
followed O
by O
apparent O
apoptosis O
, O
and O
both O
processes O
were O
specifically O
inhibited O
by O
the O
gp34 B
- O
specific O
neutralizing B
monoclonal I
antibody I
5A8 I
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 B
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa B
B I
site I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF B
- I
kappa I
B I
consisting O
of O
p50 B
and I
p65 I
subunits I
. O

The O
enhancement O
was O
again O
significantly O
inhibited O
by O
5A8 B
. O

The O
present O
study O
first O
shows O
that O
OX40 O
- O
gp34 O
interaction O
stimulates O
HIV O
- O
1 O
expression O
and O
suggests O
that O
OX40 O
triggering O
by O
gp34 B
may O
play O
an O
important O
role O
in O
enhancing O
HIV O
- O
1 O
production O
in O
both O
acutely O
and O
latently O
infected O
CD4 O
( O
+ O
) O
T O
cells O
in O
vivo O
. O

Peroxizome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
is O
a O
member O
of O
the O
nuclear B
receptor I
family I
of O
transcription B
factors I
that O
regulate O
adipocyte O
differentiation O
. O

Osteopontin B
, O
a O
component O
of O
extracellular O
matrix O
, O
is O
synthesized O
by O
macrophages O
in O
atherosclerotic O
plaques O
. O

In O
this O
study O
, O
we O
examined O
whether O
PPARgamma B
ligand O
regulates O
osteopontin O
gene O
expression O
in O
THP O
- O
1 O
cells O
, O
a O
cell O
line O
derived O
from O
human O
monocytic O
leukemia O
cells O
which O
can O
differentiate O
to O
macrophage O
upon O
stimulation O
with O
phorbol O
ester O
PMA O
. O

Troglitazone O
, O
a O
PPARgamma B
ligand O
, O
dramatically O
attenuated O
the O
PMA O
- O
induced O
osteopontin O
expression O
. O

These O
data O
indicate O
that O
troglitazone O
reduces O
osteopontin O
gene O
expression O
at O
transcriptional O
level O
through O
PPARgamma B
activation O
, O
and O
suggest O
the O
role O
of O
troglitazone O
in O
inhibiting O
the O
ability O
of O
macrophages O
to O
produce O
extracellular O
matrix O
, O
which O
is O
particularly O
relevant O
to O
atherosclerotic O
plaque O
formation O
. O

Directed O
alterations O
in O
the O
accessibility O
of O
V B
, I
D I
, I
and I
J I
gene I
segments I
target O
the O
recombinase B
to O
specific O
Ag B
receptor I
loci I
. O

Accessibility O
within O
a O
given O
locus B
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B
factors I
with O
cognate B
enhancer I
elements I
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene B
segments I
. O

Molecular O
analyses O
indicate O
that O
the O
block O
in O
NF B
- I
kappaB I
impairs O
Iglambda O
rearrangement O
at O
the O
level O
of O
recombinase B
accessibility O
. O

These O
findings O
expand O
the O
range O
of O
NF B
- I
kappaB I
action O
in O
precursor O
B O
cells O
beyond O
Igkappa B
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L B
chain I
loci I
. O

Transcription B
factor I
STAT5A B
is O
a O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
in O
B O
cells O
. O

STAT5A B
is O
a O
molecular O
regulator O
of O
proliferation O
, O
differentiation O
, O
and O
apoptosis O
in O
lymphohematopoietic O
cells O
. O

Here O
we O
show O
that O
STAT5A B
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
( O
BTK B
) O
. O

Here O
we O
show O
that O
STAT5A B
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
( O
BTK B
) O
. O

BTK B
was O
also O
capable O
of O
tyrosine O
- O
phosphorylating O
ectopically O
expressed O
recombinant B
STAT5A I
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus B
kinase I
3 I
- O
independent O
fashion O
. O

BTK B
phosphorylated O
the O
Y665F B
, I
Y668F I
, I
and I
Y682F I
, I
Y683F I
mutants I
but O
not O
the O
Y694F B
mutant I
of O
STAT5A B
. O

BTK B
phosphorylated O
the O
Y665F B
, I
Y668F I
, I
and I
Y682F I
, I
Y683F I
mutants I
but O
not O
the O
Y694F B
mutant I
of O
STAT5A B
. O

STAT5A O
mutations O
in O
the O
Src B
homology I
2 I
( I
SH2 I
) I
and I
SH3 I
domains I
did O
not O
alter O
the O
BTK B
- O
mediated O
tyrosine O
phosphorylation O
. O

Recombinant B
BTK I
proteins I
with O
mutant O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
were O
capable O
of O
phosphorylating O
STAT5A B
, O
whereas O
recombinant B
BTK I
proteins I
with O
SH1 O
/ O
kinase O
domain O
mutations O
were O
not O
. O

In O
pull O
- O
down O
experiments O
, O
only O
full B
- I
length I
BTK I
and O
its O
SH1 B
/ I
kinase I
domain I
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
) O
were O
capable O
of O
binding O
STAT5A B
. O

Ectopically O
expressed O
BTK B
kinase I
domain I
was O
capable O
of O
tyrosine O
- O
phosphorylating O
STAT5A B
both O
in O
vitro O
and O
in O
vivo O
. O

BTK B
- O
mediated O
tyrosine O
phosphorylation O
of O
ectopically O
expressed O
wild O
type O
( O
but O
not O
Tyr B
( I
694 I
) I
mutant I
) O
STAT5A B
enhanced O
its O
DNA O
binding O
activity O
. O

BTK B
- O
mediated O
tyrosine O
phosphorylation O
of O
ectopically O
expressed O
wild O
type O
( O
but O
not O
Tyr B
( I
694 I
) I
mutant I
) O
STAT5A B
enhanced O
its O
DNA O
binding O
activity O
. O

In O
BTK B
- O
competent O
chicken O
B O
cells O
, O
anti O
- O
IgM O
- O
stimulated O
tyrosine O
phosphorylation O
of O
STAT5 B
protein I
was O
prevented O
by O
pretreatment O
with O
the O
BTK B
inhibitor O
LFM O
- O
A13 O
but O
not O
by O
pretreatment O
with O
the O
JAK3 O
inhibitor O
HI O
- O
P131 O
. O

In O
BTK B
- O
competent O
chicken O
B O
cells O
, O
anti O
- O
IgM O
- O
stimulated O
tyrosine O
phosphorylation O
of O
STAT5 B
protein I
was O
prevented O
by O
pretreatment O
with O
the O
BTK B
inhibitor O
LFM O
- O
A13 O
but O
not O
by O
pretreatment O
with O
the O
JAK3 O
inhibitor O
HI O
- O
P131 O
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B
type I
human I
BTK I
but O
not O
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase B
- I
inactive I
mutant I
BTK I
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B
type I
human I
BTK I
but O
not O
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase B
- I
inactive I
mutant I
BTK I
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B
type I
human I
BTK I
but O
not O
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase B
- I
inactive I
mutant I
BTK I
. O

Similarly O
, O
anti O
- O
IgM O
stimulation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5A B
in O
BTK B
- O
competent O
B O
cells O
from O
wild O
type O
mice O
but O
not O
in O
BTK B
- O
deficient O
B O
cells O
from O
XID O
mice O
. O

Similarly O
, O
anti O
- O
IgM O
stimulation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5A B
in O
BTK B
- O
competent O
B O
cells O
from O
wild O
type O
mice O
but O
not O
in O
BTK B
- O
deficient O
B O
cells O
from O
XID O
mice O
. O

Similarly O
, O
anti O
- O
IgM O
stimulation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5A B
in O
BTK B
- O
competent O
B O
cells O
from O
wild O
type O
mice O
but O
not O
in O
BTK B
- O
deficient O
B O
cells O
from O
XID O
mice O
. O

These O
findings O
provide O
unprecedented O
experimental O
evidence O
that O
BTK B
plays O
a O
nonredundant O
and O
pivotal O
role O
in O
B O
cell O
antigen O
receptor O
- O
mediated O
STAT5A O
activation O
in O
B O
cells O

How O
cytokines B
control O
differentiation O
of O
helper O
T O
( O
TH O
) O
cells O
is O
controversial O
. O

We O
show O
that O
T B
- I
bet I
, O
without O
apparent O
assistance O
from O
interleukin B
12 I
( I
IL I
- I
12 I
) I
/ O
STAT4 B
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon B
- I
gamma I
( I
IFN I
- I
gamma I
) I
alleles I
and O
by O
inducing O
IL B
- I
12 I
receptor I
beta2 I
expression O
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

These O
results O
suggest O
that O
a O
cytokine B
does O
not O
simply O
induce O
TH O
fate O
choice O
but O
instead O
may O
act O
as O
an O
essential O
secondary O
stimulus O
that O
mediates O
selective O
survival O
of O
a O
lineage O
. O

Stat6 B
is O
necessary O
and O
sufficient O
for O
IL O
- O
4 O
' O
s O
role O
in O
Th2 O
differentiation O
and O
cell O
expansion O
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

Stat6 B
has O
been O
shown O
to O
be O
required O
for O
Th2 O
differentiation O
. O

To O
determine O
the O
roles O
of O
the O
phosphotyrosine B
binding I
adaptors I
in O
Th2 O
differentiation O
, O
we O
prepared O
a O
retrovirus O
containing O
a O
mutant O
of O
the O
human B
( I
h I
) I
IL I
- I
4R I
alpha I
- I
chain I
, O
Y497F B
, O
which O
is O
unable O
to O
recruit O
these O
adaptors O
. O

Upon O
hIL O
- O
4 O
stimulation O
, O
Y497F B
worked O
as O
well O
as O
the O
WT B
hIL I
- I
4Ralpha I
in O
driving O
Th2 O
differentiation O
, O
as O
measured O
by O
Gata3 O
up O
- O
regulation O
and O
IL O
- O
4 O
production O
. O

Furthermore O
, O
IL O
- O
4 O
- O
driven O
cell O
expansion O
was O
also O
normal O
in O
the O
cells O
infected O
with O
Y497F B
, O
although O
cells O
infected O
with O
Y497F B
were O
not O
capable O
of O
phosphorylating O
insulin B
receptor I
substrate I
2 I
. O

Furthermore O
, O
IL O
- O
4 O
- O
driven O
cell O
expansion O
was O
also O
normal O
in O
the O
cells O
infected O
with O
Y497F B
, O
although O
cells O
infected O
with O
Y497F B
were O
not O
capable O
of O
phosphorylating O
insulin B
receptor I
substrate I
2 I
. O

These O
results O
suggest O
that O
the O
signal O
pathway O
mediated O
by O
Y497 B
is O
dispensable O
for O
both O
IL B
- I
4 I
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
. O

A O
constitutively O
activated O
form O
of O
Stat6 B
introduced O
into O
CD4 O
T O
cells O
resulted O
in O
both O
Th2 O
differentiation O
and O
enhanced O
cell O
expansion O
. O

The O
effect O
of O
HIV B
- I
1 I
regulatory I
proteins I
on O
cellular O
genes O
: O
derepression O
of O
the O
IL B
- I
2 I
promoter I
by O
Tat B
. O

Increase O
secretion O
of O
IL B
- I
2 I
, O
the O
major O
T O
cell O
growth O
and O
differentiation O
cytokine B
, O
may O
play O
a O
decisive O
role O
in O
sensitization O
of O
T O
cells O
for O
activation O
induced O
apoptosis O
and O
indirect O
death O
of O
activated O
T O
cells O
through O
augmented O
virus O
replication O
. O

We O
demonstrate O
that O
increased O
IL O
- O
2 O
secretion O
is O
due O
to O
Tat B
- O
enhanced O
IL B
- I
2 I
promoter I
activation O
. O

Tat B
derepresses O
and O
activates O
the O
distal B
AP I
- I
1 I
site I
( O
position B
- I
185 I
to I
- I
177 I
) O
in O
the O
IL B
- I
2 I
promoter I
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric B
activator I
containing O
p65 B
and O
c B
- I
Jun I
binds O
to O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

OBJECTIVE O
: O
Thrombopoietin B
( O
TPO B
) O
and O
transforming B
growth I
factor I
- I
beta I
( I
1 I
) I
( O
TGF B
- I
beta I
( I
1 I
) I
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic O
cells O
. O

OBJECTIVE O
: O
Thrombopoietin B
( O
TPO B
) O
and O
transforming B
growth I
factor I
- I
beta I
( I
1 I
) I
( O
TGF B
- I
beta I
( I
1 I
) I
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic O
cells O
. O

To O
determine O
whether O
TGF B
- I
beta I
( I
1 I
) I
interferes O
directly O
with O
TPO B
- O
induced O
signal O
transduction O
in O
hematopoietic O
cells O
, O
we O
compared O
the O
regulatory O
effects O
in O
the O
TPO B
- O
responsive O
cell O
lines O
Mo O
- O
7e O
and O
HEL O
. O

To O
determine O
whether O
TGF B
- I
beta I
( I
1 I
) I
interferes O
directly O
with O
TPO B
- O
induced O
signal O
transduction O
in O
hematopoietic O
cells O
, O
we O
compared O
the O
regulatory O
effects O
in O
the O
TPO B
- O
responsive O
cell O
lines O
Mo O
- O
7e O
and O
HEL O
. O

MATERIALS O
AND O
METHODS O
: O
The O
cells O
were O
stimulated O
by O
100 O
ng O
/ O
mL O
TPO B
and O
/ O
or O
100 O
ng O
/ O
mL O
TGF B
- I
beta1 I
and O
analyzed O
for O
proliferation O
( O
3H O
thymidine O
incorporation O
) O
, O
viability O
( O
trypan O
blue O
exclusion O
) O
, O
and O
protein O
expression O
and O
phosphorylation O
( O
Western O
blot O
) O
. O

RESULTS O
: O
TPO B
enhanced O
the O
proliferation O
of O
Mo O
- O
7e O
cells O
as O
determined O
by O
3H O
- O
thymidine O
incorporation O
, O
whereas O
TGF B
- I
beta1 I
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO B
. O

RESULTS O
: O
TPO B
enhanced O
the O
proliferation O
of O
Mo O
- O
7e O
cells O
as O
determined O
by O
3H O
- O
thymidine O
incorporation O
, O
whereas O
TGF B
- I
beta1 I
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO B
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF B
- I
beta1 I
reduced O
the O
TPO B
- O
stimulated O
ERK1 B
/ O
ERK2 B
and O
STAT5 O
phosphorylation O
in O
Mo O
- O
7e O
and O
HEL O
cells O
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF B
- I
beta1 I
reduced O
the O
TPO B
- O
stimulated O
ERK1 B
/ O
ERK2 B
and O
STAT5 O
phosphorylation O
in O
Mo O
- O
7e O
and O
HEL O
cells O
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF B
- I
beta1 I
reduced O
the O
TPO B
- O
stimulated O
ERK1 B
/ O
ERK2 B
and O
STAT5 O
phosphorylation O
in O
Mo O
- O
7e O
and O
HEL O
cells O
. O

This O
effect O
was O
completely O
reversed O
by O
preincubation O
with O
a O
tyrosine O
phosphatase O
inhibitor O
( O
Na3VO4 O
) O
, O
which O
suggests O
that O
TGF B
- I
beta1 I
activated O
a O
phosphatase B
. O

Although O
STAT3 B
also O
was O
activated O
by O
TPO B
, O
STAT3 B
activation O
remained O
unaltered O
by O
TGF B
- I
beta1 I
. O

Although O
STAT3 B
also O
was O
activated O
by O
TPO B
, O
STAT3 B
activation O
remained O
unaltered O
by O
TGF B
- I
beta1 I
. O

Although O
STAT3 B
also O
was O
activated O
by O
TPO B
, O
STAT3 B
activation O
remained O
unaltered O
by O
TGF B
- I
beta1 I
. O

CONCLUSION O
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF B
- I
beta1 I
modulates O
TPO B
- O
mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO B
- O
induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK B
ERK1 I
/ I
ERK2 I
and I
STAT5 I
. O

CONCLUSION O
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF B
- I
beta1 I
modulates O
TPO B
- O
mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO B
- O
induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK B
ERK1 I
/ I
ERK2 I
and I
STAT5 I
. O

This O
final O
maturation O
step O
is O
crucial O
for O
the O
B O
cells O
to O
become O
responsive O
to O
antigens B
and O
to O
participate O
in O
the O
immune O
response O
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

In O
this O
study O
, O
we O
investigated O
a O
possible O
link O
between O
Ii B
- O
dependent O
B O
cell O
maturation O
and O
the O
NF O
- O
kappaB O
pathway O
. O

Our O
studies O
indicate O
that O
Ii B
- O
induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF B
- I
kappaB I
p65 I
/ I
RelA I
homodimer I
and O
requires O
the O
B B
cell I
- I
enriched I
coactivator I
TBP B
- I
associated I
factor I
( I
II I
) I
105 I
. O

The O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
a O
member O
of O
the O
nuclear B
hormone I
receptor I
superfamily I
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O

PPARgamma B
has O
been O
found O
recently O
to O
regulate O
macrophage O
activation O
in O
response O
to O
mitogens B
and O
inflammation O
. O

PPARgamma B
has O
been O
found O
recently O
to O
regulate O
macrophage O
activation O
in O
response O
to O
mitogens B
and O
inflammation O
. O

Our O
study O
shows O
PPARgamma B
to O
be O
preferentially O
expressed O
in O
the O
nuclei O
of O
resting O
T O
cells O
and O
to O
increase O
upon O
activation O
of O
T O
cells O
by O
either O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
phorbol O
myristyl O
acetate O
( O
PMA O
) O
. O

Inhibition O
of O
both O
the O
proliferative O
response O
and O
inflammatory O
cytokine O
expression O
in O
CD4 O
T O
cells O
was O
correlated O
with O
suppression O
of O
the O
activated O
transcription B
factors I
AP1 B
and O
NF B
- I
kappaB I
. O

These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma B
ligands I
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma B
as O
a O
negative B
regulator I
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T O
cells O
. O

PPARgamma B
may O
thus O
be O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmunity O
. O

The O
cell B
surface I
glycoprotein I
2B4 I
( O
CD244 B
) O
of O
the O
Ig B
superfamily I
is O
involved O
in O
the O
regulation O
of O
NK O
and O
T O
lymphocyte O
functions O
. O

We O
have O
recently O
identified O
CD48 B
as O
the O
high B
affinity I
counterreceptor I
for O
2B4 B
in O
both O
mice O
and O
humans O
. O

We O
have O
recently O
identified O
CD48 B
as O
the O
high B
affinity I
counterreceptor I
for O
2B4 B
in O
both O
mice O
and O
humans O
. O

The O
cytoplasmic B
domain I
of O
2B4 B
associates O
with O
src B
homology I
2 I
domain I
- I
containing I
protein I
or O
signaling B
lymphocyte I
activation I
molecule I
- I
associated I
protein I
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X O
- O
linked O
lymphoproliferative O
syndrome O
. O

EMSAs O
with O
Abs B
specific O
for O
various O
protein B
factors I
of O
the O
AP B
- I
1 I
family I
revealed O
that O
multiple O
members O
of O
the O
Jun B
family I
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B
gene I
. O

Functional O
correction O
of O
FA O
- O
C O
cells O
with O
FANCC B
suppresses O
the O
expression O
of O
interferon B
gamma I
- I
inducible I
genes I
. O

Because O
hematopoietic O
cells O
derived O
from O
Fanconi O
anemia O
( O
FA O
) O
patients O
of O
the O
C O
- O
complementation O
group O
( O
FA O
- O
C O
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon B
gamma I
( O
IFNgamma B
) O
, O
the O
products O
of O
certain O
IFNgamma B
- I
inducible I
genes I
known O
to O
influence O
hematopoietic O
cell O
survival O
were O
quantified O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

Levels O
of O
the O
IFNgamma B
- O
inducible O
factor O
IFN B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
, O
a O
negative B
trans I
- I
acting I
regulator I
of O
some O
IFNgamma B
- I
inducible I
genes I
, O
were O
quantified O
. O

Levels O
of O
the O
IFNgamma B
- O
inducible O
factor O
IFN B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
, O
a O
negative B
trans I
- I
acting I
regulator I
of O
some O
IFNgamma B
- I
inducible I
genes I
, O
were O
quantified O
. O

ICSBP B
levels O
were O
reduced O
in O
FA O
- O
C O
B O
lymphoblasts O
and O
MEFs O
. O

However O
, O
enforced O
expression O
of O
ICSBP B
failed O
to O
down O
- O
regulate O
IRF B
- I
1 I
, O
ISGF3gamma B
, O
and O
p21 B
( I
WAF1 I
) I
. O

However O
, O
enforced O
expression O
of O
ICSBP B
failed O
to O
down O
- O
regulate O
IRF B
- I
1 I
, O
ISGF3gamma B
, O
and O
p21 B
( I
WAF1 I
) I
. O

Thus O
, O
the O
FANCC B
protein I
functions O
to O
modulate O
expression O
of O
a O
family O
of O
genes O
that O
in O
normal O
cells O
are O
inducible O
only O
by O
specific O
environmental O
cues O
for O
apoptosis O
or O
mitogenic O
inhibition O
, O
but O
it O
does O
so O
independently O
of O
the O
classic O
IFN O
- O
STAT1 O
pathway O
and O
is O
not O
the O
direct O
result O
of O
reduced O
ICSBP B
expression O
. O

Here O
we O
show O
that O
glucocorticoid O
- O
induced O
inhibition O
of O
interleukin O
- O
2 O
mRNA O
expression O
in O
activated O
normal O
T O
cells O
required O
new O
protein O
synthesis O
, O
suggesting O
that O
this O
phenomenon O
is O
secondary O
to O
expression O
of O
glucocorticoid O
- O
regulated O
genes B
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes B
is O
glucocorticoid B
- I
induced I
leucine I
zipper I
( O
GILZ B
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes B
is O
glucocorticoid B
- I
induced I
leucine I
zipper I
( O
GILZ B
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

Indeed O
, O
transient O
expression O
of O
GILZ B
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter B
construct I
driven O
by O
the O
FasL B
promoter I
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Thus O
, O
GILZ B
represents O
a O
glucocorticoid O
- O
induced O
gene O
product O
that O
can O
inhibit O
a O
variety O
of O
activation O
- O
induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP B
- I
1 I
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

In O
contrast O
, O
Ad5 O
E1A O
peptide O
injection O
resulted O
in O
physical O
deletion O
of O
preexisting O
Ad5 B
E1A I
- O
specific O
CTLs B
within O
24 O
h O
after O
injection O
. O

These O
data O
suggest O
that O
ubiquitous O
expression O
of O
the O
tolerizing O
Ad5 O
E1A O
peptide O
within O
a O
short O
period O
of O
time O
causes O
activation O
- O
induced O
cell O
death O
of O
Ad5 B
E1A I
- O
specific O
CTLs B
. O

Smad3 B
and O
Smad4 B
mediate O
transforming B
growth I
factor I
- I
beta1 I
- O
induced O
IgA O
expression O
in O
murine O
B O
lymphocytes O
. O

Smad3 B
and O
Smad4 B
mediate O
transforming B
growth I
factor I
- I
beta1 I
- O
induced O
IgA O
expression O
in O
murine O
B O
lymphocytes O
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 B
that O
contains O
the O
TGF B
- I
beta I
- I
responsive I
element I
of O
the O
GLalpha B
promoter I
, O
and O
stimulated O
with O
TGF B
- I
beta1 I
. O

Similar O
to O
endogenous B
GLalpha I
transcripts I
, O
TGF B
- I
beta1 I
induces O
GLalpha B
promoter I
activity O
and O
overexpression O
of O
Smad3 B
markedly O
enhances O
the O
promoter O
activity O
. O

On O
the O
other O
hand O
, O
Smad7 B
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3 B
/ I
4 I
on O
GLalpha B
promoter I
activity O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B
, O
Smad4 B
, O
and O
Smad7 B
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF B
- I
beta1 I
to O
transcriptional O
regulation O
of O
IgA B
switching I
related I
gene I
and O
regulation O
of O
IgA O
class O
switching O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B
, O
Smad4 B
, O
and O
Smad7 B
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF B
- I
beta1 I
to O
transcriptional O
regulation O
of O
IgA B
switching I
related I
gene I
and O
regulation O
of O
IgA O
class O
switching O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B
, O
Smad4 B
, O
and O
Smad7 B
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF B
- I
beta1 I
to O
transcriptional O
regulation O
of O
IgA B
switching I
related I
gene I
and O
regulation O
of O
IgA O
class O
switching O
. O

Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase B
( O
pol B
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O

Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase B
( O
pol B
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O

Upon O
B B
cell I
receptor I
( O
BCR B
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B
zeta I
, O
downregulated O
pol B
eta I
, O
and O
mutated O
the O
Ig B
and I
bcl I
- I
6 I
genes I
. O

We O
previously O
reported O
that O
Tax B
induced O
cell O
cycle O
progression O
from O
G0 O
/ O
G1 O
phase O
to O
S O
and O
G2 O
/ O
M O
phases O
in O
human O
T O
- O
cell O
line O
Kit O
225 O
cells O
. O

To O
elucidate O
molecular O
mechanism O
of O
Tax B
- O
induced O
cell O
cycle O
progression O
, O
we O
systematically O
examined O
the O
effects O
of O
Tax B
on O
biochemical O
events O
associated O
with O
cell O
cycle O
progression O
. O

To O
elucidate O
molecular O
mechanism O
of O
Tax B
- O
induced O
cell O
cycle O
progression O
, O
we O
systematically O
examined O
the O
effects O
of O
Tax B
on O
biochemical O
events O
associated O
with O
cell O
cycle O
progression O
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

These O
modulations O
by O
Tax B
always O
paralleled O
the O
ability O
of O
Tax B
to O
activate O
the O
NF O
- O
kappaB O
transcription O
pathway O
. O

These O
modulations O
by O
Tax B
always O
paralleled O
the O
ability O
of O
Tax B
to O
activate O
the O
NF O
- O
kappaB O
transcription O
pathway O
. O

These O
results O
indicate O
the O
important O
role O
of O
Tax B
- O
mediated O
trans O
- O
activation O
of O
the O
genes O
for O
cell B
cycle I
regulatory I
molecules I
in O
Tax B
- O
induced O
cell O
cycle O
progression O
. O

These O
results O
indicate O
the O
important O
role O
of O
Tax B
- O
mediated O
trans O
- O
activation O
of O
the O
genes O
for O
cell B
cycle I
regulatory I
molecules I
in O
Tax B
- O
induced O
cell O
cycle O
progression O
. O

Induction O
of O
COX O
- O
2 O
promoter O
activity O
by O
Cot B
kinase I
occurred O
mainly O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

Strikingly O
, O
Cot B
kinase I
increased O
transactivation O
mediated O
by O
a O
GAL4 B
- I
NFAT I
fusion I
protein I
containing O
the O
N B
- I
terminal I
transactivation I
domain I
of O
NFATp B
. O

In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 O
, O
Cot B
kinase I
increases O
both O
COX B
- I
2 I
promoter I
activity O
and O
NFAT B
- O
mediated O
transactivation O
in O
a O
cyclosporin O
A O
- O
independent O
manner O
. O

These O
data O
indicate O
that O
Cot B
kinase I
up O
- O
regulates O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
through O
the O
NFAT B
response I
elements I
, O
being O
the O
Cot B
kinase I
- O
induced O
NFAT B
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Chemokines B
and O
adhesion B
molecules I
such O
as O
integrins B
play O
a O
major O
part O
in O
the O
trafficking O
, O
extravasation O
, O
and O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

Chemokines B
and O
adhesion B
molecules I
such O
as O
integrins B
play O
a O
major O
part O
in O
the O
trafficking O
, O
extravasation O
, O
and O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

Because O
the O
promoters B
of O
these O
chemokine B
genes I
contain O
kappaB B
binding I
sites I
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B
or O
antibodies B
to O
CD11b B
or O
to O
CD11c B
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF B
- I
kappaB I
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B
or O
antibodies B
to O
CD11b B
or O
to O
CD11c B
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF B
- I
kappaB I
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B
or O
antibodies B
to O
CD11b B
or O
to O
CD11c B
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF B
- I
kappaB I
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B
or O
antibodies B
to O
CD11b B
or O
to O
CD11c B
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF B
- I
kappaB I
. O

These O
results O
suggest O
that O
triggering O
of O
CD11b B
or O
CD11c B
beta I
( I
2 I
) I
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF B
- I
kappaB I
and O
subsequent O
secretion O
of O
MIP B
- I
1alpha I
and O
MIP B
- I
1beta I
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

Acyl B
- I
coenzyme I
A I
: I
cholesterol I
acyltransferase I
( O
ACAT B
) O
is O
an O
intracellular B
enzyme I
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters B
( O
P1 B
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters B
( O
P1 B
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters B
( O
P1 B
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
a O
cytokine B
that O
exerts O
many O
pro O
- O
atherosclerotic O
effects O
in O
vivo O
, O
causes O
up O
- O
regulation O
of O
ACAT B
- I
1 I
mRNA I
in O
human O
blood O
monocyte O
- O
derived O
macrophages O
and O
macrophage O
- O
like O
cells O
but O
not O
in O
other O
cell O
types O
. O

This O
region O
contains O
4 O
Sp1 B
elements I
and O
an O
IFN B
- I
gamma I
activated I
sequence I
( O
GAS B
) O
that O
overlaps O
with O
the O
second O
Sp1 B
element I
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B
factor I
STAT1 I
, O
while O
IFN B
- I
gamma I
causes O
activation O
of O
STAT1 B
such O
that O
it O
binds O
to O
the O
GAS B
/ I
Sp1 I
site I
in O
the O
ACAT B
- I
1 I
P1 I
promoter I
. O

This O
approach O
has O
the O
potential O
advantage O
of O
suppressing O
the O
expression O
of O
various O
proinflammatory B
Th2 I
cytokines I
simultaneously O
rather O
than O
suppressing O
the O
activity O
of O
a O
single O
cytokine B
. O

C57Bl O
/ O
6 O
mice O
produce O
a O
CD4 O
+ O
Th1 O
( O
interferon O
[ O
IFN O
] O
gamma O
+ O
) O
response O
, O
express O
IA B
( I
b I
) I
but O
no O
IE B
, O
and O
are O
atherosclerosis O
- O
prone O
. O

Decreasing O
Th1 O
cells O
by O
antibodies B
( O
alpha B
- I
CD4 I
) O
or O
cytokines B
( O
IL B
- I
4 I
) O
also O
caused O
> O
/ O
= O
80 O
% O
reductions O
in O
lesion O
size O
. O

Decreasing O
Th1 O
cells O
by O
antibodies B
( O
alpha B
- I
CD4 I
) O
or O
cytokines B
( O
IL B
- I
4 I
) O
also O
caused O
> O
/ O
= O
80 O
% O
reductions O
in O
lesion O
size O
. O

CONCLUSIONS O
: O
In O
mildly O
hypercholesterolemic O
C57Bl O
/ O
6 O
mice O
, O
presence O
of O
IA B
( I
b I
) I
and O
absence O
of O
IE B
regulated O
CD4 O
+ O
T O
helper O
- O
cell O
phenotype O
; O
fatty O
lesions O
were O
proportional O
to O
IFNgamma O
+ O
Th1 O
cells O
in O
both O
C57Bl O
/ O
6 O
and O
BALB O
/ O
c O
strains O
. O

Requirement O
for O
p38 B
and O
p44 B
/ I
p42 I
mitogen B
- I
activated I
protein I
kinases I
in O
RAGE B
- O
mediated O
nuclear B
factor I
- I
kappaB I
transcriptional O
activation O
and O
cytokine O
secretion O
. O

Requirement O
for O
p38 B
and O
p44 B
/ I
p42 I
mitogen B
- I
activated I
protein I
kinases I
in O
RAGE B
- O
mediated O
nuclear B
factor I
- I
kappaB I
transcriptional O
activation O
and O
cytokine O
secretion O
. O

Advanced O
glycation O
end O
product O
( O
AGE O
) O
activation O
of O
the O
signal B
- I
transducing I
receptor I
for I
AGE I
( O
RAGE B
) O
has O
been O
linked O
to O
a O
proinflammatory O
phenotypic O
change O
within O
cells O
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B
ligand I
- I
binding I
domain I
of O
RAGE B
, O
with O
anti O
- O
RAGE B
antiserum O
, O
and O
by O
coexpression O
of O
truncated B
receptors I
lacking O
the O
intracellular B
domain I
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B
ligand I
- I
binding I
domain I
of O
RAGE B
, O
with O
anti O
- O
RAGE B
antiserum O
, O
and O
by O
coexpression O
of O
truncated B
receptors I
lacking O
the O
intracellular B
domain I
. O

Signal O
transduction O
from O
RAGE B
to O
NF B
- I
kappaB I
involved O
the O
generation O
of O
reactive O
oxygen O
species O
, O
since O
reporter O
gene O
expression O
was O
blocked O
with O
the O
antioxidant O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

CML B
- I
modified I
albumin I
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
, O
but O
not O
c B
- I
Jun I
NH I
( I
2 I
) I
- I
terminal I
kinase I
. O

RAGE B
- O
mediated O
NF O
- O
kappaB O
activation O
was O
suppressed O
by O
the O
selective O
p38 B
MAPK I
inhibitor O
SB203580 O
and O
by O
coexpression O
of O
a O
kinase O
- O
dead O
p38 O
dominant O
- O
negative O
mutant O
. O

These O
results O
indicate O
that O
p38 B
MAPK I
activation O
mediates O
RAGE B
- O
induced O
NF B
- I
kappaB I
- O
dependent O
secretion O
of O
proinflammatory B
cytokines I
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

Nuclear B
NF I
- I
kappaB I
is O
induced O
in O
B O
cells O
by O
engagement O
of O
either O
the O
BCR B
or O
CD40 B
or O
by O
stimulation O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

Nuclear B
NF I
- I
kappaB I
is O
induced O
in O
B O
cells O
by O
engagement O
of O
either O
the O
BCR B
or O
CD40 B
or O
by O
stimulation O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

In O
this O
report O
we O
address O
the O
role O
of O
phosphoinositide B
3 I
' I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
in O
BCR B
- O
and O
LPS O
- O
induced O
NF O
- O
kappaB O
activation O
using O
populations O
of O
primary O
murine O
resting O
B O
cells O
. O

Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B
3 I
- I
kinase I
, O
Wortmannin O
and O
LY294002 O
, O
we O
demonstrate O
that O
PI B
3 I
- I
kinase I
activity O
is O
vital O
for O
BCR B
- O
induced O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
. O

Furthermore O
, O
we O
show O
that O
this O
is O
achieved O
via O
protein B
kinase I
C I
- O
dependent O
degradation O
of O
IkappaBalpha B
. O

Similar O
analyses O
reveal O
that O
PI B
3 I
- I
kinase I
is O
also O
critical O
in O
triggering O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
and O
IkappaBalpha B
degradation O
following O
LPS O
stimulation O
. O

Interestingly O
, O
a O
PKC O
inhibitor O
which O
blocked O
the O
BCR B
- O
induced O
IkappaBalpha B
degradation O
had O
no O
effect O
on O
the O
degradation O
of O
IkappaBalpha B
after O
LPS O
stimulation O
. O

Interestingly O
, O
a O
PKC O
inhibitor O
which O
blocked O
the O
BCR B
- O
induced O
IkappaBalpha B
degradation O
had O
no O
effect O
on O
the O
degradation O
of O
IkappaBalpha B
after O
LPS O
stimulation O
. O

Interestingly O
, O
a O
PKC O
inhibitor O
which O
blocked O
the O
BCR B
- O
induced O
IkappaBalpha B
degradation O
had O
no O
effect O
on O
the O
degradation O
of O
IkappaBalpha B
after O
LPS O
stimulation O
. O

Tetramer O
- O
guided O
epitope O
mapping O
: O
rapid O
identification O
and O
characterization O
of O
immunodominant O
CD4 O
+ O
T O
cell O
epitopes O
from O
complex O
antigens B
. O

T O
cell O
responses O
to O
Ags B
involve O
recognition O
of O
selected O
peptide B
epitopes I
contained O
within O
the O
antigenic B
protein I
. O

In O
this O
report O
, O
we O
describe O
a O
new O
approach O
for O
direct O
identification O
of O
CD4 O
+ O
T O
cell O
epitopes O
of O
complex O
Ags B
that O
uses O
human B
class I
II I
tetramers I
to O
identify O
reactive O
cells O
. O

With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 B
protein I
, O
a O
major O
Ag B
for O
HSV O
- O
2 O
, O
we O
generated O
a O
panel O
of O
class B
II I
MHC I
tetramers I
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral O
lymphocytes O
of O
an O
HSV O
- O
2 O
infected O
individual O
. O

By O
using O
tetramers B
to O
sort O
individual O
cells O
, O
we O
easily O
obtained O
a O
large O
number O
of O
clones O
specific O
to O
these O
epitopes B
. O

By O
using O
tetramers B
to O
sort O
individual O
cells O
, O
we O
easily O
obtained O
a O
large O
number O
of O
clones O
specific O
to O
these O
epitopes B
. O

This O
rapid O
approach O
to O
detecting O
CD4 O
+ O
T O
cell O
epitopes O
from O
complex O
Ags B
can O
be O
applied O
to O
any O
known O
Ag B
that O
gives O
a O
T O
cell O
response O
. O

This O
rapid O
approach O
to O
detecting O
CD4 O
+ O
T O
cell O
epitopes O
from O
complex O
Ags B
can O
be O
applied O
to O
any O
known O
Ag B
that O
gives O
a O
T O
cell O
response O
. O

CD45 B
tyrosine I
phosphatase I
controls O
common O
gamma B
- I
chain I
cytokine I
- O
mediated O
STAT B
and O
extracellular O
signal O
- O
related O
kinase O
phosphorylation O
in O
activated O
human O
lymphoblasts O
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O

In O
Western O
blots O
using O
mAbs B
detecting O
phosphorylated B
STAT I
- I
3 I
, I
STAT I
- I
5 I
, I
STAT I
- I
6 I
, O
or O
extracellular B
signal I
- I
related I
kinase I
1 I
/ I
2 I
, O
we O
found O
that O
CD45R0 O
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O

Pax5 B
determines O
the O
identity O
of O
B O
cells O
from O
the O
beginning O
to O
the O
end O
of O
B O
- O
lymphopoiesis O
. O

Pax5 B
appears O
to O
mediate O
B O
- O
lineage O
commitment O
by O
repressing O
the O
transcription O
of O
non B
- I
B I
- I
lymphoid I
genes I
and O
by O
simultaneously O
activating O
the O
expression O
of O
B B
- I
lineage I
- I
specific I
genes I
. O

Pax5 B
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors B
of O
the O
Groucho B
protein I
family I
or O
with O
positive O
regulators O
such O
as O
the O
TATA B
- I
binding I
protein I
. O

Pax5 B
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors B
of O
the O
Groucho B
protein I
family I
or O
with O
positive O
regulators O
such O
as O
the O
TATA B
- I
binding I
protein I
. O

Once O
committed O
to O
the O
B O
- O
lineage O
, O
B O
cells O
require O
Pax5 B
function O
to O
maintain O
their O
B O
- O
lymphoid O
identity O
throughout O
B O
cell O
development O

Partners O
in O
transcription O
: O
NFAT B
and O
AP B
- I
1 I
. O

Concomitant O
induction O
of O
NFAT B
and O
AP B
- I
1 I
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B
kinase I
C I
( I
PKC I
) I
/ I
Ras I
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B
and I
Jun I
families I
of O
transcription B
factors I
. O

A O
fifth O
member O
of O
the O
NFAT B
family I
, O
NFAT5 B
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B
or O
of O
interaction O
with O
AP B
- I
1 I
. O

A O
fifth O
member O
of O
the O
NFAT B
family I
, O
NFAT5 B
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B
or O
of O
interaction O
with O
AP B
- I
1 I
. O

Balanced O
activation O
of O
NFAT B
and O
AP B
- I
1 I
is O
known O
to O
be O
required O
for O
productive O
immune O
responses O
, O
but O
the O
role O
of O
NFAT O
: O
AP O
- O
1 O
interactions O
in O
other O
cell O
types O
and O
biological O
processes O
remains O
to O
be O
understood O
. O

The O
cytokines B
produced O
by O
the O
Vgamma O
subpopulation O
have O
a O
significant O
influence O
on O
the O
CD4 B
( O
+ O
) O
- O
Th O
- O
cell O
phenotype O
. O

The O
cytokines B
produced O
by O
the O
Vgamma O
subpopulation O
have O
a O
significant O
influence O
on O
the O
CD4 B
( O
+ O
) O
- O
Th O
- O
cell O
phenotype O
. O

Plasmin B
- O
induced O
expression O
of O
cytokines B
and O
tissue B
factor I
in O
human O
monocytes O
involves O
AP B
- I
1 I
and O
IKKbeta B
- O
mediated O
NF O
- O
kappaB O
activation O
. O

Plasmin B
- O
induced O
expression O
of O
cytokines B
and O
tissue B
factor I
in O
human O
monocytes O
involves O
AP B
- I
1 I
and O
IKKbeta B
- O
mediated O
NF O
- O
kappaB O
activation O
. O

Plasmin B
- O
induced O
expression O
of O
cytokines B
and O
tissue B
factor I
in O
human O
monocytes O
involves O
AP B
- I
1 I
and O
IKKbeta B
- O
mediated O
NF O
- O
kappaB O
activation O
. O

It O
was O
previously O
shown O
that O
plasmin B
activates O
human O
peripheral O
monocytes O
in O
terms O
of O
lipid O
mediator O
release O
and O
chemotactic O
migration O
. O

Here O
it O
is O
demonstrated O
that O
plasmin B
induces O
proinflammatory B
cytokine I
release O
and O
tissue B
factor I
( O
TF B
) O
expression O
by O
monocytes O
. O

Here O
it O
is O
demonstrated O
that O
plasmin B
induces O
proinflammatory B
cytokine I
release O
and O
tissue B
factor I
( O
TF B
) O
expression O
by O
monocytes O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
- O
mediated O
mRNA O
expression O
was O
inhibited O
in O
a O
concentration O
- O
dependent O
manner O
by O
the O
lysine O
analogue O
trans O
- O
4 O
- O
( O
aminomethyl O
) O
cyclohexane O
- O
1 O
- O
carboxylic O
acid O
( O
t O
- O
AMCA O
) O
. O

Increases O
in O
mRNA O
levels O
were O
followed O
by O
concentration O
- O
and O
time O
- O
dependent O
release O
of O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
and O
by O
TF B
expression O
on O
monocyte O
surfaces O
. O

Neither O
cytokines B
nor O
TF B
could O
be O
detected O
when O
monocytes O
were O
preincubated O
with O
actinomycin O
D O
or O
cycloheximide O
. O

Neither O
cytokines B
nor O
TF B
could O
be O
detected O
when O
monocytes O
were O
preincubated O
with O
actinomycin O
D O
or O
cycloheximide O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

At O
variance O
with O
endotoxic O
lipopolysaccharide O
, O
plasmin B
elicited O
the O
rapid O
degradation O
of O
another O
cytoplasmic B
NF I
- I
kappaB I
inhibitor I
, I
p105 I
. O

Proteolysis O
of O
NF O
- O
kappaB O
inhibitors O
was O
apparently O
due O
to O
transient O
activation O
of O
IkappaB B
kinase I
( I
IKK I
) I
beta I
that O
reached O
maximum O
activity O
at O
1 O
hour O
after O
plasmin B
stimulation O
. O

In O
addition O
, O
AP O
- O
1 O
binding O
was O
increased O
in O
plasmin B
- O
treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD B
, O
c B
- I
Fos I
, O
and O
FosB B
. O

In O
addition O
, O
AP O
- O
1 O
binding O
was O
increased O
in O
plasmin B
- O
treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD B
, O
c B
- I
Fos I
, O
and O
FosB B
. O

In O
addition O
, O
AP O
- O
1 O
binding O
was O
increased O
in O
plasmin B
- O
treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD B
, O
c B
- I
Fos I
, O
and O
FosB B
. O

These O
findings O
further O
substantiate O
the O
role O
of O
plasmin B
as O
a O
proinflammatory O
activator O
of O
human O
monocytes O
and O
reveal O
an O
important O
new O
link O
between O
the O
plasminogen O
- O
plasmin O
system O
and O
inflammation O
. O

STAT3 B
is O
constitutively O
active O
in O
some O
patients O
with O
Polycythemia O
rubra O
vera O
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B
, O
insulin B
- I
like I
growth I
factor I
- I
1 I
, O
thrombopoietin B
, O
interleukin B
- I
3 I
, O
and O
granulocyte B
/ I
monocyte I
colony I
- I
stimulating I
factor I
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B
, O
insulin B
- I
like I
growth I
factor I
- I
1 I
, O
thrombopoietin B
, O
interleukin B
- I
3 I
, O
and O
granulocyte B
/ I
monocyte I
colony I
- I
stimulating I
factor I
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

We O
therefore O
investigated O
a O
common O
downstream O
effector O
of O
cytokines B
, O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
. O

We O
therefore O
investigated O
a O
common O
downstream O
effector O
of O
cytokines B
, O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
. O

None O
of O
the O
subjects O
showed O
constitutive O
STAT1 B
or O
STAT5 B
activity O
. O

None O
of O
the O
subjects O
showed O
constitutive O
STAT1 B
or O
STAT5 B
activity O
. O

Western O
blotting O
demonstrated O
that O
, O
in O
the O
three O
patients O
, O
STAT3 B
is O
constitutively O
phosphorylated O
on O
Tyr O
705 O
, O
whereas O
it O
is O
unphosphorylated O
in O
the O
other O
patients O
and O
in O
controls O
. O

Interestingly O
, O
constitutive O
STAT3 B
activity O
did O
not O
correlate O
with O
the O
duration O
of O
disease O
or O
the O
treatment O
regimen O
. O

CONCLUSION O
: O
Our O
data O
suggest O
that O
constitutive O
phosphorylation O
and O
activation O
of O
STAT3 B
is O
not O
a O
secondary O
event O
induced O
by O
mutagenizing O
agents O
or O
by O
prolonged O
hyperproliferation O
of O
hematopoietic O
cells O
, O
but O
rather O
represents O
a O
primary O
molecular O
aberration O
. O

Bruton B
' I
s I
tyrosine I
kinase I
( O
Btk B
) O
, O
a O
member O
of O
the O
Tec B
family I
of I
cytosolic I
kinases I
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O

BAP B
/ I
TFII I
- I
I I
, O
a O
protein O
implicated O
in O
transcriptional O
regulation O
, O
is O
associated O
with O
Btk B
in O
B O
cells O
and O
is O
transiently O
phosphorylated O
on O
tyrosine O
following O
B O
cell O
receptor O
engagement O
. O

BAP B
/ I
TFII I
- I
I I
is O
a O
substrate O
for O
Btk B
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine O
upon O
coexpression O
with O
Btk B
in O
mammalian O
cells O
. O

BAP B
/ I
TFII I
- I
I I
is O
a O
substrate O
for O
Btk B
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine O
upon O
coexpression O
with O
Btk B
in O
mammalian O
cells O
. O

In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP B
/ I
TFII I
- I
I I
tyrosine O
phosphorylation O
following O
B O
cell O
receptor O
stimulation O
, O
site O
- O
directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites O
of O
BAP B
/ I
TFII I
- I
I I
phosphorylation O
by O
Btk B
in O
vitro O
. O

These O
residues O
, O
Tyr248 O
, O
Tyr357 O
, O
and O
Tyr462 O
, O
were O
also O
found O
to O
be O
the O
major O
sites O
for O
Btk B
- O
dependent O
phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
in O
vivo O
. O

Phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
by O
Btk B
may O
link O
engagement O
of O
receptors O
such O
as O
surface O
immunoglobulin B
to O
modulation O
of O
gene O
expression O
. O

Phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
by O
Btk B
may O
link O
engagement O
of O
receptors O
such O
as O
surface O
immunoglobulin B
to O
modulation O
of O
gene O
expression O
. O

Mice O
deficient O
in O
the O
interferon B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR B
/ I
ABL I
oncoprotein I
. O

Interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
induces O
ICSBP B
expression O
and O
is O
an O
effective O
therapy O
for O
CML O
. O

This O
study O
examined O
whether O
enforced O
expression O
of O
ICSBP B
might O
antagonize O
BCR O
/ O
ABL O
- O
induced O
leukemia O
; O
results O
demonstrated O
that O
ICSBP O
- O
modified O
cells O
generated O
a O
protective O
CD8 O
( O
+ O
) O
cytotoxic O
T O
- O
cell O
response O
against O
BCR O
/ O
ABL O
- O
transformed O
BaF3 O
cells O
in O
a O
murine O
leukemia O
model O
. O

ICSBP B
expression O
represents O
a O
novel O
means O
of O
stimulating O
a O
host O
immune O
response O
to O
BCR O
/ O
ABL O
( O
+ O
) O
leukemia O
cells O
and O
a O
potential O
strategy O
for O
immunotherapy O
of O
CML O
. O

However O
, O
most O
effector O
CD8 O
+ O
T O
cells O
recovered O
after O
exposure O
to O
Ag B
do O
not O
produce O
sufficient O
IL B
- I
2 I
to O
sustain O
growth O
, O
and O
depend O
on O
CD4 O
+ O
T O
helper O
cells O
for O
this O
obligate O
growth O
factor O
. O

To O
evaluate O
transcriptional O
regulation O
of O
the O
IL B
- I
2 I
gene I
in O
CD8 O
+ O
T O
cells O
, O
we O
stably O
transfected O
reporter B
genes I
into O
Ag B
- O
specific O
CD8 O
+ O
T O
cell O
clones O
. O

Mutation O
of O
the O
nonconsensus B
- I
150 I
AP I
- I
1 I
site I
to O
a O
consensus B
AP I
- I
1 I
site I
, O
or O
insertion O
of O
a O
CD28RE B
/ I
AP I
- I
1 I
consensus I
site I
upstream O
of O
the O
native O
- B
150 I
CD28RE I
/ I
AP I
- I
1 I
site I
restored O
transactivation O
of O
the O
altered O
promoter B
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B
fibroblast I
growth I
factor I
( O
bFGF B
) O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
, O
when O
cultured O
with O
stem B
cell I
factor I
( O
SCF B
) O
replacing O
bFGF B
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B
fibroblast I
growth I
factor I
( O
bFGF B
) O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
, O
when O
cultured O
with O
stem B
cell I
factor I
( O
SCF B
) O
replacing O
bFGF B
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B
fibroblast I
growth I
factor I
( O
bFGF B
) O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
, O
when O
cultured O
with O
stem B
cell I
factor I
( O
SCF B
) O
replacing O
bFGF B
. O

Those O
cells O
were O
positive O
for O
stem B
cell I
markers I
, O
c B
- I
kit I
and O
CD34 B
, O
and O
a O
myeloid B
cell I
marker I
, I
F4 I
/ I
80 I
. O

Among O
various O
cytokines B
, O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
and O
beta B
- I
major I
globin I
. O

SCF B
and O
IL B
- I
3 I
induced O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
an O
A O
- O
6 O
hematopoietic O
stem O
cell O
line O
. O

Distinct O
BMI B
- I
1 I
and O
EZH2 B
expression O
patterns O
in O
thymocytes O
and O
mature O
T O
cells O
suggest O
a O
role O
for O
Polycomb B
genes I
in O
human O
T O
cell O
differentiation O
. O

BMI B
- I
1 I
and O
EZH2 B
Polycomb B
- I
group I
( I
PcG I
) I
proteins I
belong O
to O
two O
distinct O
protein O
complexes O
involved O
in O
the O
regulation O
of O
hematopoiesis O
. O

By O
contrast O
, O
subcapsular O
immature O
double O
- O
negative O
( O
DN O
) O
( O
CD4 O
( O
- O
) O
/ O
CD8 O
( O
- O
) O
) O
T O
cells O
in O
the O
thymus O
coexpressed O
BMI B
- I
1 I
and O
EZH2 B
or O
were O
BMI O
- O
1 O
single O
positive O
. O

Their O
descendants O
, O
double O
- O
positive O
( O
DP O
; O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
+ O
) O
) O
cortical O
thymocytes O
, O
expressed O
EZH2 B
without O
BMI B
- I
1 I
. O

Maturation O
of O
DP O
cortical O
thymocytes O
to O
single O
- O
positive O
( O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
- O
) O
or O
CD8 O
( O
+ O
) O
/ O
CD4 O
( O
- O
) O
) O
medullar O
thymocytes O
correlated O
with O
decreased O
detectability O
of O
EZH2 B
and O
continued O
relative O
absence O
of O
BMI B
- I
1 I
. O

Our O
data O
show O
that O
BMI B
- I
1 I
and O
EZH2 B
expression O
in O
mature O
peripheral O
T O
cells O
is O
mutually O
exclusive O
and O
linked O
to O
proliferation O
status O
, O
and O
that O
this O
pattern O
is O
not O
yet O
established O
in O
thymocytes O
of O
the O
cortex O
and O
medulla O
. O

Epstein O
- O
Barr O
Virus O
and O
its O
glycoprotein B
- I
350 I
upregulate O
IL B
- I
6 I
in O
human O
B O
- O
lymphocytes O
via O
CD21 B
, O
involving O
activation O
of O
NF B
- I
kappaB I
and O
different O
signaling O
pathways O
. O

EBV O
binds O
to O
CR2 B
through O
its O
major B
envelope I
glycoprotein I
- I
350 I
( O
gp350 B
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O

EBV O
binds O
to O
CR2 B
through O
its O
major B
envelope I
glycoprotein I
- I
350 I
( O
gp350 B
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O

We O
had O
previously O
shown O
that O
EBV O
is O
capable O
of O
modulating O
the O
synthesis O
of O
a O
number O
of O
cytokines B
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant B
gp350 I
( O
rgp350 B
) O
and O
EBV O
upregulate O
IL B
- I
6 I
mRNA I
synthesis O
in O
B O
cells O
, O
EBV O
- O
induced O
IL O
- O
6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i O
. O
e O
. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B
) O
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant B
gp350 I
( O
rgp350 B
) O
and O
EBV O
upregulate O
IL B
- I
6 I
mRNA I
synthesis O
in O
B O
cells O
, O
EBV O
- O
induced O
IL O
- O
6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i O
. O
e O
. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B
) O
. O

Moreover O
, O
the O
half O
- O
life O
of O
EBV O
- O
induced O
IL B
- I
6 I
mRNA I
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA O
induced O
by O
rgp350 B
( O
about O
6 O
hours O
) O
. O

Both O
EBV O
and O
gp350 B
enhance O
the O
binding O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
as O
determined O
by O
band O
- O
shift O
and O
augment O
NF B
- I
kappaB I
- O
mediated O
activation O
of O
a O
CAT B
reporter I
plasmid I
. O

Furthermore O
, O
we O
demonstrate O
that O
while O
the O
activation O
of O
IL O
- O
6 O
gene O
expression O
by O
gp350 B
is O
mediated O
primarily O
by O
the O
protein O
kinase O
C O
pathway O
, O
EBV O
can O
mediate O
its O
effects O
through O
multiple O
signaling O
pathways O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus B
envelope I
glycoprotein I
to O
CR2 B
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
leading O
to O
the O
upregulation O
of O
IL O
- O
6 O
gene O
expression O
in O
these O
lymphocytes O
. O

The O
differences O
between O
N O
- O
OH O
- O
AAF O
mutation O
in O
the O
endogenous B
gene I
and O
transgene B
can O
be O
partially O
explained O
by O
the O
structures O
of O
the O
two O
genes O
. O

Caspase B
- O
dependent O
cleavage O
of O
the O
hematopoietic B
specific I
adaptor I
protein I
Gads I
alters O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
is O
a O
SH2 B
and I
SH3 I
domain I
- O
containing O
, O
hematopoietic B
- I
specific I
adaptor I
protein I
that O
functions O
in O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Here O
we O
demonstrate O
that O
the O
unique O
region O
of O
Gads B
contains O
a O
capase B
cleavage I
site I
. O

Induction O
of O
apoptosis O
in O
lymphocytes O
results O
in O
detectable O
Gads B
cleavage O
by O
60 O
min O
. O

Gads B
cleavage O
is O
blocked O
in O
vivo O
by O
treating O
cells O
with O
a O
caspase O
3 O
inhibitor O
. O

A O
putative B
caspase I
3 I
cleavage I
site I
was O
identified O
within O
the O
unique O
region O
and O
mutation O
of O
this O
site O
prevented O
Gads B
cleavage O
in O
vitro O
, O
and O
in O
vivo O
. O

The O
Gads B
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP B
- I
76 I
and O
LAT B
. O

The O
Gads B
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP B
- I
76 I
and O
LAT B
. O

Expression O
of O
the O
Gads B
cleavage O
products O
in O
Jurkat O
T O
cells O
inhibited O
NFAT O
activation O
following O
TCR O
cross O
linking O
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B
cell I
receptor I
by O
disrupting O
cross O
talk O
between O
SLP B
- I
76 I
and O
LAT B
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B
cell I
receptor I
by O
disrupting O
cross O
talk O
between O
SLP B
- I
76 I
and O
LAT B
. O

Targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
promoter I
via O
CREB O
- O
Rel O
cross O
- O
talk O
during O
mitogen B
and O
oncogenic O
molecular O
signaling O
in O
activated O
T O
- O
cells O
. O

Targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
promoter I
via O
CREB O
- O
Rel O
cross O
- O
talk O
during O
mitogen B
and O
oncogenic O
molecular O
signaling O
in O
activated O
T O
- O
cells O
. O

In O
this O
report O
, O
we O
explore O
the O
mechanisms O
of O
targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
in O
response O
to O
mitogenic O
and O
oncogenic O
molecular O
signals O
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

Mutational O
analysis O
of O
p300 B
reveals O
differential O
structural O
requirements O
for O
the O
N O
- O
terminal O
p300 O
module O
by O
individual O
cis B
- I
elements I
within O
the O
IL B
- I
2 I
promoter I
. O

These O
findings O
provide O
evidence O
that O
p300 B
assembles O
at O
the O
IL B
- I
2 I
promoter I
to O
form O
an O
enhanceosome O
- O
like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE B
- I
TRE I
element I
of O
the O
IL B
- I
2 I
promoter I
through O
specific O
protein O
module O
- O
targeted O
associations O
in O
activated O
T O
- O
cells O
. O

RESULTS O
: O
Cytokine B
- O
driven O
Th2 O
polarization O
of O
naive O
T O
cells O
is O
associated O
with O
marked O
upregulation O
of O
GATA B
- I
3 I
expression O
, O
whereas O
a O
reciprocal O
expression O
pattern O
accompanies O
differentiation O
towards O
the O
Th1 O
cytokine O
phenotype O
. O

The O
HSR O
attenuated O
leukocyte O
infiltration O
into O
CNS O
assessed O
by O
quantitation O
of O
perivascular O
infiltrates O
, O
and O
by O
reduced O
staining O
for O
CD4 B
and O
CD25 B
immunopositive O
T O
- O
cells O
. O

The O
HSR O
attenuated O
leukocyte O
infiltration O
into O
CNS O
assessed O
by O
quantitation O
of O
perivascular O
infiltrates O
, O
and O
by O
reduced O
staining O
for O
CD4 B
and O
CD25 B
immunopositive O
T O
- O
cells O
. O

T O
- O
cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon B
gamma I
( O
IFNgamma B
) O
in O
response O
to O
MOG B
( I
35 I
- I
55 I
) I
, O
was O
also O
decreased O
by O
the O
HSR O
. O

The O
HSR O
reduced O
inflammatory O
gene O
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE O
, O
including O
the O
early O
increase O
in O
RANTES B
( O
regulated B
on I
activation I
of I
normal I
T I
- I
cell I
expressed I
and I
secreted I
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric B
oxide I
synthase I
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
, O
but O
not O
CBFbeta B
- I
smooth I
muscle I
myosin I
heavy I
chain I
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B
- O
deficient O
embryonic O
stem O
cells O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
, O
but O
not O
CBFbeta B
- I
smooth I
muscle I
myosin I
heavy I
chain I
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B
- O
deficient O
embryonic O
stem O
cells O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
is O
the O
non B
- I
DNA I
- I
binding I
subunit I
of O
the O
heterodimeric B
CBFs I
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full B
- I
length I
Cbfb I
transgenes I
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization B
domain I
of O
CBFbeta B
. O

In O
contrast O
, O
the O
CBFbeta B
- O
smooth B
muscle I
myosin I
heavy I
chain I
( I
SMMHC I
) I
fusion I
protein I
generated O
by O
the O
inv B
( I
16 I
) I
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo O
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb O
- O
deficient O
ES O
cells O
. O

Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta B
- O
SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC B
portion I
of O
the O
fusion B
protein I
. O

Results O
also O
show O
that O
the O
CBFbeta B
- I
SMMHC I
fusion I
protein I
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B
or O
Cbfb B
. O

Results O
also O
show O
that O
the O
CBFbeta B
- I
SMMHC I
fusion I
protein I
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B
or O
Cbfb B
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV B
- I
DNA I
, O
EBV B
- I
encoded I
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV B
- I
DNA I
fragments I
containing O
the O
terminal B
repeats I
. O

Oxidized B
low I
density I
lipoprotein I
( O
oxLDL B
) O
is O
inflammatory O
and O
signals O
through O
PPARs B
. O

Oxidized B
low I
density I
lipoprotein I
( O
oxLDL B
) O
is O
inflammatory O
and O
signals O
through O
PPARs B
. O

We O
showed O
, O
by O
phospholipase O
A O
( O
1 O
) O
digestion O
, O
that O
PPARgamma O
agonists O
in O
oxLDL B
arise O
from O
the O
small O
pool O
of O
alkyl O
phosphatidylcholines O
in O
LDL B
. O

We O
showed O
, O
by O
phospholipase O
A O
( O
1 O
) O
digestion O
, O
that O
PPARgamma O
agonists O
in O
oxLDL B
arise O
from O
the O
small O
pool O
of O
alkyl O
phosphatidylcholines O
in O
LDL B
. O

We O
identified O
an O
abundant O
oxidatively O
fragmented O
alkyl O
phospholipid O
in O
oxLDL B
, O
hexadecyl O
azelaoyl O
phosphatidylcholine O
( O
azPC O
) O
, O
as O
a O
high O
affinity O
ligand O
and O
agonist O
for O
PPARgamma B
. O

We O
identified O
an O
abundant O
oxidatively O
fragmented O
alkyl O
phospholipid O
in O
oxLDL B
, O
hexadecyl O
azelaoyl O
phosphatidylcholine O
( O
azPC O
) O
, O
as O
a O
high O
affinity O
ligand O
and O
agonist O
for O
PPARgamma B
. O

Overexpression O
of O
PPARalpha B
or O
PPARgamma B
revealed O
that O
azPC O
was O
a O
specific O
PPARgamma O
agonist O
. O

Overexpression O
of O
PPARalpha B
or O
PPARgamma B
revealed O
that O
azPC O
was O
a O
specific O
PPARgamma O
agonist O
. O

The O
scavenger B
receptor I
CD36 I
is O
encoded O
by O
a O
PPRE B
- I
responsive I
gene I
, O
and O
azPC O
enhanced O
expression O
of O
CD36 B
in O
primary O
human O
monocytes O
. O

Thus O
, O
certain O
alkyl O
phospholipid O
oxidation O
products O
in O
oxLDL B
are O
specific O
, O
high O
affinity O
extracellular O
ligands O
and O
agonists O
for O
PPARgamma B
that O
induce O
PPAR B
- I
responsive I
genes I

Thus O
, O
certain O
alkyl O
phospholipid O
oxidation O
products O
in O
oxLDL B
are O
specific O
, O
high O
affinity O
extracellular O
ligands O
and O
agonists O
for O
PPARgamma B
that O
induce O
PPAR B
- I
responsive I
genes I

Methionine B
adenosyltransferase I
( O
MAT B
) O
catalyzes O
the O
biosynthesis O
of O
S B
- I
adenosylmethionine I
( O
AdoMet B
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

Methionine B
adenosyltransferase I
( O
MAT B
) O
catalyzes O
the O
biosynthesis O
of O
S B
- I
adenosylmethionine I
( O
AdoMet B
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

Down O
- O
regulation O
of O
the O
MAT B
II I
beta I
subunit I
expression O
causes O
a O
6 O
- O
10 O
- O
fold O
increase O
in O
intracellular O
AdoMet B
levels O
. O

To O
understand O
the O
mechanism O
by O
which O
the O
beta B
subunit I
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B
gene I
, O
determined O
its O
organization O
, O
characterized O
its O
5 B
' I
- I
flanking I
sequences I
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter B
. O

The O
inclusion O
of O
sequences O
up O
to O
position O
- O
115 O
provided O
full O
activity O
; O
this O
was O
attributed O
to O
a O
TATA B
at O
- O
32 O
. O

Mutation O
of O
both O
the O
Sp1 B
site I
at O
+ O
9 O
and O
the O
TATA B
at O
- O
32 O
reduced O
promoter O
activity O
to O
its O
minimal O
level O
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti B
- I
Sp1 I
antibody I
on O
complex O
formation O
, O
whereas O
the O
anti B
- I
Sp3 I
antibody I
had O
a O
strong O
effect O
on O
protein O
. O
DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 B
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 B
site I
. O

Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 B
and O
Sp3 B
in O
complexes O
formed O
on O
the O
MAT2B B
promoter I
. O

Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 B
and O
Sp3 B
in O
complexes O
formed O
on O
the O
MAT2B B
promoter I
. O

The O
data O
show O
that O
the O
5 B
' I
- I
untranslated I
sequences I
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B
gene I
and O
identifies O
the O
Sp1 B
site I
at O
+ O
9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet B
levels O
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
STAT B
and O
IRF B
signal I
transducing I
molecules I
in O
influenza O
A O
virus O
- O
infected O
cells O
. O

Expression O
of O
Mad1 B
in O
T O
cells O
leads O
to O
reduced O
thymic O
cellularity O
and O
impaired O
mitogen O
- O
induced O
proliferation O
. O

To O
investigate O
Mad1 B
function O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
that O
express O
a O
Mad1 B
transgene I
in O
T O
lineage O
cells O
under O
the O
control O
of O
the O
proximal B
lck I
promoter I
. O

The O
growth O
inhibition O
caused O
by O
Mad1 B
is O
overcome O
by O
expression O
of O
active B
c I
- I
Myc I
. O

We O
used O
several O
agents O
active O
on O
signal O
transduction O
pathways O
in O
cytokine O
expression O
, O
such O
as O
the O
protein O
kinase O
C O
inhibitor O
staurosporin O
, O
antioxidant O
agents O
including O
N O
- O
acetyl O
cysteine O
( O
NAC O
) O
and O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
inhibitor O
SB203580 O
. O

Benzene O
- O
extracted O
components O
showed O
effects O
mimicking O
DEPs O
on O
IL O
- O
8 O
gene O
expression O
, O
release O
of O
several O
cytokines B
( O
IL B
- I
8 I
; O
granulocyte B
macrophage I
colony I
- I
stimulating I
factor I
; O
and O
regulated O
on O
activation O
, O
normal O
T O
cells O
expressed O
and O
secreted O
) O
and O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
activation O
. O

We O
also O
found O
that O
NAC O
, O
PDTC O
, O
and O
SB203580 O
suppressed O
the O
activities O
of O
DEPs O
and O
their O
benzene O
extracts O
, O
suggesting O
the O
roles O
of O
oxidants O
- O
mediated O
NF O
- O
kappa O
B O
activation O
and O
p38MAPK B
pathways O
. O

Activation O
of O
NF B
- I
kappaB I
and O
production O
of O
NF B
- I
kappaB I
- O
dependent O
chemokines B
are O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
neutrophilic O
lung O
inflammation O
. O

Notch1 B
regulates O
maturation O
of O
CD4 O
+ O
and O
CD8 O
+ O
thymocytes O
by O
modulating O
TCR O
signal O
strength O
. O

We O
demonstrate O
in O
this O
report O
that O
retroviral O
expression O
of O
activated O
Notch1 B
in O
mouse O
thymocytes O
abrogates O
differentiation O
of O
immature O
CD4 O
+ O
CD8 O
+ O
thymocytes O
into O
both O
CD4 O
and O
CD8 O
mature O
single O
- O
positive O
T O
cells O
. O

The O
ability O
of O
Notch1 B
to O
inhibit O
T O
cell O
development O
was O
observed O
in O
vitro O
and O
in O
vivo O
with O
both O
normal O
and O
TCR O
transgenic O
thymocytes O
. O

Notch1 B
- O
mediated O
developmental O
arrest O
was O
dose O
dependent O
and O
was O
associated O
with O
impaired O
thymocyte O
responses O
to O
TCR O
stimulation O
. O

Notch1 B
also O
inhibited O
TCR O
- O
mediated O
signaling O
in O
Jurkat O
T O
cells O
. O

These O
data O
indicate O
that O
constitutively O
active O
Notch1 B
abrogates O
CD4 O
+ O
and O
CD8 O
+ O
maturation O
by O
interfering O
with O
TCR O
signal O
strength O
and O
provide O
an O
explanation O
for O
the O
physiological O
regulation O
of O
Notch O
expression O
during O
thymocyte O
development O
. O

Consistent O
with O
this O
biologic O
function O
, O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
Rta B
protein I
powerfully O
stimulates O
the O
promoter B
of O
its O
own O
gene O
, O
Rp B
, O
in O
EBV O
- O
positive O
B O
cells O
in O
transient O
- O
transfection O
reporter O
- O
based O
assays O
. O

Consistent O
with O
this O
biologic O
function O
, O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
Rta B
protein I
powerfully O
stimulates O
the O
promoter B
of O
its O
own O
gene O
, O
Rp B
, O
in O
EBV O
- O
positive O
B O
cells O
in O
transient O
- O
transfection O
reporter O
- O
based O
assays O
. O

We O
analyzed O
the O
activity O
of O
RpCAT B
in O
response O
to O
Rta B
by O
deletional O
and O
site O
- O
directed O
mutagenesis O
. O

We O
analyzed O
the O
activity O
of O
RpCAT B
in O
response O
to O
Rta B
by O
deletional O
and O
site O
- O
directed O
mutagenesis O
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B
factor I
Zif268 I
and O
the O
viral B
transactivator I
ZEBRA I
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B
by O
Rta B
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B
factor I
Zif268 I
and O
the O
viral B
transactivator I
ZEBRA I
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B
by O
Rta B
. O

Gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 B
and O
Sp3 B
as O
the O
predominant O
cellular B
proteins I
bound O
to O
Rp B
near O
- O
45 O
. O

Gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 B
and O
Sp3 B
as O
the O
predominant O
cellular B
proteins I
bound O
to O
Rp B
near O
- O
45 O
. O

Gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 B
and O
Sp3 B
as O
the O
predominant O
cellular B
proteins I
bound O
to O
Rp B
near O
- O
45 O
. O

During O
the O
lytic O
cycle O
, O
ZEBRA B
bound O
Rp B
near O
the O
Sp1 B
/ I
Sp3 I
site I
. O

During O
the O
lytic O
cycle O
, O
ZEBRA B
bound O
Rp B
near O
the O
Sp1 B
/ I
Sp3 I
site I
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 B
and O
Sp3 B
transcription B
factors I
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B
promoter I
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 B
and O
Sp3 B
transcription B
factors I
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B
promoter I
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

Here O
, O
we O
demonstrate O
that O
engineered O
down O
- O
regulation O
of O
HIF B
- I
1alpha I
by O
intratumoral O
gene O
transfer O
of O
an O
antisense B
HIF I
- I
1alpha I
plasmid I
leads O
to O
the O
down O
- O
regulation O
of O
VEGF B
, O
and O
decreased O
tumor O
microvessel O
density O
. O

Runx2 B
: O
a O
novel O
oncogenic O
effector O
revealed O
by O
in O
vivo O
complementation O
and O
retroviral O
tagging O
. O

The O
Runx2 B
( O
Cbfa1 B
, O
Pebp2alphaA B
, O
Aml3 B
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T O
- O
cell O
lymphomas O
of O
CD2 O
- O
MYC O
transgenic O
mice O
. O

The O
Runx2 B
( O
Cbfa1 B
, O
Pebp2alphaA B
, O
Aml3 B
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T O
- O
cell O
lymphomas O
of O
CD2 O
- O
MYC O
transgenic O
mice O
. O

The O
Runx2 B
( O
Cbfa1 B
, O
Pebp2alphaA B
, O
Aml3 B
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T O
- O
cell O
lymphomas O
of O
CD2 O
- O
MYC O
transgenic O
mice O
. O

The O
Runx2 B
( O
Cbfa1 B
, O
Pebp2alphaA B
, O
Aml3 B
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T O
- O
cell O
lymphomas O
of O
CD2 O
- O
MYC O
transgenic O
mice O
. O

We O
have O
recently O
shown O
that O
over O
- O
expression O
of O
the O
full O
- O
length O
, O
most O
highly O
expressed O
Runx2 B
isoform O
in O
the O
thymus O
perturbs O
T O
- O
cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc B
. O

We O
have O
recently O
shown O
that O
over O
- O
expression O
of O
the O
full O
- O
length O
, O
most O
highly O
expressed O
Runx2 B
isoform O
in O
the O
thymus O
perturbs O
T O
- O
cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc B
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

However O
, O
Runx2 B
appeared O
to O
have O
a O
dominant O
effect O
on O
the O
tumour O
phenotype O
in O
each O
case O
, O
with O
most O
tumours O
conforming O
to O
the O
CD3 O
( O
+ O
) O
, O
CD8 O
( O
+ O
) O
, O
CD4 O
( O
+ O
/ O
- O
) O
phenotype O
seen O
in O
CD2 O
- O
Runx2 O
mice O
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

These O
results O
indicate O
that O
Runx2 B
makes O
a O
distinct O
contribution O
to O
T O
- O
cell O
lymphoma O
development O
which O
does O
not O
coincide O
with O
any O
of O
the O
oncogene O
complementation O
groups O
previously O
identified O
by O
retroviral O
tagging O
. O

However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 B
with O
specific O
monoclonal B
antibodies I
. O

Interestingly O
, O
we O
demonstrated O
that O
stimulation O
by O
tumor O
cells O
was O
required O
to O
trigger O
the O
inhibitory O
effect O
of O
p58 B
on O
the O
lytic O
activity O
of O
antigen O
- O
specific O
CTLs O
and O
that O
stimulation O
of O
the O
inhibitory O
function O
of O
p58 B
by O
tumor O
cells O
correlated O
with O
an O
inhibition O
of O
nuclear O
factor O
- O
kappaB O
activation O
in O
p58 O
+ O
tumor O
- O
specific O
CTLS O
. O

Interestingly O
, O
we O
demonstrated O
that O
stimulation O
by O
tumor O
cells O
was O
required O
to O
trigger O
the O
inhibitory O
effect O
of O
p58 B
on O
the O
lytic O
activity O
of O
antigen O
- O
specific O
CTLs O
and O
that O
stimulation O
of O
the O
inhibitory O
function O
of O
p58 B
by O
tumor O
cells O
correlated O
with O
an O
inhibition O
of O
nuclear O
factor O
- O
kappaB O
activation O
in O
p58 O
+ O
tumor O
- O
specific O
CTLS O
. O

Culture O
with O
the O
murine O
fetal O
liver O
cell O
line O
AFT024 O
and O
defined O
cytokines B
was O
capable O
of O
inducing O
TCF B
- I
1 I
mRNA I
. O

The O
TCF B
- I
1 I
isoform I
found O
in O
CD56 O
( O
+ O
bright O
) O
cells O
, O
which O
express O
lectin B
but O
not O
immunoglobulin B
class I
I I
recognizing O
inhibitory B
receptors I
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

contextual O
requirements O
for O
the O
function O
of O
bright B
. O

Bright B
( O
B B
cell I
regulator I
of I
IgH I
transcription I
) O
is O
a O
B O
cell O
- O
specific O
, O
matrix B
associating I
region I
- I
binding I
protein I
that O
transactivates O
gene O
expression O
from O
the O
IgH B
intronic I
enhancer I
( O
E B
mu I
) O
. O

We O
show O
here O
that O
Bright B
has O
multiple O
contextual O
requirements O
to O
function O
as O
a O
transcriptional B
activator I
. O

Bright B
can O
not O
transactivate O
via O
out O
of O
context O
, O
concatenated B
binding I
sites I
. O

Two O
of O
the O
three O
previously O
identified O
binding B
sites I
in O
E B
mu I
are O
required O
for O
full O
Bright B
transactivation O
. O

The O
Bright B
DNA I
binding I
domain I
defined O
a O
new O
family O
, O
which O
includes O
SWI1 B
, O
a O
component O
of O
the O
SWI B
. I
SNF I
complex I
shown O
to O
have O
high O
mobility O
group O
- O
like O
DNA O
binding O
characteristics O
. O

Similar O
to O
one O
group O
of O
high B
mobility I
group I
box I
proteins I
, O
Bright B
distorts O
E B
mu I
binding I
site I
- O
containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E B
mu I
remodeling O
. O

Transfection O
studies O
further O
implicate O
Bright B
in O
facilitating O
spatially O
separated O
promoter O
- O
enhancer O
interactions O
in O
both O
transient O
and O
stable O
assays O
. O

Finally O
, O
we O
show O
that O
overexpression O
of O
Bright B
leads O
to O
enhanced O
DNase O
I O
sensitivity O
of O
the O
endogenous O
E B
mu I
matrix O
associating O
regions O
. O

These O
data O
further O
suggest O
that O
Bright B
may O
contribute O
to O
increased O
gene O
expression O
by O
remodeling O
the O
immunoglobulin B
locus I
during O
B O
cell O
development O
. O

Gadd45gamma B
is O
dispensable O
for O
normal O
mouse O
development O
and O
T O
- O
cell O
proliferation O
. O

Gadd45gamma B
, O
a O
family O
member O
of O
the O
growth B
arrest I
and I
DNA I
damage I
- I
inducible I
gene I
family I
45 I
( O
Gadd45 B
) O
, O
is O
strongly O
induced O
by O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
peripheral O
T O
cells O
. O

Gadd45gamma B
, O
a O
family O
member O
of O
the O
growth B
arrest I
and I
DNA I
damage I
- I
inducible I
gene I
family I
45 I
( O
Gadd45 B
) O
, O
is O
strongly O
induced O
by O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
peripheral O
T O
cells O
. O

While O
in O
most O
tissues O
all O
Gadd45 B
family I
members I
are O
expressed O
, O
Gadd45gamma B
is O
the O
only O
member O
that O
is O
induced O
by O
IL B
- I
2 I
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Previous O
studies O
with O
ectopically O
overexpressed O
Gadd45gamma B
in O
various O
cell O
lines O
implicated O
its O
function O
in O
negative O
growth O
control O
. O

To O
analyze O
the O
physiological O
role O
of O
Gadd45gamma B
we O
used O
homologous O
recombination O
to O
generate O
mice O
lacking O
Gadd45gamma B
. O

To O
analyze O
the O
physiological O
role O
of O
Gadd45gamma B
we O
used O
homologous O
recombination O
to O
generate O
mice O
lacking O
Gadd45gamma B
. O

Gadd45gamma B
- O
deficient O
mice O
develop O
normally O
, O
are O
indistinguishable O
from O
their O
littermates O
, O
and O
are O
fertile O
. O

Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma B
is O
not O
impaired O
and O
Gadd45gamma B
- O
deficient O
T O
lymphocytes O
show O
normal O
responses O
to O
IL B
- I
2 I
. O

Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma B
is O
not O
impaired O
and O
Gadd45gamma B
- O
deficient O
T O
lymphocytes O
show O
normal O
responses O
to O
IL B
- I
2 I
. O

These O
data O
demonstrate O
that O
Gadd45gamma B
is O
not O
essential O
for O
normal O
mouse O
development O
and O
hematopoiesis O
, O
possibly O
due O
to O
functional O
redundancy O
among O
the O
Gadd45 B
family I
members I
. O

Gadd45gamma B
is O
also O
dispensable O
for O
IL B
- I
2 I
- O
induced O
T O
- O
cell O
proliferation O
. O

We O
studied O
the O
expression O
of O
apoptosis O
- O
associated O
genes O
, O
bcl B
- I
xL I
, O
bad B
, O
caspase B
- I
3 I
, O
and O
c B
- I
myc I
family I
genes I
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

We O
observed O
that O
the O
mRNA O
levels O
of O
myc B
family I
genes I
, O
c B
- I
myc I
and O
max B
, O
were O
markedly O
reduced O
in O
MG O
thymuses O
. O

The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc B
, O
such O
as O
STAM B
, O
prothymosin B
- I
alpha I
, O
and O
NFkappaB B

The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc B
, O
such O
as O
STAM B
, O
prothymosin B
- I
alpha I
, O
and O
NFkappaB B

Skin O
lesions O
of O
dermatophytosis O
are O
thought O
to O
be O
a O
result O
of O
a O
T O
cell O
- O
dependent O
inflammatory O
response O
that O
is O
mediated O
by O
various O
cytokines B
. O

Skin O
lesions O
of O
dermatophytosis O
are O
thought O
to O
be O
a O
result O
of O
a O
T O
cell O
- O
dependent O
inflammatory O
response O
that O
is O
mediated O
by O
various O
cytokines B
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

Activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathways O
leads O
to O
cellular O
differentiation O
and O
/ O
or O
proliferation O
in O
a O
wide O
variety O
of O
cell O
types O
, O
including O
developing O
thymocytes O
. O

The O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
proteins I
E12 B
and O
E47 B
and O
an O
inhibitor B
HLH I
protein I
, O
Id3 B
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

The O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
proteins I
E12 B
and O
E47 B
and O
an O
inhibitor B
HLH I
protein I
, O
Id3 B
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

The O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
proteins I
E12 B
and O
E47 B
and O
an O
inhibitor B
HLH I
protein I
, O
Id3 B
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

We O
show O
here O
that O
E2A B
DNA O
binding O
is O
lowered O
in O
primary O
immature O
thymocytes O
consequent O
to O
T O
cell O
receptor O
( O
TCR O
) O
- O
mediated O
ligation O
. O

Whereas O
expression O
of O
E2A O
mRNA O
and O
protein O
are O
unaltered O
, O
Id3 B
transcripts I
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR B
. O

Activation O
of O
Id3 O
transcription O
is O
regulated O
in O
a O
dose O
- O
dependent O
manner O
by O
the O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK B
) O
MAPK B
module O
. O

Activation O
of O
Id3 O
transcription O
is O
regulated O
in O
a O
dose O
- O
dependent O
manner O
by O
the O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK B
) O
MAPK B
module O
. O

These O
observations O
directly O
connect O
the O
ERK B
MAPK B
cascade O
and O
HLH B
proteins I
in O
a O
linear O
pathway O
. O

These O
observations O
directly O
connect O
the O
ERK B
MAPK B
cascade O
and O
HLH B
proteins I
in O
a O
linear O
pathway O
. O

CD28 B
and O
T O
cell O
co O
- O
stimulation O
. O

Focusing O
on O
recent O
advances O
in O
our O
understanding O
of O
CD28 B
, O
we O
discuss O
four O
areas O
of O
T O
cell O
activation O
where O
co O
- O
stimulation O
may O
play O
a O
role O
. O

We O
previously O
reported O
that O
ER O
- O
27191 O
( O
4 O
- O
[ O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
hexahydro O
- O
7 O
, O
7 O
, O
10 O
, O
10 O
- O
tetramethyl O
- O
1 O
- O
( O
3 O
- O
pyridylmethyl O
) O
anthra O
[ O
1 O
, O
2 O
- O
b O
] O
pyrrol O
- O
3 O
- O
yl O
] O
benzoic O
acid O
) O
is O
a O
potent O
antagonist O
of O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
ER O
- O
35795 O
( O
( O
2E O
, O
4E O
, O
6E O
) O
- O
7 O
- O
[ O
1 O
- O
( O
1 O
- O
methylethyl O
) O
- O

8 O
- O
chloro O
- O
1 O
, O
2 O
, O
3 O
, O
4 O
- O
tetrahydroquinolin O
- O
6 O
- O
yl O
] O
- O
6 O
- O
fluoro O
- O
3 O
- O
methyl O
- O
2 O
, O
4 O
, O
6 O
- O
nonatrienoic O
acid O
) O
is O
a O
novel O
retinoid B
X I
receptor I
( O
RXR B
) O
- O
specific O
agonist O
. O

By O
using O
these O
compounds O
, O
we O
investigated O
whether O
distinct O
RAR B
- O
dependent O
and O
RXR B
- O
dependent O
pathways O
operate O
to O
mediate O
the O
diverse O
activities O
of O
retinoids O
, O
particularly O
, O
the O
effects O
of O
the O
RXR B
pathway O
on O
cellular O
function O
. O

By O
using O
these O
compounds O
, O
we O
investigated O
whether O
distinct O
RAR B
- O
dependent O
and O
RXR B
- O
dependent O
pathways O
operate O
to O
mediate O
the O
diverse O
activities O
of O
retinoids O
, O
particularly O
, O
the O
effects O
of O
the O
RXR B
pathway O
on O
cellular O
function O
. O

By O
using O
these O
compounds O
, O
we O
investigated O
whether O
distinct O
RAR B
- O
dependent O
and O
RXR B
- O
dependent O
pathways O
operate O
to O
mediate O
the O
diverse O
activities O
of O
retinoids O
, O
particularly O
, O
the O
effects O
of O
the O
RXR B
pathway O
on O
cellular O
function O
. O

However O
, O
the O
differentiation O
induced O
by O
the O
ER O
- O
35795 O
was O
not O
antagonized O
at O
all O
by O
the O
RAR B
antagonist O
, O
but O
was O
inhibited O
by O
an O
RXR B
homodimer I
antagonist O
( O
LGD100754 O
, O
( O
2E O
, O
4E O
, O
6Z O
) O
- O
7 O
- O
( O
3 O
- O
n O
- O
propoxy O
- O
5 O
, O
6 O
, O
7 O
, O
8 O
- O
tetrahydro O
- O
5 O
, O
5 O
, O
8 O
, O
8 O
- O
tetramethylnaphthale O
- O
2 O
- O
yl O
) O
- O
3 O
- O
methylocta O
- O
2 O
, O
4 O
, O
6 O
- O
trienoic O
acid O
) O

Its O
agonistic O
action O
on O
RXR B
/ I
RAR I
heterodimer I
, O
on O
the O
other O
hand O
, O
was O
neutralized O
by O
the O
RAR B
antagonist O
. O

During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta B
mRNA I
, O
while O
the O
RXR B
had O
no O
effect O
. O

Interestingly O
, O
a O
functional O
RXR B
- O
pathway O
was O
also O
seen O
in O
lipopolysaccharide O
- O
induced O
inhibition O
of O
mouse O
splenocyte O
proliferation O
. O

These O
results O
strongly O
suggest O
the O
existence O
of O
a O
pharmacological O
RXR B
- O
dependent O
pathway O
that O
is O
activated O
by O
a O
ligand O
that O
can O
bind O
to O
RXR B
. O

These O
results O
strongly O
suggest O
the O
existence O
of O
a O
pharmacological O
RXR B
- O
dependent O
pathway O
that O
is O
activated O
by O
a O
ligand O
that O
can O
bind O
to O
RXR B
. O

Targeting O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP B
- I
1 I
) O
into O
lipid O
rafts O
inhibits O
CD3 B
- O
induced O
T O
cell O
activation O
. O

To O
study O
the O
mechanism O
by O
which O
protein B
tyrosine I
phosphatases I
( O
PTPs B
) O
regulate O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B
in O
subdomains O
of O
plasma O
membrane O
. O

To O
study O
the O
mechanism O
by O
which O
protein B
tyrosine I
phosphatases I
( O
PTPs B
) O
regulate O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B
in O
subdomains O
of O
plasma O
membrane O
. O

To O
study O
the O
mechanism O
by O
which O
protein B
tyrosine I
phosphatases I
( O
PTPs B
) O
regulate O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B
in O
subdomains O
of O
plasma O
membrane O
. O

We O
report O
here O
that O
the O
bulk O
PTP B
activity O
associated O
with O
T O
cell O
membrane O
is O
present O
outside O
the O
lipid O
rafts O
, O
as O
determined O
by O
sucrose O
density O
gradient O
sedimentation O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

We O
further O
demonstrated O
that O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs B
are O
inhibited O
. O

We O
further O
demonstrated O
that O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs B
are O
inhibited O
. O

It O
suggests O
that O
a O
restricted O
partition O
of O
PTPs B
among O
membrane O
subdomains O
may O
regulate O
protein O
tyrosine O
phosphorylation O
in O
T O
cell O
membrane O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck B
/ I
SHP I
- I
1 I
chimera I
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
CD3 B
zeta I
/ I
epsilon I
, O
IL O
- O
2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF B
- I
AT I
. O

Collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs B
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR B
/ O
CD3 B
activation O

Collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs B
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR B
/ O
CD3 B
activation O

Collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs B
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR B
/ O
CD3 B
activation O

Although O
interleukin B
( I
IL I
) I
- I
12 I
and O
IL B
- I
4 I
polarize O
naive O
CD4 O
( O
+ O
) O
T O
cells O
toward O
T O
helper O
cell O
type O
1 O
( O
Th1 O
) O
or O
Th2 O
phenotypes O
, O
it O
is O
not O
known O
whether O
cytokines B
instruct O
the O
developmental O
fate O
in O
uncommitted O
progenitors O
or O
select O
for O
outgrowth O
of O
cells O
that O
have O
stochastically O
committed O
to O
a O
particular O
fate O
. O

We O
have O
shown O
that O
estrogen B
receptor I
( O
ERalpha B
, O
ERbeta B
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

We O
have O
shown O
that O
estrogen B
receptor I
( O
ERalpha B
, O
ERbeta B
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

In O
this O
study O
, O
T O
cell O
nuclear O
extracts O
from O
female O
lupus O
patients O
and O
normal O
donors O
were O
tested O
for O
biologically O
active O
ER B
proteins I
capable O
of O
binding O
to O
the O
human B
estrogen I
response I
element I
( O
hERE B
) O
by O
electrophoretic O
mobility O
shift O
assays O
. O

Monocytes O
are O
extremely O
important O
cells O
for O
regulating O
the O
cytokine O
network O
and O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
and O
interleukin B
- I
( I
IL I
) I
10 I
, O
which O
are O
mainly O
synthesized O
by O
monocytes O
, O
are O
representative O
cytokines B
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O

Monocytes O
are O
extremely O
important O
cells O
for O
regulating O
the O
cytokine O
network O
and O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
and O
interleukin B
- I
( I
IL I
) I
10 I
, O
which O
are O
mainly O
synthesized O
by O
monocytes O
, O
are O
representative O
cytokines B
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O

The O
value O
of O
TNFalpha B
and O
IL B
- I
10 I
in O
the O
culture O
medium O
of O
monocytes O
was O
measured O
and O
each O
mRNA O
expression O
was O
assayed O
. O

The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein B
kinase I
C I
( O
PKC B
) O
and O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
were O
also O
evaluated O
. O

The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein B
kinase I
C I
( O
PKC B
) O
and O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
were O
also O
evaluated O
. O

GM O
decreased O
the O
TNFalpha B
production O
of O
LPS O
- O
stimulated O
monocytes O
as O
shown O
by O
the O
inhibition O
of O
mRNA O
expression O
and O
increased O
the O
IL B
- I
10 I
production O
of O
LPS O
- O
stimulated O
monocytes O
. O

GM O
also O
suppressed O
the O
NFkappaB B
activity O
of O
LPS O
- O
stimulated O
monocytes O
. O

UTI O
decreased O
the O
TNFalpha B
production O
of O
LPS O
- O
stimulated O
monocytes O
, O
but O
did O
not O
inhibit O
the O
TNFalpha B
mRNA I
expression O
. O

The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM O
on O
the O
TNFalpha B
production O
of O
activated O
human O
monocytes O
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B
activation O
, O
while O
the O
mechanism O
of O
UTI O
inhibiting O
TNFalpha B
production O
of O
human O
monocytes O
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha B
. O

The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM O
on O
the O
TNFalpha B
production O
of O
activated O
human O
monocytes O
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B
activation O
, O
while O
the O
mechanism O
of O
UTI O
inhibiting O
TNFalpha B
production O
of O
human O
monocytes O
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha B
. O

The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM O
on O
the O
TNFalpha B
production O
of O
activated O
human O
monocytes O
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B
activation O
, O
while O
the O
mechanism O
of O
UTI O
inhibiting O
TNFalpha B
production O
of O
human O
monocytes O
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha B
. O

The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM O
on O
the O
TNFalpha B
production O
of O
activated O
human O
monocytes O
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B
activation O
, O
while O
the O
mechanism O
of O
UTI O
inhibiting O
TNFalpha B
production O
of O
human O
monocytes O
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha B
. O

Monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
is O
a O
potent O
chemokine B
that O
stimulates O
the O
migration O
of O
monocytes O
into O
the O
intima O
of O
the O
arterial O
wall O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 B
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 B
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Surface B
immunoglobulin I
and O
IL B
- I
4R I
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B
- O
resistance O
that O
differentially O
depend O
on O
PKC B
and O
STAT6 B
, O
respectively O
. O

Surface B
immunoglobulin I
and O
IL B
- I
4R I
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B
- O
resistance O
that O
differentially O
depend O
on O
PKC B
and O
STAT6 B
, O
respectively O
. O

Surface B
immunoglobulin I
and O
IL B
- I
4R I
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B
- O
resistance O
that O
differentially O
depend O
on O
PKC B
and O
STAT6 B
, O
respectively O
. O

Further O
, O
surface O
immunoglobulin O
signaling O
for O
inducible O
Fas B
- O
resistance O
bypasses O
Btk B
, O
requires O
NF B
- I
kappaB I
, O
and O
entails O
new O
macromolecular O
synthesis O
. O

Further O
, O
surface O
immunoglobulin O
signaling O
for O
inducible O
Fas B
- O
resistance O
bypasses O
Btk B
, O
requires O
NF B
- I
kappaB I
, O
and O
entails O
new O
macromolecular O
synthesis O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

faim B
was O
identified O
by O
differential O
display O
and O
exists O
in O
two O
alternatively O
spliced O
forms O
; O
faim B
- I
S I
is O
broadly O
expressed O
, O
but O
faim O
- O
L O
expression O
is O
tissue O
- O
specific O
. O

Inducible O
resistance O
to O
Fas B
killing O
is O
hypothesized O
to O
protect O
foreign O
antigen O
- O
specific O
B O
cells O
during O
potentially O
hazardous O
interactions O
with O
FasL O
- O
bearing O
T O
cells O
, O
whereas O
autoreactive O
B O
cells O
fail O
to O
become O
Fas B
- O
resistant O
and O
are O
deleted O
via O
Fas B
- O
dependent O
cytotoxicity O
. O

Inducible O
resistance O
to O
Fas B
killing O
is O
hypothesized O
to O
protect O
foreign O
antigen O
- O
specific O
B O
cells O
during O
potentially O
hazardous O
interactions O
with O
FasL O
- O
bearing O
T O
cells O
, O
whereas O
autoreactive O
B O
cells O
fail O
to O
become O
Fas B
- O
resistant O
and O
are O
deleted O
via O
Fas B
- O
dependent O
cytotoxicity O
. O

Inducible O
resistance O
to O
Fas B
killing O
is O
hypothesized O
to O
protect O
foreign O
antigen O
- O
specific O
B O
cells O
during O
potentially O
hazardous O
interactions O
with O
FasL O
- O
bearing O
T O
cells O
, O
whereas O
autoreactive O
B O
cells O
fail O
to O
become O
Fas B
- O
resistant O
and O
are O
deleted O
via O
Fas B
- O
dependent O
cytotoxicity O
. O

Inadvertent O
or O
aberrant O
acquisition O
of O
Fas B
- O
resistance O
may O
permit O
autoreactive O
B O
cells O
to O
escape O
Fas B
deletion O
, O
and O
malignant O
lymphocytes O
to O
impede O
anti O
- O
tumor O
immunity O
. O

Inadvertent O
or O
aberrant O
acquisition O
of O
Fas B
- O
resistance O
may O
permit O
autoreactive O
B O
cells O
to O
escape O
Fas B
deletion O
, O
and O
malignant O
lymphocytes O
to O
impede O
anti O
- O
tumor O
immunity O
. O

AKT B
, O
which O
has O
been O
shown O
to O
mediate O
NO O
production O
, O
was O
also O
phosphorylated O
upon O
SDF1 B
alpha I
stimulation O
. O

Lack O
of O
NF B
- I
kappa I
B I
induction O
correlated O
with O
increased O
death O
in O
response O
to O
antigen B
. O

In O
contrast O
, O
we O
found O
a O
complete O
lack O
of O
constitutive O
expression O
of O
the O
epsilon B
isoform I
of I
Protein I
Kinase I
C I
( O
PKC B
) O
in O
DP O
thymocytes O
, O
although O
it O
was O
present O
in O
mature O
thymocytes O
and O
peripheral O
T O
cells O
. O

CD2 O
stimulation O
leads O
to O
the O
delayed O
and O
prolonged O
activation O
of O
STAT1 B
in O
T O
cells O
but O
not O
NK O
cells O
. O

OBJECTIVE O
: O
T O
lymphocytes O
can O
be O
activated O
by O
soluble O
factors O
such O
as O
cytokines B
or O
through O
direct O
cell O
- O
cell O
interactions O
. O

Although O
cytokine B
receptors I
are O
known O
to O
signal O
through O
STAT B
family I
transcription I
factors I
, O
the O
mechanisms O
by O
which O
other O
cell B
- I
surface I
molecules I
, O
such O
as O
CD2 B
, O
transduce O
signals O
is O
unclear O
. O

The O
goal O
of O
this O
study O
was O
to O
determine O
whether O
stimulation O
of O
T O
cells O
through O
CD2 B
recapitulates O
aspects O
of O
cytokine B
- O
induced O
T O
- O
cell O
activation O
by O
use O
of O
STAT B
transcription I
factors I
. O

The O
goal O
of O
this O
study O
was O
to O
determine O
whether O
stimulation O
of O
T O
cells O
through O
CD2 B
recapitulates O
aspects O
of O
cytokine B
- O
induced O
T O
- O
cell O
activation O
by O
use O
of O
STAT B
transcription I
factors I
. O

RESULTS O
: O
Stimulation O
of O
CD2 B
on O
primary O
T O
lymphocytes O
leads O
to O
the O
tyrosine O
phosphorylation O
, O
nuclear O
translocation O
, O
and O
DNA O
binding O
of O
STAT1 B
. O

RESULTS O
: O
Stimulation O
of O
CD2 B
on O
primary O
T O
lymphocytes O
leads O
to O
the O
tyrosine O
phosphorylation O
, O
nuclear O
translocation O
, O
and O
DNA O
binding O
of O
STAT1 B
. O

In O
contrast O
to O
stimulation O
by O
cytokines B
, O
the O
activation O
of O
STAT1 B
in O
response O
to O
CD2 O
ligation O
is O
delayed O
and O
does O
not O
involve O
Jak B
kinases I
. O

In O
contrast O
to O
stimulation O
by O
cytokines B
, O
the O
activation O
of O
STAT1 B
in O
response O
to O
CD2 O
ligation O
is O
delayed O
and O
does O
not O
involve O
Jak B
kinases I
. O

Furthermore O
, O
while O
STAT O
phosphorylation O
induced O
by O
cytokines B
is O
generally O
transient O
, O
STAT1 O
phosphorylation O
following O
CD2 O
stimulation O
persists O
for O
a O
period O
of O
days O
. O

Transcription O
of O
key O
target O
genes O
such O
as O
IRF1 B
and O
c B
- I
fos I
proceeds O
with O
delayed O
kinetics O
following O
CD2 O
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT O
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 O
ligation O
. O

This O
pathway O
appears O
to O
be O
restricted O
to O
T O
cells O
, O
as O
stimulation O
of O
CD2 B
on O
NK O
cells O
does O
not O
lead O
to O
STAT1 O
activation O
. O

CONCLUSION O
: O
Stimulation O
of O
T O
cells O
through O
cell B
- I
surface I
molecules I
such O
as O
CD2 B
involves O
activation O
of O
STAT B
transcription I
factors I
, O
thus O
recapitulating O
elements O
of O
cytokine O
signaling O
. O

NFATc1 B
and O
NFATc2 B
together O
control O
both O
T O
and O
B O
cell O
activation O
and O
differentiation O
. O

NFATc1 B
and O
NFATc2 B
together O
control O
both O
T O
and O
B O
cell O
activation O
and O
differentiation O
. O

To O
investigate O
further O
the O
two O
most O
prominent O
NFAT B
family I
members I
, O
NFATc1 B
and O
NFATc2 B
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O

To O
investigate O
further O
the O
two O
most O
prominent O
NFAT B
family I
members I
, O
NFATc1 B
and O
NFATc2 B
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O

Nevertheless O
, O
doubly O
deficient O
B O
cells O
were O
hyperactivated O
, O
as O
evidenced O
by O
extremely O
elevated O
serum O
IgG1 B
and O
IgE B
, O
as O
well O
as O
plasma O
cell O
expansion O
and O
infiltration O
of O
end O
organs O
. O

Nevertheless O
, O
doubly O
deficient O
B O
cells O
were O
hyperactivated O
, O
as O
evidenced O
by O
extremely O
elevated O
serum O
IgG1 B
and O
IgE B
, O
as O
well O
as O
plasma O
cell O
expansion O
and O
infiltration O
of O
end O
organs O
. O

Thus O
, O
in O
T O
cells O
, O
NFATc1 B
and O
NFATc2 B
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B O
cells O
, O
NFATs B
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O

Thus O
, O
in O
T O
cells O
, O
NFATc1 B
and O
NFATc2 B
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B O
cells O
, O
NFATs B
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O

Thus O
, O
in O
T O
cells O
, O
NFATc1 B
and O
NFATc2 B
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B O
cells O
, O
NFATs B
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O

The O
PML B
protein I
is O
induced O
by O
interferon B
, O
involved O
in O
major B
histocompatibility I
complex I
class I
I I
presentation O
, O
and O
necessary O
for O
certain O
types O
of O
apoptosis O
. O

SUMO O
- O
1 O
modification O
of O
PML B
is O
known O
to O
be O
required O
for O
the O
formation O
of O
PML O
bodies O
. O

To O
examine O
whether O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV B
immediate I
- I
early I
genes I
BZLF1 B
( I
Z I
) I
and O
BRLF1 B
( I
R I
) I
in O
EBV O
- O
positive O
cell O
lines O
and O
examined O
PML B
localization O
. O

Both O
Z O
and O
R O
expression O
resulted O
in O
PML B
dispersion O
in O
EBV O
- O
positive O
cells O
. O

We O
show O
that O
dispersion O
of O
PML O
bodies O
by O
Z B
requires O
a O
portion O
of O
the O
transcriptional B
activation I
domain I
of O
Z B
but O
not O
the O
DNA O
- O
binding O
function O
. O

We O
show O
that O
dispersion O
of O
PML O
bodies O
by O
Z B
requires O
a O
portion O
of O
the O
transcriptional B
activation I
domain I
of O
Z B
but O
not O
the O
DNA O
- O
binding O
function O
. O

As O
was O
previously O
reported O
for O
the O
HSV B
- I
1 I
ICP0 I
and I
CMV I
IE1 I
proteins I
, O
Z B
reduces O
the O
amount O
of O
SUMO B
- I
1 I
- I
modified I
PML I
. O

We O
also O
found O
that O
Z B
itself O
is O
SUMO O
- O
1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z B
competes O
with O
PML B
for O
limiting O
amounts O
of O
SUMO B
- I
1 I
. O

We O
also O
found O
that O
Z B
itself O
is O
SUMO O
- O
1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z B
competes O
with O
PML B
for O
limiting O
amounts O
of O
SUMO B
- I
1 I
. O

We O
also O
found O
that O
Z B
itself O
is O
SUMO O
- O
1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z B
competes O
with O
PML B
for O
limiting O
amounts O
of O
SUMO B
- I
1 I
. O

Furthermore O
, O
Z B
may O
potentially O
alter O
the O
function O
of O
a O
variety O
of O
cellular O
proteins O
by O
inhibiting O
SUMO O
- O
1 O
modification O

To O
elucidate O
whether O
troglitazone O
exerts O
an O
antiinflammatory O
effect O
in O
humans O
, O
in O
vivo O
, O
we O
investigated O
the O
suppression O
of O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
in O
mononuclear O
cells O
( O
MNC O
) O
by O
this O
drug O
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
IkappaBalpha B
, O
and O
p47 B
( I
phox I
) I
subunit I
and O
ROS O
generation O
were O
determined O
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

There O
was O
a O
fall O
in O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
and O
p47 B
( I
phox I
) I
subunit I
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha B
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

The O
involvement O
of O
the O
tyrosine B
kinases I
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases B
. O

Specific O
missense O
mutations O
in O
NEMO B
result O
in O
hyper O
- O
IgM O
syndrome O
with O
hypohydrotic O
ectodermal O
dysplasia O
. O

The O
gene O
that O
encodes O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
essential I
modulator I
( O
or O
NEMO B
, O
also O
known O
as O
IKKgamma B
) O
is O
required O
for O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

The O
gene O
that O
encodes O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
essential I
modulator I
( O
or O
NEMO B
, O
also O
known O
as O
IKKgamma B
) O
is O
required O
for O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

We O
describe O
mutations O
in O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
that O
result O
in O
an O
X O
- O
linked O
primary O
immunodeficiency O
characterized O
by O
hyper O
- O
IgM O
syndrome O
and O
hypohydrotic O
ectodermal O
dysplasia O
( O
XHM O
- O
ED O
) O
. O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

CD40L B
. O

Nevertheless O
, O
innate O
immunity O
is O
preserved O
in O
XHM O
- O
ED O
patients O
because O
APCs O
retain O
the O
capacity O
to O
respond O
to O
stimulation O
by O
lipopolysaccharide O
or O
Staphylococcus B
aureus I
Cowan I
' I
s I
antigen I
( O
SAC B
) O
. O

Overall O
, O
the O
phenotype O
observed O
in O
XHM O
- O
ED O
patients O
shows O
that O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 B
- O
mediated O
NF O
- O
kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class O
- O
switching O
. O

Overall O
, O
the O
phenotype O
observed O
in O
XHM O
- O
ED O
patients O
shows O
that O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 B
- O
mediated O
NF O
- O
kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class O
- O
switching O
. O

METHODS O
: O
Expression O
of O
oestrogen B
receptors I
( O
ER B
) O
and O
progesterone B
receptors I
( O
PR B
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O

METHODS O
: O
Expression O
of O
oestrogen B
receptors I
( O
ER B
) O
and O
progesterone B
receptors I
( O
PR B
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O

The O
cells O
positive O
for O
ER B
or O
PR B
were O
confirmed O
by O
spatial O
location O
, O
dual O
immunolabelling O
, O
and O
histochemical O
staining O
. O

The O
cells O
positive O
for O
ER B
or O
PR B
were O
confirmed O
by O
spatial O
location O
, O
dual O
immunolabelling O
, O
and O
histochemical O
staining O
. O

RESULTS O
: O
Consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4 O
+ O
( O
T O
helper O
/ O
inducer O
) O
, O
CD8 O
+ O
( O
cytotoxic O
/ O
suppressor O
) O
, O
CD68 O
+ O
( O
macrophages O
) O
, O
mast O
cells O
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal B
antibodies I
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast O
cells O
tested O
positive O
for O
ER B
/ O
PR O
labelling O
with O
their O
polyclonal B
and I
monoclonal I
antibodies I
. O

The O
expression O
of O
ER B
/ O
PR B
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast O
cells O
( O
r O
= O
0 O
. O
973 O
, O
p O
< O
0 O
. O
001 O
for O
ER B
; O
r O
= O
0 O
. O
955 O
, O
p O
< O
0 O
. O
001 O
for O
PR B
) O
. O

The O
expression O
of O
ER B
/ O
PR B
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast O
cells O
( O
r O
= O
0 O
. O
973 O
, O
p O
< O
0 O
. O
001 O
for O
ER B
; O
r O
= O
0 O
. O
955 O
, O
p O
< O
0 O
. O
001 O
for O
PR B
) O
. O

The O
expression O
of O
ER B
/ O
PR B
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast O
cells O
( O
r O
= O
0 O
. O
973 O
, O
p O
< O
0 O
. O
001 O
for O
ER B
; O
r O
= O
0 O
. O
955 O
, O
p O
< O
0 O
. O
001 O
for O
PR B
) O
. O

The O
expression O
of O
ER B
/ O
PR B
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast O
cells O
( O
r O
= O
0 O
. O
973 O
, O
p O
< O
0 O
. O
001 O
for O
ER B
; O
r O
= O
0 O
. O
955 O
, O
p O
< O
0 O
. O
001 O
for O
PR B
) O
. O

Fewer O
than O
5 O
% O
of O
mast O
cells O
were O
found O
to O
be O
negative O
for O
ER B
/ O
PR B
expression O
. O

Fewer O
than O
5 O
% O
of O
mast O
cells O
were O
found O
to O
be O
negative O
for O
ER B
/ O
PR B
expression O
. O

CONCLUSIONS O
: O
Mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
, O
or O
other O
immune O
cells O
, O
express O
ER B
/ O
PR B
in O
human O
upper O
airways O
. O

CONCLUSIONS O
: O
Mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
, O
or O
other O
immune O
cells O
, O
express O
ER B
/ O
PR B
in O
human O
upper O
airways O
. O

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein B

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein B

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein B

tyrosine I
phosphatase I
( O
PTPase B
) O
and O
/ O
or O
protein B
kinase I
C I
( O
PKC B
) O
. O

The O
results O
demonstrate O
that O
both O
A O
/ O
R O
and O
redox O
imbalance O
led O
to O
I O
kappa O
B O
alpha O
degradation O
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 B
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF B
kappa I
B I
and O
subsequent O
nuclear O
translocation O
of O
the O
activated B
p65 I
subunit I
. O

Inhibition O
of O
PKC B
blocked O
I B
kappa I
B I
alpha I
degradation O
and O
p65 B
translocation O
in O
A O
/ O
R O
- O
challenged O
, O
but O
not O
redox O
- O
altered O
, O
endothelial O
cells O
. O

Inhibition O
of O
PKC B
blocked O
I B
kappa I
B I
alpha I
degradation O
and O
p65 B
translocation O
in O
A O
/ O
R O
- O
challenged O
, O
but O
not O
redox O
- O
altered O
, O
endothelial O
cells O
. O

However O
, O
both O
A O
/ O
R O
- O
and O
redox O
- O
induced O
NF O
kappa O
B O
activation O
was O
blocked O
by O
inhibition O
of O
PTK B
. O

Similarly O
, O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
were O
blocked O
by O
inhibition O
of O
PKC B
or O
PTK B
, O
while O
only O
PTK B
inhibited O
the O
redox O
- O
induced O
adhesion O
response O
. O

Similarly O
, O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
were O
blocked O
by O
inhibition O
of O
PKC B
or O
PTK B
, O
while O
only O
PTK B
inhibited O
the O
redox O
- O
induced O
adhesion O
response O
. O

Similarly O
, O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
were O
blocked O
by O
inhibition O
of O
PKC B
or O
PTK B
, O
while O
only O
PTK B
inhibited O
the O
redox O
- O
induced O
adhesion O
response O
. O

Collectively O
, O
these O
findings O
indicate O
that O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
are O
mediated O
by O
both O
PKC B
and O
PTK B
, O
which O
signal O
rapid O
activation O
of O
NF B
kappa I
B I
. O

Collectively O
, O
these O
findings O
indicate O
that O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
are O
mediated O
by O
both O
PKC B
and O
PTK B
, O
which O
signal O
rapid O
activation O
of O
NF B
kappa I
B I
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B
, O
TNF B
receptor I
1 I
or O
the O
aromatic B
hydrocarbon I
receptor I
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase B
- I
9 I
. O

ZVAD O
- O
FMK O
, O
a O
broad O
- O
spectrum O
inhibitor O
of O
caspases B
, O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
completely O
. O

Unlike O
Fas B
- O
mediated O
apoptosis O
, O
the O
initiator B
caspase I
, O
caspase B
- I
8 I
, O
was O
not O
involved O
in O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
. O

The O
activation O
of O
caspases B
occurs O
downstream O
of O
mitochondrial O
damage O
, O
and O
the O
dysfunction O
of O
mitochondria O
appears O
to O
be O
sufficient O
for O
triggering O
all O
downstream O
events O
leading O
to O
apoptosis O
. O

Inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
mediated O
by O
SOCS1 B
. O

Interleukin B
6 I
( O
IL B
- I
6 I
) O
is O
a O
cytokine B
produced O
by O
immune O
and O
nonimmune O
cells O
and O
exhibits O
functional O
pleiotropy O
and O
redundancy O
. O

Here O
, O
we O
describe O
a O
novel O
function O
of O
IL B
- I
6 I
: O
the O
negative O
regulation O
of O
CD4 B
+ O
Th1 O
cell O
differentiation O
. O

While O
IL B
- I
6 I
- O
directed O
CD4 B
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL B
- I
4 I
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
independent O
of O
IL B
- I
4 I
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Inhibition O
of O
IFNgamma B
receptor O
- O
mediated O
signals O
by O
IL B
- I
6 I
prevents O
autoregulation O
of O
IFNgamma B
gene I
expression O
by O
IFNgamma B
during O
CD4 O
+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Inhibition O
of O
IFNgamma B
receptor O
- O
mediated O
signals O
by O
IL B
- I
6 I
prevents O
autoregulation O
of O
IFNgamma B
gene I
expression O
by O
IFNgamma B
during O
CD4 O
+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Thus O
, O
IL B
- I
6 I
promotes O
CD4 B
+ O
Th2 O
differentiation O
and O
inhibits O
Th1 O
differentiation O
by O
two O
independent O
molecular O
mechanisms O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

This O
interaction O
is O
reciprocal O
, O
since O
C B
/ I
EBP I
dimer I
binding O
to O
a O
strong O
C B
/ I
EBP I
site I
leads O
to O
enhanced O
CREB B
- I
1 I
recruitment O
to O
ATF B
/ I
CREB I
sites I
that O
are O
weakly O
bound O
by O
CREB B
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF B
/ I
CREB I
binding I
site I
affected O
basal O
LTR B
activity O
as O
well O
as O
LTR B
function O
following O
interleukin B
- I
6 I
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C O
/ O
EBP O
activation O
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF B
/ I
CREB I
binding I
site I
affected O
basal O
LTR B
activity O
as O
well O
as O
LTR B
function O
following O
interleukin B
- I
6 I
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C O
/ O
EBP O
activation O
. O

OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated B
bovine I
serum I
albumin I
( O
mBSA B
) O
and O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
. O

METHODS O
: O
Mice O
were O
injected O
intraarticularly O
with O
mBSA B
on O
day O
0 O
and O
subcutaneously O
with O
recombinant B
human I
IL I
- I
1beta I
on O
days O
0 O
- O
2 O
. O

RESULTS O
: O
C57BL O
/ O
6 O
( O
B6 O
) O
, O
129 O
/ O
Sv O
, O
and O
( O
B6 O
x O
129 O
/ O
Sv O
) O
F1 O
hybrid O
mice O
, O
all O
H O
- O
2b O
strains O
, O
were O
susceptible O
to O
mBSA B
/ O
IL O
- O
1 O
- O
induced O
arthritis O
, O
whereas O
C3H O
/ O
HeJ O
( O
H O
- O
2k O
) O
mice O
were O
not O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

CONCLUSION O
: O
Arthritis O
induced O
by O
mBSA B
/ O
IL B
- I
1 I
is O
strain O
specific O
and O
dependent O
on O
CD4 O
+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB B
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody B
. O

CONCLUSION O
: O
Arthritis O
induced O
by O
mBSA B
/ O
IL B
- I
1 I
is O
strain O
specific O
and O
dependent O
on O
CD4 O
+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB B
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody B
. O

CONCLUSION O
: O
Arthritis O
induced O
by O
mBSA B
/ O
IL B
- I
1 I
is O
strain O
specific O
and O
dependent O
on O
CD4 O
+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB B
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody B
. O

Our O
results O
demonstrate O
that O
RARalpha B
is O
dispensable O
for O
granulopoiesis O
, O
as O
RARalpha O
( O
- O
/ O
- O
) O
mice O
have O
a O
normal O
granulocyte O
population O
despite O
an O
impaired O
ability O
to O
respond O
to O
retinoids O
. O

However O
, O
although O
it O
is O
not O
absolutely O
required O
, O
RARalpha B
can O
bidirectionally O
modulate O
granulopoiesis O
. O

RARalpha B
stimulates O
differentiation O
in O
response O
to O
exogenous O
retinoic O
acid O
. O

Conversely O
, O
RARalpha B
acts O
to O
limit O
differentiation O
in O
the O
absence O
of O
ligand B
because O
granulocyte O
precursors O
from O
RARalpha O
( O
- O
/ O
- O
) O
mice O
differentiate O
earlier O
in O
culture O
. O

Conversely O
, O
RARalpha B
acts O
to O
limit O
differentiation O
in O
the O
absence O
of O
ligand B
because O
granulocyte O
precursors O
from O
RARalpha O
( O
- O
/ O
- O
) O
mice O
differentiate O
earlier O
in O
culture O
. O

Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha B
fusion B
proteins I
expressed O
in O
APL O
cells O
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded B
RARalpha I
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 B
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 B
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 B
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 B
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

In O
human O
T O
cells O
CBFalpha2 B
is O
usually O
transcribed O
from O
a O
different B
promoter I
( O
distal B
promoter I
) O
than O
in O
myeloid O
cells O
( O
proximal B
promoter I
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

Lymphokine B
dependence O
of O
STAT3 O
activation O
produced O
by O
surface O
immunoglobulin O
cross O
- O
linking O
and O
by O
phorbol O
ester O
plus O
calcium O
ionophore O
treatment O
in O
B O
cells O
. O

Stimulation O
of O
B O
cells O
by O
surface B
immunoglobulin I
( O
sIg B
) O
triggering O
, O
or O
through O
the O
mitogenic O
combination O
of O
phorbol O
ester O
and O
calcium O
ionophore O
, O
is O
accompanied O
by O
activation O
of O
STAT B
transcription I
factors I
. O

sIg B
- O
induced O
activation O
of O
STAT3 B
was O
partially O
inhibited O
in O
B O
cells O
obtained O
from O
IL O
- O
6 O
- O
or O
IL O
- O
10 O
- O
deficient O
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B
antibodies I
directed O
against O
either O
of O
these O
lymphokines B
. O

sIg B
- O
induced O
activation O
of O
STAT3 B
was O
partially O
inhibited O
in O
B O
cells O
obtained O
from O
IL O
- O
6 O
- O
or O
IL O
- O
10 O
- O
deficient O
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B
antibodies I
directed O
against O
either O
of O
these O
lymphokines B
. O

sIg B
- O
induced O
activation O
of O
STAT3 B
was O
partially O
inhibited O
in O
B O
cells O
obtained O
from O
IL O
- O
6 O
- O
or O
IL O
- O
10 O
- O
deficient O
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B
antibodies I
directed O
against O
either O
of O
these O
lymphokines B
. O

sIg B
- O
induced O
STAT3 O
activation O
was O
completely O
inhibited O
by O
combining O
IL B
- I
6 I
- I
and I
IL I
- I
10 I
- I
specific I
neutralizing I
antibodies I
, O
or O
by O
adding O
individual O
neutralizing B
antibodies I
to O
B O
cells O
obtained O
from O
lymphokine O
- O
deficient O
animals O
. O

Transcription B
factor I
AP I
- I
4 I
is O
a O
ligand B
for O
immunoglobulin B
- I
kappa I
promoter I
E I
- I
box I
elements I
. O

These O
conserved O
motifs O
do O
not O
stimulate O
transcription O
in O
the O
absence O
of O
an O
octamer B
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription B
factor I
AP I
- I
4 I
, O
and O
not O
E47 B
, O
interacts O
specifically O
with O
the O
kappa B
promoter I
E I
- I
boxes I
when O
tested O
in O
electrophoretic O
mobility O
- O
shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human O
and O
murine O
B O
- O
cell O
lines O
. O

Furthermore O
, O
AP B
- I
4 I
, O
unlike O
E47 B
, O
did O
not O
act O
as O
a O
transactivator B
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B
promoters I
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B
element I
has O
been O
mutated O
. O

Furthermore O
, O
AP B
- I
4 I
, O
unlike O
E47 B
, O
did O
not O
act O
as O
a O
transactivator B
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B
promoters I
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B
element I
has O
been O
mutated O
. O

The O
DNA B
binding I
domain I
of O
the O
Drosophila B
transcription I
factor I
( O
Antennapedia B
) O
, O
a O
60 B
amino I
acid I
protein I
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B
to O
enhance O
their O
immunogenicity O
. O

The O
DNA B
binding I
domain I
of O
the O
Drosophila B
transcription I
factor I
( O
Antennapedia B
) O
, O
a O
60 B
amino I
acid I
protein I
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B
to O
enhance O
their O
immunogenicity O
. O

Protein B
Kinase I
A I
( O
PKA B
) O
, O
a O
cAMP B
kinase I
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B
cytokine I
activity O
, O
was O
increased O
in O
EBV O
- O
CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

These O
results O
show O
that O
the O
BMC O
inhibition O
is O
mediated O
by O
soluble B
factors I
( O
cytokines B
) O
and O
that O
cell O
- O
cell O
contact O
in O
this O
autologous O
system O
is O
not O
required O
, O
so O
that O
BMC O
( O
at O
least O
partially O
, O
via O
cytokine O
production O
) O
promote O
TH2 O
polarization O
in O
culture O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV O
- O
CTL O
generation O
, O
and O
TH2 B
associated O
PKA B
, O
CCR3 B
, O
and O
STAT B
- I
6 I
phosphorylation O
are O
enhanced O
by O
BMC O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV O
- O
CTL O
generation O
, O
and O
TH2 B
associated O
PKA B
, O
CCR3 B
, O
and O
STAT B
- I
6 I
phosphorylation O
are O
enhanced O
by O
BMC O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV O
- O
CTL O
generation O
, O
and O
TH2 B
associated O
PKA B
, O
CCR3 B
, O
and O
STAT B
- I
6 I
phosphorylation O
are O
enhanced O
by O
BMC O
. O

RNase O
protection O
assays O
showed O
a O
similar O
transcriptional O
pattern O
for O
both O
age O
groups O
that O
indicates O
that O
aging O
has O
no O
affect O
on O
transcription O
initiation O
or O
alternative O
splicing O
for O
either O
isoform B
. O

Proliferative O
responses O
of O
lymphoid O
cells O
to O
IL B
- I
2 I
and O
IL B
- I
4 I
depend O
on O
activation O
of O
the O
cells O
, O
but O
the O
mechanism O
( O
s O
) O
by O
which O
activation O
enhances O
cellular O
competence O
to O
respond O
to O
cytokines B
is O
not O
fully O
understood O
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

However O
, O
transgenic O
cells O
exhibited O
a O
dramatic O
defect O
in O
Stat5A O
activation O
treatment O
with O
IL B
- I
2 I
, O
and O
a O
similar O
defect O
was O
observed O
for O
IL B
- I
4 I
- O
induced O
Stat5 B
. O

Sequential O
involvement O
of O
NFAT B
and O
Egr B
transcription B
factors I
in O
FasL O
regulation O
. O

Sequential O
involvement O
of O
NFAT B
and O
Egr B
transcription B
factors I
in O
FasL O
regulation O
. O

The O
critical O
function O
of O
NFAT B
proteins I
in O
maintaining O
lymphoid O
homeostasis O
was O
revealed O
in O
mice O
lacking O
both O
NFATp B
and O
NFAT4 B
( O
DKO O
) O
. O

The O
critical O
function O
of O
NFAT B
proteins I
in O
maintaining O
lymphoid O
homeostasis O
was O
revealed O
in O
mice O
lacking O
both O
NFATp B
and O
NFAT4 B
( O
DKO O
) O
. O

DKO O
mice O
exhibit O
increased O
lymphoproliferation O
, O
decreased O
activation O
- O
induced O
cell O
death O
, O
and O
impaired O
induction O
of O
FasL B
. O

The O
transcription B
factors I
Egr2 B
and O
Egr3 B
are O
potent O
activators O
of O
FasL O
expression O
. O

The O
transcription B
factors I
Egr2 B
and O
Egr3 B
are O
potent O
activators O
of O
FasL O
expression O
. O

Here O
we O
find O
that O
Egr2 B
and O
Egr3 B
are O
NFAT B
target I
genes I
. O

Here O
we O
find O
that O
Egr2 B
and O
Egr3 B
are O
NFAT B
target I
genes I
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Further O
, O
Egr3 B
expression O
is O
enriched O
in O
Th1 O
cells O
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL B
in O
the O
Th1 O
versus O
Th2 O
subset O
. O

Further O
, O
Egr3 B
expression O
is O
enriched O
in O
Th1 O
cells O
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL B
in O
the O
Th1 O
versus O
Th2 O
subset O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

These O
data O
provide O
insight O
into O
SCN O
unresponsive O
to O
standard O
G B
- I
CSF I
treatment O
and O
to O
the O
potential O
corrective O
action O
of O
combined O
treatment O
with O
G B
- I
CSF I
and O
corticosteroids O
through O
synergistic O
activation O
of O
STAT5 B
. O

We O
have O
studied O
in O
cultured O
human O
mesangial O
cells O
( O
CHMC O
) O
several O
effects O
of O
9 O
- O
cis O
retinoic O
acid O
( O
9 O
- O
cRA O
) O
, O
an O
activator O
of O
both O
retinoic B
acid I
receptors I
( O
RARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
. O

We O
have O
studied O
in O
cultured O
human O
mesangial O
cells O
( O
CHMC O
) O
several O
effects O
of O
9 O
- O
cis O
retinoic O
acid O
( O
9 O
- O
cRA O
) O
, O
an O
activator O
of O
both O
retinoic B
acid I
receptors I
( O
RARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B
adhesion I
molecules I
, O
fibronectin B
and O
osteopontin B
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B
adhesion I
molecules I
, O
fibronectin B
and O
osteopontin B
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

In O
mammals O
, O
defensins B
are O
among O
the O
most O
abundant O
of O
these O
broad O
- O
spectrum O
antibiotics O
, O
and O
are O
expressed O
in O
epithelial O
and O
hematopoietic O
cells O
. O

Multiple O
signals O
required O
for O
cyclic B
AMP I
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
binding O
protein O
interaction O
induced O
by O
CD3 O
/ O
CD28 O
costimulation O
. O

The O
optimal O
activation O
of O
cAMP B
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
, O
similar O
to O
the O
full O
activation O
of O
T O
lymphocytes O
, O
requires O
the O
stimulation O
of O
both O
CD3 B
and O
CD28 B
. O

The O
optimal O
activation O
of O
cAMP B
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
, O
similar O
to O
the O
full O
activation O
of O
T O
lymphocytes O
, O
requires O
the O
stimulation O
of O
both O
CD3 B
and O
CD28 B
. O

The O
optimal O
activation O
of O
cAMP B
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
, O
similar O
to O
the O
full O
activation O
of O
T O
lymphocytes O
, O
requires O
the O
stimulation O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

Extracellular B
signal I
- I
regulated I
kinase I
, I
CaMKIV I
, O
and O
p38 B
MAPK I
were O
also O
the O
kinases O
involved O
in O
CREB B
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3 B
/ I
CD28 I
. O

A O
reconstitution O
experiment O
illustrated O
that O
optimum O
CREB B
- O
CBP B
interaction O
and O
CREB B
trans O
- O
activation O
were O
attained O
when O
these O
three O
kinase O
pathways O
were O
simultaneously O
activated O
in O
T O
cells O
. O

A O
reconstitution O
experiment O
illustrated O
that O
optimum O
CREB B
- O
CBP B
interaction O
and O
CREB B
trans O
- O
activation O
were O
attained O
when O
these O
three O
kinase O
pathways O
were O
simultaneously O
activated O
in O
T O
cells O
. O

A O
reconstitution O
experiment O
illustrated O
that O
optimum O
CREB B
- O
CBP B
interaction O
and O
CREB B
trans O
- O
activation O
were O
attained O
when O
these O
three O
kinase O
pathways O
were O
simultaneously O
activated O
in O
T O
cells O
. O

Our O
results O
demonstrate O
that O
coordinated O
activation O
of O
different O
kinases B
leads O
to O
full O
activation O
of O
CREB B
. O

Our O
results O
demonstrate O
that O
coordinated O
activation O
of O
different O
kinases B
leads O
to O
full O
activation O
of O
CREB B
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB B
- O
CBP B
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B
and O
CD28 B
are O
stimulated O
. O

These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB B
- O
CBP B
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B
and O
CD28 B
are O
stimulated O
. O

These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB B
- O
CBP B
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B
and O
CD28 B
are O
stimulated O
. O

These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB B
- O
CBP B
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B
and O
CD28 B
are O
stimulated O
. O

Signaling O
through O
the O
TCR B
and O
costimulatory O
signals O
primarily O
control O
transcription O
of O
the O
IL B
- I
2 I
gene I
in O
naive O
T O
cells O
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B
receptor I
( O
AHR B
) O
, O
a O
member O
of O
the O
bHLH B
- I
PAS I
family I
of I
transcription I
factors I
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL B
- I
2 I
in O
murine O
fetal O
thymocytes O
. O

The O
AHR B
is O
abundant O
in O
the O
thymus O
and O
may O
play O
a O
role O
for O
the O
development O
of O
the O
immune O
system O
. O

The O
IL B
- I
2 I
gene I
can O
be O
induced O
by O
the O
AHR B
also O
in O
thymocytes O
in O
vivo O
after O
injection O
of O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
, O
a O
potent O
ligand O
of O
the O
AHR B
. O

The O
IL B
- I
2 I
gene I
can O
be O
induced O
by O
the O
AHR B
also O
in O
thymocytes O
in O
vivo O
after O
injection O
of O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
, O
a O
potent O
ligand O
of O
the O
AHR B
. O

The O
AHR B
mediates O
the O
IL O
- O
2 O
induction O
as O
shown O
with O
AHR B
- O
deficient O
mice O
. O

The O
AHR B
mediates O
the O
IL O
- O
2 O
induction O
as O
shown O
with O
AHR B
- O
deficient O
mice O
. O

However O
, O
in O
spleen O
cells O
in O
vitro O
costimulation O
via O
the O
TCR B
is O
necessary O
for O
optimal O
IL B
- I
2 I
gene I
induction O
. O

Thus O
, O
the O
IL B
- I
2 I
promoter I
region I
contains O
novel O
distal B
regulatory I
elements I
that O
can O
be O
addressed O
by O
the O
AHR B
to O
induce O
IL B
- I
2 I
and O
can O
cooperate O
with O
the O
proximal B
promoter I

Visualization O
of O
Syk B
- I
antigen I
receptor I
interactions O
using O
green B
fluorescent I
protein I
: O
differential O
roles O
for O
Syk B
and O
Lyn B
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

Visualization O
of O
Syk B
- I
antigen I
receptor I
interactions O
using O
green B
fluorescent I
protein I
: O
differential O
roles O
for O
Syk B
and O
Lyn B
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

The O
cross O
- O
linking O
of O
the O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor O
- O
associated O
, O
protein B
tyrosine I
kinases I
of O
both O
the O
Src B
and I
Syk I
families I
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green B
fluorescent I
protein I
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green B
fluorescent I
protein I
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green B
fluorescent I
protein I
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green B
fluorescent I
protein I
. O

Treatment O
of O
these O
cells O
with O
anti B
- I
IgM I
Abs I
leads O
to O
the O
recruitment O
of O
the O
kinase B
from O
cytoplasmic O
and O
nuclear O
compartments O
to O
the O
site O
of O
the O
cross B
- I
linked I
receptor I
at O
the O
plasma O
membrane O
. O

Syk B
is O
not O
demonstrably O
associated O
with O
the O
internalized B
receptor I
. O

Catalytically O
active O
Syk B
promotes O
and O
stabilizes O
the O
formation O
of O
tightly B
capped I
BCR I
complexes I
at O
the O
plasma O
membrane O
. O

Lyn B
is O
not O
required O
for O
the O
recruitment O
of O
Syk B
to O
the O
cross B
- I
linked I
receptor I
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR B
complexes I
. O

Lyn B
is O
not O
required O
for O
the O
recruitment O
of O
Syk B
to O
the O
cross B
- I
linked I
receptor I
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR B
complexes I
. O

In O
the O
absence O
of O
Lyn B
, O
receptor B
- I
Syk I
complexes I
at O
the O
plasma O
membrane O
are O
long O
lived O
, O
and O
the O
receptor O
- O
mediated O
activation O
of O
the O
NF B
- I
AT I
transcription I
factor I
is O
enhanced O
. O

Thus O
, O
Lyn B
appears O
to O
function O
to O
negatively O
regulate O
aspects O
of O
BCR B
- O
dependent O
signaling O
by O
stimulating O
receptor O
internalization O
and O
down O
- O
regulation O
. O

Thus O
, O
Lyn B
appears O
to O
function O
to O
negatively O
regulate O
aspects O
of O
BCR B
- O
dependent O
signaling O
by O
stimulating O
receptor O
internalization O
and O
down O
- O
regulation O
. O

This O
study O
established O
a O
UUO O
model O
in O
angiotensin B
type I
1a I
receptor I
( O
AT1a B
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin B
II I
through O
AT1a B
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK O
) O
. O

This O
study O
established O
a O
UUO O
model O
in O
angiotensin B
type I
1a I
receptor I
( O
AT1a B
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin B
II I
through O
AT1a B
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK O
) O
. O

The O
results O
provide O
direct O
evidence O
that O
angiotensin B
II I
acting O
via O
the O
AT1a B
plays O
a O
pivotal O
role O
in O
the O
development O
of O
tubulointerstitial O
fibrosis O
in O
UUO O
. O

Down O
- O
regulation O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
in O
classical O
Hodgkin O
disease O
but O
not O
in O
lymphocyte O
predominant O
Hodgkin O
disease O
correlates O
with O
immunoglobulin O
transcription O
. O

In O
contrast O
to O
the O
tumor O
cells O
( O
L O
& O
H O
cells O
) O
of O
lymphocyte O
predominant O
Hodgkin O
disease O
( O
LPHD O
) O
, O
Hodgkin O
and O
Reed O
- O
Sternberg O
( O
HRS O
) O
cells O
of O
classical O
Hodgkin O
disease O
( O
cHD O
) O
are O
unable O
to O
transcribe O
immunoglobulin B
, O
despite O
the O
presence O
of O
rearranged B
immunoglobulin I
genes I
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B B
- I
cell I
transcription I
factors I
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription B
factors I
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Our O
results O
demonstrate O
an O
absence O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
in O
cHD O
and O
a O
striking O
overexpression O
of O
Oct2 B
in O
LPHD O
. O

Our O
results O
demonstrate O
an O
absence O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
in O
cHD O
and O
a O
striking O
overexpression O
of O
Oct2 B
in O
LPHD O
. O

Furthermore O
, O
the O
reintroduction O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
into O
cultured O
HRS O
cells O
restored O
the O
activity O
of O
cotransduced O
immunoglobulin B
promoter I
constructs I
. O

Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin B
V I
genes I
in O
cHD O
but O
is O
most O
likely O
due O
to O
a O
down O
- O
regulation O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
. O

This O
study O
further O
revealed O
Oct2 B
as O
a O
new O
and O
valuable O
marker O
for O
the O
identification O
of O
L O
& O
H O
cells O
and O
their O
distinction O
from O
HRS O
cells O
. O

The O
impairment O
of O
immunoglobulin O
transcription O
with O
a O
down O
- O
regulated O
synthesis O
of O
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
is O
the O
first O
established O
general O
recurrent O
defect O
found O
in O
HRS O
cells O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

We O
examined O
the O
activity O
of O
Tax B
in O
transcription O
through O
AP B
- I
1 I
- I
binding I
sites I
( O
AP B
- I
1 I
site I
) O
in O
T O
cells O
. O

Transient O
transfection O
studies O
showed O
that O
Tax B
activated O
the O
expression O
of O
a O
luciferase B
gene I
regulated O
by O
two O
copies O
of O
an O
AP B
- I
1 I
site I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Tax B
activates O
the O
expression O
of O
viral B
and I
cellular I
genes I
through O
two O
different O
enhancers O
: O
a O
cAMP B
- I
responsive I
( I
CRE I
) I
- I
like I
element I
and O
a O
kappaB B
element I
. O

Tax703 B
preferentially O
activated O
the O
kappaB B
element I
but O
not O
the O
CRE O
- O
like O
one O
, O
whereas O
TaxM22 B
showed O
the O
reverse O
. O

Tax703 B
preferentially O
activated O
the O
kappaB B
element I
but O
not O
the O
CRE O
- O
like O
one O
, O
whereas O
TaxM22 B
showed O
the O
reverse O
. O

In O
addition O
, O
Tax703 B
and O
Tax B
, O
but O
not O
TaxM22 B
, O
converted O
cell O
growth O
of O
a O
mouse O
T O
- O
cell O
line O
from O
being O
interleukin O
( O
IL O
) O
- O
2 O
- O
dependent O
to O
being O
IL O
- O
2 O
- O
independent O
. O

In O
addition O
, O
Tax703 B
and O
Tax B
, O
but O
not O
TaxM22 B
, O
converted O
cell O
growth O
of O
a O
mouse O
T O
- O
cell O
line O
from O
being O
interleukin O
( O
IL O
) O
- O
2 O
- O
dependent O
to O
being O
IL O
- O
2 O
- O
independent O
. O

In O
addition O
, O
Tax703 B
and O
Tax B
, O
but O
not O
TaxM22 B
, O
converted O
cell O
growth O
of O
a O
mouse O
T O
- O
cell O
line O
from O
being O
interleukin O
( O
IL O
) O
- O
2 O
- O
dependent O
to O
being O
IL O
- O
2 O
- O
independent O
. O

Unlike O
the O
wild B
- I
type I
Tax I
, O
Tax703 B
and O
TaxM22 B
only O
weakly O
activated O
the O
AP B
- I
1 I
site I
in O
the O
T O
- O
cell O
line O
. O

Unlike O
the O
wild B
- I
type I
Tax I
, O
Tax703 B
and O
TaxM22 B
only O
weakly O
activated O
the O
AP B
- I
1 I
site I
in O
the O
T O
- O
cell O
line O
. O

Thus O
, O
Tax B
seems O
to O
activate O
the O
AP B
- I
1 I
site I
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B
or I
CRE I
- I
like I
elements I
, O
and O
the O
activation O
of O
the O
AP B
- I
1 I
site I
is O
dispensable O
for O
IL O
- O
2 O
- O
independent O
growth O
of O
CTLL O
- O
2 O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B
induced O
strong O
binding O
activity O
to O
an O
AP B
- I
1 I
site I
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 B
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP B
- I
1 I
site I
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B
induced O
strong O
binding O
activity O
to O
an O
AP B
- I
1 I
site I
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 B
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP B
- I
1 I
site I
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B
induced O
strong O
binding O
activity O
to O
an O
AP B
- I
1 I
site I
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 B
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP B
- I
1 I
site I
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B
. O

The O
binding B
complex I
induced O
by O
Tax B
in O
CTLL O
- O
2 O
contained O
JunD B
and O
Fra B
- I
2 I
. O

The O
binding B
complex I
induced O
by O
Tax B
in O
CTLL O
- O
2 O
contained O
JunD B
and O
Fra B
- I
2 I
. O

Activation O
of O
transcription O
through O
the O
AP B
- I
1 I
site I
in O
Jurkat O
cells O
by O
JunD B
and O
/ O
or O
Fra B
- I
2 I
was O
weak O
. O

c B
- I
Jun I
, O
JunB B
, O
and O
c B
- I
Fos I
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax B
. O

c B
- I
Jun I
, O
JunB B
, O
and O
c B
- I
Fos I
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax B
. O

Thus O
, O
the O
induction O
of O
AP B
- I
1 I
mRNA I
by O
Tax B
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP B
- I
1 I
site I
by O
Tax B
. O

Thus O
, O
the O
induction O
of O
AP B
- I
1 I
mRNA I
by O
Tax B
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP B
- I
1 I
site I
by O
Tax B
. O

Our O
results O
suggest O
that O
Tax B
activates O
the O
transcription O
of O
cellular B
genes I
with O
AP B
- I
1 I
sites I
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP B
- I
1 I
proteins I
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE B
- I
like I
and I
kappaB I
elements I
. O

Incubation O
of O
SF O
with O
neutralizing B
antibodies I
against O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
but O
not O
antibodies B
against O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
significantly O
reduced O
the O
induction O
of O
p65 O
/ O
p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

A O
property O
of O
SF O
that O
is O
independent O
of O
TNF B
- I
alpha I
and O
other O
cytokines B
is O
responsible O
for O
the O
induction O
of O
a O
novel O
slowly O
migrating O
NF B
- I
kappaB I
- I
binding I
complex I
. O

These O
leukemic O
cells O
are O
resistant O
to O
Fas O
- O
mediated O
apoptosis O
despite O
expressing O
high O
levels O
of O
Fas B
. O

Treatment O
of O
leukemic O
LGL O
with O
the O
JAK O
- O
selective O
tyrosine O
kinase O
inhibitor O
AG O
- O
490 O
induced O
apoptosis O
with O
a O
corresponding O
decrease O
in O
STAT B
- O
DNA O
binding O
activity O
. O

Using O
a O
luciferase O
reporter O
assay O
, O
we O
demonstrated O
that O
v O
- O
src O
overexpression O
in O
NIH3T3 O
induced O
STAT3 B
- O
dependent O
transcriptional O
activity O
from O
the O
mcl B
- I
1 I
promoter I
and O
increased O
endogenous O
Mcl O
- O
1 O
protein O
levels O
. O

We O
conclude O
that O
STAT3 B
activation O
contributed O
to O
accumulation O
of O
the O
leukemic O
LGL O
clones O
. O

These O
findings O
suggest O
that O
investigation O
should O
focus O
on O
novel O
strategies O
targeting O
STAT3 B
in O
the O
treatment O
of O
LGL O
leukemia O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti B
- I
CD3 I
antibody I
in O
vitro O
demonstrated O
reduced O
induction O
of O
c B
- I
Jun I
, O
JunB B
, O
JunD B
and O
Fra B
- I
2 I
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti B
- I
CD3 I
antibody I
in O
vitro O
demonstrated O
reduced O
induction O
of O
c B
- I
Jun I
, O
JunB B
, O
JunD B
and O
Fra B
- I
2 I
. O

LIGHT B
, O
a O
TNF B
- I
like I
molecule I
, O
costimulates O
T O
cell O
proliferation O
and O
is O
required O
for O
dendritic O
cell O
- O
mediated O
allogeneic O
T O
cell O
response O
. O

LIGHT B
is O
a O
recently O
identified O
member O
of O
the O
TNF B
superfamily I
and O
its O
receptors O
, O
herpesvirus B
entry I
mediator I
and O
lymphotoxin B
beta I
receptor I
, O
are O
found O
in O
T O
cells O
and O
stromal O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
LIGHT B
is O
selectively O
expressed O
on O
immature O
dendritic O
cells O
( O
DCs O
) O
generated O
from O
human O
PBMCs O
. O

In O
contrast O
, O
LIGHT B
is O
not O
detectable O
in O
DCs O
either O
freshly O
isolated O
from O
PBMCs O
or O
rendered O
mature O
in O
vitro O
by O
LPS O
treatment O
. O

Blockade O
of O
LIGHT B
by O
its O
soluble B
receptors I
, O
lymphotoxin B
beta I
receptor I
- I
Ig I
or O
HVEM B
- I
Ig I
, O
inhibits O
the O
induction O
of O
DC O
- O
mediated O
primary O
allogeneic O
T O
cell O
response O
. O

Furthermore O
, O
engagement O
of O
LIGHT B
costimulates O
human O
T O
cell O
proliferation O
, O
amplifies O
the O
NF O
- O
kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O

Our O
results O
suggest O
that O
LIGHT B
is O
a O
costimulatory B
molecule I
involved O
in O
DC O
- O
mediated O
cellular O
immune O
responses O
. O

Activity O
of O
the O
distal B
region I
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long B
terminal I
repeat I
( O
LTR B
) O
, O
which O
contains O
binding B
sites I
for O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

The O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV B
- I
1 I
LTR I
distal I
enhancer I
region I
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant B
Ets I
- I
1 I
lacking I
trans I
- I
activation I
domains I
on O
the O
transcriptional O
activity O
of O
the O
LTR B
. O

We O
demonstrated O
that O
expression O
of O
dnEts B
markedly O
suppressed O
HIV O
- O
1 O
infection O
of O
a O
T O
cell O
line O
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines B
produced O
by O
eosinophils O
, O
including O
the O
proallergic B
cytokine I
IL I
- I
4 I
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
family O
of O
transcription O
factors O
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines B
produced O
by O
eosinophils O
, O
including O
the O
proallergic B
cytokine I
IL I
- I
4 I
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
family O
of O
transcription O
factors O
. O

NFAT B
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA O
- O
binding O
assays O
, O
and O
RT O
- O
PCR O
analysis O
of O
eosinophil B
mRNA I
. O

A O
brief O
incubation O
with O
the O
T B
( I
H I
) I
2 I
cytokines I
IL B
- I
4 I
and O
IL B
- I
5 I
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc B
. O

Eosinophil O
nuclear O
extracts O
contain O
multiple O
factors O
that O
can O
specifically O
recognize O
the O
IL B
- I
4 I
promoter I
P1 I
NFAT I
site I
in O
DNA O
- O
binding O
assays O
, O
including O
NFATp B
. O

CONCLUSION O
: O
NFATp B
and O
NFATc B
can O
regulate O
the O
expression O
of O
cytokines B
and O
other O
genes O
in O
eosinophils O
but O
appear O
to O
be O
regulated O
by O
a O
novel O
signal O
transduction O
mechanism O
in O
these O
cells O
. O

CONCLUSION O
: O
NFATp B
and O
NFATc B
can O
regulate O
the O
expression O
of O
cytokines B
and O
other O
genes O
in O
eosinophils O
but O
appear O
to O
be O
regulated O
by O
a O
novel O
signal O
transduction O
mechanism O
in O
these O
cells O
. O

CONCLUSION O
: O
NFATp B
and O
NFATc B
can O
regulate O
the O
expression O
of O
cytokines B
and O
other O
genes O
in O
eosinophils O
but O
appear O
to O
be O
regulated O
by O
a O
novel O
signal O
transduction O
mechanism O
in O
these O
cells O
. O

BLyS B
BINDS O
TO O
B O
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES O
ACTIVATION O
OF O
THE O
TRANSCRIPTION B
FACTORS I
NF B
- I
kappaB I
AND O
ELF B
- I
1 I
. O

B B
lymphocyte I
stimulator I
( O
BLyS B
) O
is O
a O
novel O
member O
of O
the O
TNF B
family I
of I
proteins I
expressed O
by O
myeloid O
cells O
as O
membrane O
- O
bound O
and O
soluble O
forms O
. O

BLyS B
was O
shown O
to O
act O
specifically O
on O
B O
cells O
, O
inducing O
proliferation O
and O
immunoglobulin O
production O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled B
BLyS I
to O
its O
cognate B
receptor I
on O
human O
B O
lymphocytes O
and O
examine O
intracellular O
events O
initiated O
by O
BLyS B
binding O
. O

Similar O
to O
other O
TNF B
family I
members I
, O
BLyS B
is O
present O
in O
solution O
as O
a O
homotrimer B
as O
determined O
by O
gel O
filtration O
chromatography O
and O
light O
scattering O
analysis O
. O

Similar O
to O
other O
TNF B
family I
members I
, O
BLyS B
is O
present O
in O
solution O
as O
a O
homotrimer B
as O
determined O
by O
gel O
filtration O
chromatography O
and O
light O
scattering O
analysis O
. O

BLyS B
binding O
to O
B O
cells O
is O
specific O
as O
other O
TNF B
family I
members I
tested O
did O
not O
compete O
for O
( O
125 O
) O
I O
- O
BLyS B
binding O
. O

BLyS B
binding O
to O
B O
cells O
is O
specific O
as O
other O
TNF B
family I
members I
tested O
did O
not O
compete O
for O
( O
125 O
) O
I O
- O
BLyS B
binding O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

Design O
and O
use O
of O
an O
inducibly O
activated O
human O
immunodeficiency O
virus O
type O
1 O
Nef B
to O
study O
immune O
modulation O
. O

One O
of O
the O
challenges O
in O
defining O
the O
molecular O
events O
regulated O
by O
Nef B
has O
been O
obtaining O
good O
expression O
of O
Nef B
protein I
in O
T O
cells O
. O

This O
has O
been O
attributed O
to O
effects O
of O
Nef B
on O
cell O
proliferation O
and O
apoptosis O
. O

Using O
this O
inducible O
Nef B
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 B
and O
HLA B
- I
A2 I
downmodulation O
in O
a O
SupT1 O
T O
- O
cell O
line O
. O

Using O
this O
inducible O
Nef B
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 B
and O
HLA B
- I
A2 I
downmodulation O
in O
a O
SupT1 O
T O
- O
cell O
line O
. O

In O
contrast O
, O
50 O
% O
downmodulation O
of O
HLA B
- I
A2 I
by O
Nef B
required O
16 O
to O
24 O
h O
and O
about O
50 O
- O
to O
100 O
- O
fold O
- O
greater O
concentrations O
of O
4 O
- O
HT O
. O

These O
data O
suggest O
that O
HLA B
- I
A2 I
downmodulation O
may O
require O
certain O
threshold O
levels O
of O
active O
Nef B
. O

The O
differential O
timing O
of O
CD4 B
and O
HLA B
- I
A2 I
downmodulation O
may O
have O
implications O
for O
HIV O
pathogenesis O
and O
immune O
evasion O
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B
against O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B
against O
IFN B
- I
gamma I
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B
against O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B
against O
IFN B
- I
gamma I
. O

All O
these O
findings O
suggest O
that O
uninfected O
PBMC O
can O
undergo O
activation O
of O
signal O
transduction O
and O
apoptosis O
after O
exposure O
to O
bystander O
HIV O
- O
infected O
cells O
, O
subsequent O
to O
the O
induction O
of O
cytokines B
such O
as O
IFNs B
and O
TNF B
- I
alpha I
. O

All O
these O
findings O
suggest O
that O
uninfected O
PBMC O
can O
undergo O
activation O
of O
signal O
transduction O
and O
apoptosis O
after O
exposure O
to O
bystander O
HIV O
- O
infected O
cells O
, O
subsequent O
to O
the O
induction O
of O
cytokines B
such O
as O
IFNs B
and O
TNF B
- I
alpha I
. O

The O
physical O
association O
of O
protein B
kinase I
C I
theta I
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa B
B I
factor I
kinase I
( I
IKK I
) I
complex I
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR B
and O
CD28 B
. O

The O
physical O
association O
of O
protein B
kinase I
C I
theta I
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa B
B I
factor I
kinase I
( I
IKK I
) I
complex I
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR B
and O
CD28 B
. O

We O
investigated O
the O
role O
of O
protein B
kinase I
C I
theta I
( O
PKCtheta B
) O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

Among O
six O
or O
so O
PKC B
isoforms I
expressed O
in O
T O
cells O
, O
only O
PKCtheta B
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR B
with O
Ag B
. O

Among O
six O
or O
so O
PKC B
isoforms I
expressed O
in O
T O
cells O
, O
only O
PKCtheta B
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR B
with O
Ag B
. O

Among O
six O
or O
so O
PKC B
isoforms I
expressed O
in O
T O
cells O
, O
only O
PKCtheta B
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR B
with O
Ag B
. O

Signaling O
via O
both O
the O
TCR B
and O
CD28 B
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit B
IkappaB I
kinase I
( I
IKK I
) I
complex I
in O
primary O
human O
T O
lymphocytes O
; O
this O
activation O
could O
be O
inhibited O
by O
a O
Ca O
( O
2 O
+ O
) O
- O
independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O

Signaling O
via O
both O
the O
TCR B
and O
CD28 B
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit B
IkappaB I
kinase I
( I
IKK I
) I
complex I
in O
primary O
human O
T O
lymphocytes O
; O
this O
activation O
could O
be O
inhibited O
by O
a O
Ca O
( O
2 O
+ O
) O
- O
independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O

Moreover O
, O
endogenous O
PKCtheta B
physically O
associates O
with O
activated O
IKK B
complexes I
in O
CD3 O
/ O
CD28 O
- O
costimulated O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
same O
set O
of O
stimuli O
also O
induced O
relocation O
of O
endogenous O
PKCtheta B
and O
IKKs B
to O
a O
GM1 O
ganglioside O
- O
enriched O
, O
detergent O
- O
insoluble O
membrane O
compartment O
in O
primary O
T O
cells O
. O

The O
same O
set O
of O
stimuli O
also O
induced O
relocation O
of O
endogenous O
PKCtheta B
and O
IKKs B
to O
a O
GM1 O
ganglioside O
- O
enriched O
, O
detergent O
- O
insoluble O
membrane O
compartment O
in O
primary O
T O
cells O
. O

IKKs B
recruited O
to O
these O
lipid O
rafts O
were O
capable O
of O
phosphorylating O
a O
recombinant O
IkappaBalpha O
sustrate O
. O

Confocal O
microscopy O
further O
demonstrated O
that O
exogenously O
expressed O
PKCtheta B
and O
IKKss B
colocalize O
in O
the O
membrane O
of O
CD3 O
/ O
CD28 O
- O
costimulated O
Jurkat O
T O
cells O
. O

Confocal O
microscopy O
further O
demonstrated O
that O
exogenously O
expressed O
PKCtheta B
and O
IKKss B
colocalize O
in O
the O
membrane O
of O
CD3 O
/ O
CD28 O
- O
costimulated O
Jurkat O
T O
cells O
. O

Constitutively O
active O
but O
not O
kinase B
- I
inactive I
PKCtheta I
activated O
IKKbeta B
in O
Jurkat O
T O
cells O
. O

Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta B
by O
the O
TCR B
and O
CD28 B
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B
complexes I
in O
the O
T O
cell O
membrane O

Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta B
by O
the O
TCR B
and O
CD28 B
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B
complexes I
in O
the O
T O
cell O
membrane O

Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta B
by O
the O
TCR B
and O
CD28 B
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B
complexes I
in O
the O
T O
cell O
membrane O

T O
- O
cell O
- O
mediated O
regulation O
of O
osteoclastogenesis O
by O
signalling O
cross O
- O
talk O
between O
RANKL B
and O
IFN B
- I
gamma I
. O

Bone O
resorption O
is O
regulated O
by O
the O
immune O
system O
, O
where O
T O
- O
cell O
expression O
of O
RANKL B
( O
receptor B
activator I
of I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
ligand I
) O
, O
a O
member O
of O
the O
tumour B
- I
necrosis I
factor I
family I
that O
is O
essential O
for O
osteoclastogenesis O
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O

However O
, O
whether O
activated O
T O
cells O
maintain O
bone O
homeostasis O
by O
counterbalancing O
the O
action O
of O
RANKL B
remains O
unknown O
. O

Here O
we O
show O
that O
T O
- O
cell O
production O
of O
interferon B
( I
IFN I
) I
- I
gamma I
strongly O
suppresses O
osteoclastogenesis O
by O
interfering O
with O
the O
RANKL B
- O
RANK O
signalling O
pathway O
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

This O
inhibition O
of O
osteoclastogenesis O
is O
rescued O
by O
overexpressing O
TRAF6 B
in O
precursor O
cells O
, O
which O
indicates O
that O
TRAF6 B
is O
the O
target O
critical O
for O
the O
IFN B
- I
gamma I
action O
. O

This O
inhibition O
of O
osteoclastogenesis O
is O
rescued O
by O
overexpressing O
TRAF6 B
in O
precursor O
cells O
, O
which O
indicates O
that O
TRAF6 B
is O
the O
target O
critical O
for O
the O
IFN B
- I
gamma I
action O
. O

Furthermore O
, O
we O
provide O
evidence O
that O
the O
accelerated O
degradation O
of O
TRAF6 B
requires O
both O
its O
ubiquitination O
, O
which O
is O
initiated O
by O
RANKL B
, O
and O
IFN B
- I
gamma I
- O
induced O
activation O
of O
the O
ubiquitin O
- O
proteasome O
system O
. O

Furthermore O
, O
we O
provide O
evidence O
that O
the O
accelerated O
degradation O
of O
TRAF6 B
requires O
both O
its O
ubiquitination O
, O
which O
is O
initiated O
by O
RANKL B
, O
and O
IFN B
- I
gamma I
- O
induced O
activation O
of O
the O
ubiquitin O
- O
proteasome O
system O
. O

Our O
study O
shows O
that O
there O
is O
cross O
- O
talk O
between O
the O
tumour B
necrosis I
factor I
and O
IFN B
families I
of O
cytokines B
, O
through O
which O
IFN B
- I
gamma I
provides O
a O
negative O
link O
between O
T O
- O
cell O
activation O
and O
bone O
resorption O
. O

Stromal B
- I
derived I
factor I
1 I
and O
thrombopoietin B
regulate O
distinct O
aspects O
of O
human O
megakaryopoiesis O
. O

The O
role O
of O
the O
chemokine B
binding O
stromal B
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B
( O
TPO B
) O
have O
not O
been O
determined O
. O

The O
role O
of O
the O
chemokine B
binding O
stromal B
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B
( O
TPO B
) O
have O
not O
been O
determined O
. O

The O
role O
of O
the O
chemokine B
binding O
stromal B
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B
( O
TPO B
) O
have O
not O
been O
determined O
. O

In O
this O
study O
it O
was O
found O
that O
SDF B
- I
1 I
, O
unlike O
TPO B
, O
does O
not O
stimulate O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cell O
proliferation O
or O
differentiation O
or O
have O
an O
antiapoptotic O
effect O
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl B
- I
inositol I
3 I
- I
kinase I
( O
PI B
- I
3K I
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP B
- I
9 I
and O
VEGF B
, O
the O
inhibition O
of O
MAPK B
p42 I
/ I
44 I
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Hence O
, O
it O
is O
suggested O
that O
the O
proliferative O
effect O
of O
TPO B
is O
more O
related O
to O
activation O
of O
the O
JAK O
- O
STAT O
pathway O
( O
unique O
to O
TPO B
) O
, O
and O
the O
PI O
- O
3K O
- O
AKT O
axis O
is O
differentially O
involved O
in O
TPO O
- O
and O
SDF O
- O
1 O
- O
dependent O
signaling O
. O

Hence O
, O
it O
is O
suggested O
that O
the O
proliferative O
effect O
of O
TPO B
is O
more O
related O
to O
activation O
of O
the O
JAK O
- O
STAT O
pathway O
( O
unique O
to O
TPO B
) O
, O
and O
the O
PI O
- O
3K O
- O
AKT O
axis O
is O
differentially O
involved O
in O
TPO O
- O
and O
SDF O
- O
1 O
- O
dependent O
signaling O
. O

Accordingly O
, O
PI B
- I
3K I
is O
involved O
in O
TPO B
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen B
and O
vitronectin B
, O
and O
SDF B
- I
1 I
- O
mediated O
migration O
. O

Accordingly O
, O
PI B
- I
3K I
is O
involved O
in O
TPO B
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen B
and O
vitronectin B
, O
and O
SDF B
- I
1 I
- O
mediated O
migration O
. O

Accordingly O
, O
PI B
- I
3K I
is O
involved O
in O
TPO B
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen B
and O
vitronectin B
, O
and O
SDF B
- I
1 I
- O
mediated O
migration O
. O

This O
study O
expands O
the O
understanding O
of O
the O
role O
of O
SDF B
- I
1 I
and O
TPO B
in O
normal O
human O
megakaryopoiesis O
and O
indicates O
the O
molecular O
basis O
of O
the O
observed O
differences O
in O
cellular O
responses O
. O

Key O
molecules O
mediating O
TEC O
/ O
thymocytes O
interactions O
include O
cytokines B
and O
growth B
factors I
secreted O
by O
the O
two O
cell O
types O
and O
adhesion B
receptors I
mediating O
cell O
contact O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross O
- O
linking O
of O
the O
alpha3 B
, O
alpha6 B
, O
beta1 B
and I
beta4 I
integrins I
, O
thus O
implying O
that O
the O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
can O
signal O
during O
thymocyte O
adhesion O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross O
- O
linking O
of O
the O
alpha3 B
, O
alpha6 B
, O
beta1 B
and I
beta4 I
integrins I
, O
thus O
implying O
that O
the O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
can O
signal O
during O
thymocyte O
adhesion O
. O

We O
found O
that O
adhesion O
of O
unstimulated O
T O
cell O
i O
) O
involved O
beta1 O
, O
but O
not O
beta4 O
integrin O
functions O
at O
the O
surface O
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 B
, O
but O
not O
alpha2beta1 B
heterodimers I
at O
the O
TEC O
surface O
and O
iii O
) O
up O
- O
regulated O
the O
nuclear O
binding O
activity O
of O
NF B
- I
kappaB I
transcription I
factor I
and O
the O
IL O
- O
6 O
secretion O
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
/ O
ionomycin O
- O
stimulated O
EL4 O
cells O
, O
SKAT B
- I
2 I
was O
found O
to O
up O
- O
regulate O
the O
activity O
of O
the O
IL B
- I
4 I
but I
not I
the I
IL I
- I
5 I
promoter I
, O
contrasting O
with O
the O
ability O
of O
GATA B
- I
3 I
to O
activate O
both O
promoters B
. O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

The O
hsp70 B
co I
- I
chaperone I
Hip I
has O
been O
recovered O
in O
receptor B
. I
hsp90 I
heterocomplexes I
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate O
, O
and O
Hip B
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O

Here O
we O
show O
that O
immunodepletion O
of O
Hip B
from O
reticulocyte O
lysate O
or O
addition O
of O
high O
levels O
of O
Hip B
to O
the O
purified O
five O
- O
protein O
system O
does O
not O
affect O
GR O
. O
hsp90 O
heterocomplex O
assembly O
or O
the O
activation O
of O
steroid O
binding O
activity O
that O
occurs O
with O
assembly O
. O

Here O
we O
show O
that O
immunodepletion O
of O
Hip B
from O
reticulocyte O
lysate O
or O
addition O
of O
high O
levels O
of O
Hip B
to O
the O
purified O
five O
- O
protein O
system O
does O
not O
affect O
GR O
. O
hsp90 O
heterocomplex O
assembly O
or O
the O
activation O
of O
steroid O
binding O
activity O
that O
occurs O
with O
assembly O
. O

Despite O
the O
fact O
that O
Hip B
does O
not O
affect O
assembly O
, O
it O
is O
recovered O
in O
GR B
. I
hsp90 I
heterocomplexes I
assembled O
by O
both O
systems O
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

We O
conclude O
that O
Hip B
is O
not O
a O
component O
of O
the O
assembly O
machinery O
but O
that O
it O
could O
play O
a O
regulatory O
role O
in O
opposition O
to O
BAG B
- I
1 I
. O

STAT4 B
and O
STAT6 B
are O
essential O
for O
the O
development O
of O
CD4 O
( O
+ O
) O
Th1 O
and O
Th2 O
development O
, O
respectively O
. O

STAT4 B
and O
STAT6 B
are O
essential O
for O
the O
development O
of O
CD4 O
( O
+ O
) O
Th1 O
and O
Th2 O
development O
, O
respectively O
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
ability O
of O
Tax B
to O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
( O
AP B
- I
1 I
site I
) O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

However O
, O
the O
HTLV B
- I
1 I
genes I
, O
including O
tax B
, O
are O
not O
significantly O
expressed O
in O
fresh O
leukemia O
cells O
from O
ATL O
patients O
. O

In O
addition O
, O
caspase B
- I
3 I
, O
an O
executioner O
of O
apoptosis O
, O
was O
activated O
and O
its O
substrate O
, O
poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
, O
was O
cleaved O
during O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
- O
induced O
apoptosis O
. O

Effects O
of O
deregulated O
Raf O
activation O
on O
integrin B
, O
cytokine O
- O
receptor O
expression O
and O
the O
induction O
of O
apoptosis O
in O
hematopoietic O
cells O
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

Continuous O
deltaRaf B
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous B
cytokines I
and O
altered O
the O
morphology O
of O
the O
FD O
/ O
deltaRaf O
: O
ER O
cells O
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 O
cells O
) O
whereas O
the O
parental O
cytokine O
- O
dependent O
FDC O
- O
P1 O
cells O
grew O
in O
smaller O
grape O
- O
like O
clusters O
( O
< O
10 O
cells O
) O
. O

Elevation O
of O
intracellular O
cAMP O
in O
T O
cells O
, O
induced O
by O
agents O
such O
as O
IL B
- I
1alpha I
or O
PGs B
, O
inhibits O
T O
cell O
activation O
. O

In O
effector O
T O
cells O
, O
an O
increase O
in O
the O
level O
of O
intracellular O
cAMP O
inhibits O
cytokine B
production O
in O
Th1 O
cells O
but O
stimulates O
cytokine B
production O
in O
Th2 O
cells O
. O

In O
effector O
T O
cells O
, O
an O
increase O
in O
the O
level O
of O
intracellular O
cAMP O
inhibits O
cytokine B
production O
in O
Th1 O
cells O
but O
stimulates O
cytokine B
production O
in O
Th2 O
cells O
. O

This O
appears O
to O
be O
a O
Th2 O
- O
selective O
event O
because O
cAMP O
barely O
increased O
p38 B
phosphorylation O
in O
Th1 O
cells O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Replacement O
of O
the O
two O
tyrosine O
residues O
completely O
abolished O
STAT3 B
activation O
, O
although O
replacing O
either O
tyrosine O
residue O
alone O
retained O
it O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 B
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 B
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 B
. O

Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
transforms O
cytokine B
- O
dependent O
T O
lymphocytes O
and O
causes O
adult O
T O
cell O
leukemia O
. O

Janus B
tyrosine I
kinase I
( I
Jak I
) I
3 I
and O
transcription B
factors I
Stat5a B
and O
Stat5b B
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV O
- O
1 O
- O
transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV O
- O
1 O
- O
infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3 O
- O
Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

Janus B
tyrosine I
kinase I
( I
Jak I
) I
3 I
and O
transcription B
factors I
Stat5a B
and O
Stat5b B
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV O
- O
1 O
- O
transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV O
- O
1 O
- O
infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3 O
- O
Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B
, O
Stat5a B
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B
Ab I
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 B
- I
responsive I
beta I

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B
, O
Stat5a B
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B
Ab I
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 B
- I
responsive I
beta I

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B
, O
Stat5a B
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B
Ab I
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 B
- I
responsive I
beta I

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B
, O
Stat5a B
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B
Ab I
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 B
- I
responsive I
beta I

The O
present O
work O
focuses O
on O
a O
region O
of O
Wp B
which O
in O
reporter O
assays O
confers O
B O
- O
cell O
- O
specific O
activity O
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

We O
suggest O
that O
Wp B
regulation O
by O
BSAP B
helps O
to O
ensure O
the O
B O
- O
cell O
specificity O
of O
EBV O
' O
s O
growth O
- O
transforming O
function O
. O

We O
suggest O
that O
Wp B
regulation O
by O
BSAP B
helps O
to O
ensure O
the O
B O
- O
cell O
specificity O
of O
EBV O
' O
s O
growth O
- O
transforming O
function O
. O

Two O
sequences O
in O
the O
Tip B
protein I
were O
previously O
shown O
to O
be O
involved O
in O
binding O
to O
Lck B
. O

We O
show O
here O
that O
the O
other O
Lck B
- I
binding I
domain I
, O
residues O
104 O
- O
113 O
, O
binds O
to O
the O
carboxyl B
- I
terminal I
half I
of O
Lck B
and O
that O
this O
binding O
does O
not O
require O
the O
Lck B
SH3 I
domain I
. O

Mutated O
Tip B
containing O
only O
one O
functional O
Lck B
- I
binding I
domain I
can O
bind O
stably O
to O
Lck B
, O
although O
not O
as O
strongly O
as O
wild B
- I
type I
Tip I
. O

Mutated O
Tip B
containing O
only O
one O
functional O
Lck B
- I
binding I
domain I
can O
bind O
stably O
to O
Lck B
, O
although O
not O
as O
strongly O
as O
wild B
- I
type I
Tip I
. O

Interaction O
of O
Tip B
with O
Lck B
through O
either O
Lck B
- I
binding I
domain I
increases O
the O
activity O
of O
Lck B
in O
vivo O
. O

Interaction O
of O
Tip B
with O
Lck B
through O
either O
Lck B
- I
binding I
domain I
increases O
the O
activity O
of O
Lck B
in O
vivo O
. O

Interaction O
of O
Tip B
with O
Lck B
through O
either O
Lck B
- I
binding I
domain I
increases O
the O
activity O
of O
Lck B
in O
vivo O
. O

Simultaneous O
binding O
of O
both O
domains O
is O
required O
for O
maximal O
activation O
of O
Lck B
. O

The O
transient O
expression O
of O
Tip B
in O
T O
cells O
was O
found O
to O
stimulate O
both O
Stat3 B
- O
dependent O
and O
NF B
- I
AT I
- O
dependent O
transcription O
. O

The O
transient O
expression O
of O
Tip B
in O
T O
cells O
was O
found O
to O
stimulate O
both O
Stat3 B
- O
dependent O
and O
NF B
- I
AT I
- O
dependent O
transcription O
. O

Mutant O
forms O
of O
Tip B
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck B
- I
binding I
domains I
retained O
the O
ability O
to O
stimulate O
Stat3 B
- O
dependent O
transcription O
. O

Mutant O
forms O
of O
Tip B
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck B
- I
binding I
domains I
retained O
the O
ability O
to O
stimulate O
Stat3 B
- O
dependent O
transcription O
. O

Tip B
lacking O
the O
proline O
- O
rich O
Lck B
- I
binding I
domain I
exhibited O
almost O
wild O
- O
type O
activity O
in O
this O
assay O
. O

In O
contrast O
, O
ablation O
of O
either O
Lck B
- I
binding I
domain I
abolished O
the O
ability O
of O
Tip B
to O
stimulate O
NF B
- I
AT I
- O
dependent O
transcription O
. O

Full O
biological O
activity O
of O
Tip B
, O
therefore O
, O
appears O
to O
require O
both O
Lck B
- I
binding I
domains I
. O

We O
have O
previously O
reported O
that O
the O
activation O
of O
resting O
human O
immature O
peripheral O
blood O
T O
( O
PBT O
) O
lymphocytes O
is O
associated O
with O
the O
loss O
of O
retinoid B
X I
receptor I
alpha I
( O
RXRalpha B
) O
expression O
. O

In O
the O
present O
study O
, O
we O
have O
demonstrated O
that O
, O
unlike O
resting O
cells O
, O
activation O
of O
cycling O
human O
mature O
PBT O
lymphocytes O
, O
and O
T O
lymphocyte O
leukemia O
cell O
lines O
is O
accompanied O
by O
the O
accumulation O
of O
RXRalpha B
mRNA O
and O
protein O
. O

Interestingly O
, O
cyclosporin O
A O
further O
augmented O
RXRalpha B
expression O
, O
indicating O
the O
involvement O
of O
calcineurin O
pathways O
in O
the O
process O
. O

Transfection O
analysis O
in O
Jurkat O
cells O
, O
using O
RXRE O
- O
dependent O
reporter O
assays O
, O
showed O
that O
RXRalpha B
accumulated O
during O
T O
cell O
activation O
was O
transcriptionally O
inactive O
. O

To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen O
- O
activated O
protein O
kinase O
pathways O
, O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
and O
extracellular B
signal I
- I
regulated I
kinase I
( O
ERK B
) O
, O
in O
modulating O
RXRE O
- O
dependent O
transcription O
, O
was O
explored O
. O

To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen O
- O
activated O
protein O
kinase O
pathways O
, O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
and O
extracellular B
signal I
- I
regulated I
kinase I
( O
ERK B
) O
, O
in O
modulating O
RXRE O
- O
dependent O
transcription O
, O
was O
explored O
. O

The O
expression O
of O
constitutively O
active O
MAP B
/ I
ERK I
kinase I
kinase I
1 I
( O
MEKK1 B
) O
inhibited O
RXRE O
- O
dependent O
transcription O
, O
whereas O
dominant B
negative I
MEKK1 I
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK B
signaling O
pathways O
in O
the O
process O
. O

The O
expression O
of O
constitutively O
active O
MAP B
/ I
ERK I
kinase I
kinase I
1 I
( O
MEKK1 B
) O
inhibited O
RXRE O
- O
dependent O
transcription O
, O
whereas O
dominant B
negative I
MEKK1 I
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK B
signaling O
pathways O
in O
the O
process O
. O

In O
contrast O
, O
expression O
of O
constitutively B
active I
MEK1 I
, O
which O
activates O
ERK B
pathway O
, O
enhanced O
RXRE O
- O
dependent O
activation O
. O

When O
both O
were O
activated O
simultaneously O
, O
JNK B
pathway O
was O
dominant O
over O
ERK B
pathway O
and O
resulted O
in O
inhibition O
of O
RXRE O
- O
mediated O
transcription O
. O

When O
both O
were O
activated O
simultaneously O
, O
JNK B
pathway O
was O
dominant O
over O
ERK B
pathway O
and O
resulted O
in O
inhibition O
of O
RXRE O
- O
mediated O
transcription O
. O

These O
data O
demonstrate O
a O
dual O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
activation O
of O
resting O
and O
cycling O
T O
lymphocytes O
and O
indicate O
a O
dynamic O
balance O
between O
JNK O
and O
ERK O
pathways O
in O
modulating O
RXRE O
- O
mediated O
transactivation O
. O

The O
proteasome B
regulates O
receptor O
- O
mediated O
endocytosis O
of O
interleukin B
- I
2 I
. O

Recent O
studies O
have O
increasingly O
implicated O
the O
proteasome B
in O
the O
regulation O
of O
cell B
surface I
receptors I
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
the O
proteasome B
for O
ligand O
- O
dependent O
endocytosis O
and O
degradation O
of O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- I
interleukin I
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
complex I
. O

Proteasome O
inhibitors O
impaired O
internalization O
of O
IL B
- I
2 I
. I
IL I
- I
2R I
and O
prevented O
the O
lysosomal O
degradation O
of O
this O
cytokine B
. O

Based O
on O
time O
- O
course O
studies O
, O
proteasome B
activity O
is O
primarily O
required O
after O
initial O
endocytosis O
of O
the O
IL B
- I
2 I
. I
IL I
- I
2R I
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Therefore O
, O
a O
functional O
proteasome B
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL B
- I
2R I
/ I
ligand I
complex I
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL B
- I
2 I
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O

OBJECTIVE O
: O
The O
transcription B
factor I
NF I
- I
E2 I
, O
a O
heterodimeric B
protein I
complex I
composed O
of O
p45 B
and O
small O
Maf B
family I
proteins I
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

We O
have O
established O
optimal O
conditions O
for O
the O
measurement O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
human O
white O
cells O
using O
a O
whole O
- O
cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
as O
the O
ligand O
, O
and O
the O
subsequent O
determination O
of O
the O
GR B
content O
in O
normal O
human O
lymphocytes O
and O
in O
leukemic O
cells O
of O
patients O
with O
various O
forms O
of O
acute O
and O
chronic O
leukemia O
. O

We O
have O
established O
optimal O
conditions O
for O
the O
measurement O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
human O
white O
cells O
using O
a O
whole O
- O
cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
as O
the O
ligand O
, O
and O
the O
subsequent O
determination O
of O
the O
GR B
content O
in O
normal O
human O
lymphocytes O
and O
in O
leukemic O
cells O
of O
patients O
with O
various O
forms O
of O
acute O
and O
chronic O
leukemia O
. O

A O
number O
of O
leukemia O
cell O
lines O
in O
continuous O
culture O
were O
also O
subjected O
to O
the O
GR B
assay O
, O
and O
the O
results O
were O
correlated O
with O
the O
sensitivity O
of O
these O
cell O
lines O
to O
glucocorticoid O
steroids O
in O
vitro O
. O

The O
GR B
content O
of O
normal O
human O
lymphocytes O
amounted O
to O
4 O
, O
850 O
+ O
/ O
- O
1 O
, O
340 O
( O
mean O
+ O
/ O
- O
SD O
) O
receptors O
/ O
cell O
. O

The O
mean O
equilibrium O
dissociation O
constant O
( O
KD O
) O
of O
the O
interaction O
of O
[ O
3H O
] O
dexamethasone O
with O
the O
GR B
was O
1 O
. O
2 O
x O
10 O
( O
- O
8 O
) O
M O
. O

The O
GR B
content O
of O
the O
blast O
cells O
obtained O
from O
eight O
patients O
suffering O
from O
acute O
leukemia O
and O
four O
patients O
with O
a O
blast O
crisis O
of O
chronic O
myelocytic O
leukemia O
was O
found O
to O
be O
highly O
variable O
( O
3 O
, O
230 O
- O
29 O
, O
900 O
receptors O
/ O
cell O
) O
, O
while O
the O
lymphocytes O
of O
six O
patients O
with O
chronic O
lymphatic O
leukemia O
contained O
a O
rather O
stable O
GR B
content O
( O
2 O
, O
930 O
- O
5 O
, O
120 O
receptors O
/ O
cell O
) O
, O
which O
was O
comparable O
with O
that O
of O
normal O
lymphocytes O
. O

The O
GR B
content O
of O
the O
blast O
cells O
obtained O
from O
eight O
patients O
suffering O
from O
acute O
leukemia O
and O
four O
patients O
with O
a O
blast O
crisis O
of O
chronic O
myelocytic O
leukemia O
was O
found O
to O
be O
highly O
variable O
( O
3 O
, O
230 O
- O
29 O
, O
900 O
receptors O
/ O
cell O
) O
, O
while O
the O
lymphocytes O
of O
six O
patients O
with O
chronic O
lymphatic O
leukemia O
contained O
a O
rather O
stable O
GR B
content O
( O
2 O
, O
930 O
- O
5 O
, O
120 O
receptors O
/ O
cell O
) O
, O
which O
was O
comparable O
with O
that O
of O
normal O
lymphocytes O
. O

GR B
was O
identified O
in O
all O
the O
12 O
malignant O
continuous O
white O
cell O
lines O
studied O
. O

Large O
cells O
contained O
more O
GR B
than O
the O
smaller O
ones O
. O

There O
was O
no O
apparent O
correlation O
between O
the O
GR B
concentration O
and O
the O
sensitivity O
of O
the O
cells O
in O
vitro O
to O
glucocorticoids O
as O
judged O
by O
[ O
3H O
] O
thymidine O
incorporation O
studies O
. O

Distribution O
of O
the O
surface O
markers O
in O
the O
leukemic O
cell O
lines O
did O
not O
relate O
to O
the O
GR B
concentration O
. O

We O
conclude O
that O
the O
presence O
of O
GR B
is O
probably O
a O
universal O
feature O
of O
the O
leukemic O
cells O
, O
and O
, O
from O
a O
clinical O
standpoint O
, O
probably O
does O
not O
alone O
imply O
steroid O
responsiveness O
. O

Phytohemagglutinin B
treatment O
increases O
levels O
about O
3 O
- O
fold O
. O

The O
Src B
- I
like I
protein I
- I
tyrosine I
kinase I
Fyn B
is O
associated O
with O
T B
- I
cell I
antigen I
receptor I
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE B
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE B
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

The O
stimulation O
of O
SRE B
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn B
but O
also O
with O
normal B
( I
wild I
- I
type I
) I
Fyn I
. O

The O
stimulation O
of O
SRE B
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn B
but O
also O
with O
normal B
( I
wild I
- I
type I
) I
Fyn I
. O

SRE B
was O
also O
stimulated O
by O
both O
normal B
and I
active I
Lck I
. O

Under O
the O
same O
conditions O
, O
Lck B
did O
not O
stimulate O
IL B
- I
2 I
promoter I
unless O
it O
was O
activated O
by O
mutation O
. O

Csk B
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B
family I
kinases I
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum B
response I
element I
and O
Fyn O
- O
mediated O
enhancement O
of O
IL B
- I
2 I
promoter I
activity O
. O

These O
data O
suggest O
that O
Fyn B
and O
Lck B
, O
whose O
activities O
are O
regulated O
by O
Csk B
, O
are O
involved O
in O
different O
phases O
of O
T O
- O
cell O
activation O
. O

These O
data O
suggest O
that O
Fyn B
and O
Lck B
, O
whose O
activities O
are O
regulated O
by O
Csk B
, O
are O
involved O
in O
different O
phases O
of O
T O
- O
cell O
activation O
. O

These O
data O
suggest O
that O
Fyn B
and O
Lck B
, O
whose O
activities O
are O
regulated O
by O
Csk B
, O
are O
involved O
in O
different O
phases O
of O
T O
- O
cell O
activation O
. O

The O
predominant O
inducible O
form O
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
is O
a O
heteromeric B
complex I
containing O
two O
Rel B
- I
related I
DNA I
- I
binding I
subunits I
, O
termed B
p65 I
and O
p50 B
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 B
and I
p50 I
subunits I
are O
expressed O
independently O
as O
stable B
homodimers I
, O
p65 B
stimulates O
kappa O
B O
- O
directed O
transcription O
, O
whereas O
p50 B
functions O
as O
a O
kappa O
B O
- O
specific O
repressor O
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 B
and I
p50 I
subunits I
are O
expressed O
independently O
as O
stable B
homodimers I
, O
p65 B
stimulates O
kappa O
B O
- O
directed O
transcription O
, O
whereas O
p50 B
functions O
as O
a O
kappa O
B O
- O
specific O
repressor O
. O

While O
authentic O
p50 B
homodimers I
( O
previously O
termed O
KBF1 B
) O
have O
been O
detected O
in O
nuclear O
extracts O
from O
nontransfected O
cells O
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 B
homodimers I
in O
vivo O
was O
lacking O
. O

Site O
- O
directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein B
kinase I
A I
( O
RRPS B
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91 O
- O
amino O
- O
acid O
segment O
of O
the O
Rel B
homology I
domain I
that O
mediates O
self O
- O
association O
. O

Site O
- O
directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein B
kinase I
A I
( O
RRPS B
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91 O
- O
amino O
- O
acid O
segment O
of O
the O
Rel B
homology I
domain I
that O
mediates O
self O
- O
association O
. O

In O
contrast O
, O
mutations O
at O
these O
two O
sites O
do O
not O
affect O
heterodimerization O
of O
p65 B
with O
p50 B
or O
its O
functional O
interaction O
with O
I O
kappa O
B O
alpha O
. O

In O
contrast O
, O
mutations O
at O
these O
two O
sites O
do O
not O
affect O
heterodimerization O
of O
p65 B
with O
p50 B
or O
its O
functional O
interaction O
with O
I O
kappa O
B O
alpha O
. O

These O
later O
findings O
indicate O
that O
neither O
homo O
- O
nor O
heterodimer O
formation O
is O
an O
absolute O
prerequisite O
for O
I B
kappa I
B I
alpha I
recognition O
of O
p65 B
. O

Taken O
together O
with O
prior O
in O
vivo O
transcription O
studies O
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 B
and I
p50 I
homodimers I
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF B
- I
kappa I
B I
/ O
Rel B
- O
directed O
gene O
expression O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
, O
a O
cytokine B
with O
pleiotropic O
biological O
effects O
, O
is O
produced O
by O
a O
variety O
of O
cell O
types O
in O
response O
to O
induction O
by O
diverse O
stimuli O
. O

In O
this O
paper O
, O
TNF B
- I
alpha I
mRNA I
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine O
T O
cell O
clone O
by O
stimulation O
with O
T B
cell I
receptor I
( O
TCR B
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

Activation O
can O
be O
achieved O
in O
vitro O
by O
increased O
ionic O
strength O
, O
dilution O
or O
gel O
filtration O
and O
is O
manifested O
by O
an O
increased O
affinity O
of O
steroid B
- I
receptor I
complex I
for O
DNA B
and O
an O
altered O
elution O
profile O
from O
ion O
- O
exchange O
resins O
. O

Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs B
alpha I
, O
Gi B
alpha I
1 I
, O
and O
p21ras B
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O

The O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
promoter I
cis I
- I
acting I
element I
CLE0 B
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 B
and O
NFAT B
. O

The O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
promoter I
cis I
- I
acting I
element I
CLE0 B
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 B
and O
NFAT B
. O

The O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
promoter I
cis I
- I
acting I
element I
CLE0 B
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 B
and O
NFAT B
. O

Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis B
- I
acting I
element I
( O
positions B
- I
54 I
to I
- I
40 I
) O
, O
referred O
to O
as O
CLE0 B
, O
is O
a O
target O
for O
the O
induction O
signals O
. O

We O
observed O
induction O
with O
templates O
containing O
intact O
CLE0 B
but O
not O
with O
templates O
with O
deleted B
or I
mutated I
CLE0 I
. O

We O
also O
observed O
that O
two O
distinct O
signals O
were O
required O
for O
the O
stimulation O
through O
CLE0 B
, O
since O
only O
extracts O
from O
cells O
treated O
with O
both O
phorbol O
myristate O
acetate O
and O
A23187 O
supported O
optimal O
induction O
. O

The O
presence O
of O
CLE0 B
- I
like I
elements I
in O
the O
promoters B
of O
interleukin B
- I
3 I
( I
IL I
- I
3 I
) I
, I
IL I
- I
4 I
, I
IL I
- I
5 I
, I
GM I
- I
CSF I
, I
and I
NFAT I
sites I
in O
the O
IL B
- I
2 I
promoter I
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T O
- O
cell O
activation O
. O

Identification O
and O
characterization O
of O
an O
Alu B
- I
containing I
, I
T I
- I
cell I
- I
specific I
enhancer I
located O
in O
the O
last O
intron B
of O
the O
human B
CD8 I
alpha I
gene I
. O

In O
addition O
, O
the O
5 B
' I
end I
of O
the O
enhancer B
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA B
- I
3 I
, I
bHLH I
, I
and I
LyF I
- I
1 I
binding I
sites I
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
human B
CD8 I
alpha I
gene I
is O
regulated O
by O
the O
interaction O
of O
multiple O
T B
- I
cell I
nuclear I
proteins I
with O
a O
transcriptional O
enhancer O
located O
in O
the O
last O
intron B
of O
the O
gene O
. O

A O
series O
of O
transient O
transfections O
performed O
with O
human B
IL I
- I
3 I
- I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
reporter I
plasmids I
in O
T O
and O
non O
- O
T O
cells O
revealed O
that O
a O
plasmid B
containing O
319 O
bp O
of O
5 B
' I
flanking I
sequences I
was O
active O
exclusively O
in O
T O
cells O
. O

DNaseI B
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA O
- O
144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49 B
- I
bp I
region I
contains O
a O
nuclear B
protein I
binding I
region I
that O
includes O
consensus B
AP I
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

A O
[ O
3H O
] O
dexamethasone O
radioligand O
- O
binding O
assay O
was O
used O
to O
measure O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
and O
dissociation O
constant O
( O
Kd O
) O
in O
PBMC O
from O
normal O
donors O
and O
patients O
with O
SR O
asthma O
, O
cultured O
in O
the O
absence O
and O
presence O
of O
these O
cytokines B
. O

A O
[ O
3H O
] O
dexamethasone O
radioligand O
- O
binding O
assay O
was O
used O
to O
measure O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
and O
dissociation O
constant O
( O
Kd O
) O
in O
PBMC O
from O
normal O
donors O
and O
patients O
with O
SR O
asthma O
, O
cultured O
in O
the O
absence O
and O
presence O
of O
these O
cytokines B
. O

These O
effects O
of O
IL B
- I
2 I
+ O
IL B
- I
4 I
on O
PBMC O
GR B
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co O
- O
incubation O
with O
IFN B
- I
gamma I
. O

These O
observations O
suggest O
that O
with O
persistent O
inflammation O
certain O
cytokines B
may O
contribute O
to O
an O
impaired O
response O
to O
glucocorticoids O
. O

The O
leukocyte O
migration O
inhibition O
response O
to O
certain O
breast B
cancer I
- I
related I
antigens I
( O
MCF B
- I
7 I
and O
MuMTV B
) O
: O
their O
potential O
as O
discriminants O
. O

We O
have O
used O
the O
leukocyte O
migration O
inhibition O
( O
LMI O
) O
response O
to O
assay O
the O
response O
to O
several O
potential O
breast O
cancer O
- O
related O
antigens O
, O
including O
MuMTV B
, O
MPMV B
, O
and O
a O
breast O
cancer O
cultured O
cell O
line O
, O
MCF O
- O
7 O
, O
in O
96 O
breast O
cancer O
patients O
, O
in O
32 O
women O
with O
benign O
breast O
disease O
, O
and O
in O
67 O
normal O
women O
. O

We O
have O
used O
the O
leukocyte O
migration O
inhibition O
( O
LMI O
) O
response O
to O
assay O
the O
response O
to O
several O
potential O
breast O
cancer O
- O
related O
antigens O
, O
including O
MuMTV B
, O
MPMV B
, O
and O
a O
breast O
cancer O
cultured O
cell O
line O
, O
MCF O
- O
7 O
, O
in O
96 O
breast O
cancer O
patients O
, O
in O
32 O
women O
with O
benign O
breast O
disease O
, O
and O
in O
67 O
normal O
women O
. O

Breast O
cancer O
patients O
showed O
significant O
responses O
to O
MuMTV B
( O
49 O
% O
and O
to O
MCF O
- O
7 O
( O
50 O
% O
) O
, O
but O
not O
to O
MPMV B
( O
29 O
% O
) O
. O

Breast O
cancer O
patients O
showed O
significant O
responses O
to O
MuMTV B
( O
49 O
% O
and O
to O
MCF O
- O
7 O
( O
50 O
% O
) O
, O
but O
not O
to O
MPMV B
( O
29 O
% O
) O
. O

In O
a O
paired O
- O
antigen O
study O
using O
MuMTV B
and O
MCF B
- I
7 I
, O
75 O
% O
of O
the O
breast O
cancer O
patients O
responded O
, O
versus O
18 O
% O
of O
the O
normal O
women O
( O
P O
less O
than O
0 O
. O
0050 O
) O
. O

The O
overall O
responses O
to O
MuMTV B
and O
MCF B
- I
7 I
were O
analyzed O
with O
reference O
to O
certain O
prognostic O
factors O
, O
but O
showed O
no O
relation O
to O
age O
, O
menstrual O
status O
, O
estrogen O
receptor O
status O
, O
or O
stage O
of O
disease O
. O

The O
above O
reactions O
suggest O
that O
a O
large O
proportion O
of O
breast O
cancer O
patients O
exhibit O
presensitization O
to O
antigenfs O
found O
in O
MuMTV B
and O
MCF B
- I
7 I
, O
which O
may O
be O
cross O
- O
reactive O
with O
antigens O
in O
the O
primary O
cancer O
. O

Here O
it O
is O
shown O
that O
ZEBRA B
also O
behaves O
as O
a O
sequence B
- I
specific I
transcriptional I
activator I
in O
Saccharomyces O
cerevisiae O
. O

Deletional O
mutagenesis O
defined O
three O
regions O
of O
ZEBRA B
that O
participate O
in O
activation O
in O
S O
. O
cerevisiae O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

However O
, O
when O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL B
4 O
and O
assayed O
on O
GAL4 B
binding I
sites I
, O
regions B
YII I
and I
YIII I
were O
each O
sufficient O
to O
confer O
activation O
in O
S O
. O
cerevisiae O
. O

Regions O
of O
ZEBRA B
which O
affected O
activation O
in O
S O
. O
cerevisiae O
were O
also O
required O
in O
human O
B O
lymphocytes O
. O

The O
amino B
- I
terminal I
region I
of O
ZEBRA B
( O
aa B
1 I
to I
98 I
) O
was O
required O
for O
activation O
both O
in O
S O
. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy B
- I
terminal I
18 I
aa I
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

Thus O
, O
the O
behavior O
of O
ZEBRA B
in O
human O
B O
cells O
and O
S O
. O
cerevisiae O
suggests O
that O
the O
protein O
contains O
universal B
activation I
motifs I
that O
interact O
with O
conserved O
components O
of O
the O
transcription O
machinery O
. O

However O
, O
certain O
deletion B
mutants I
of O
ZEBRA B
containing O
mutations O
in O
the O
N B
- I
terminal I
region I
exhibited O
discordant O
behaviors O
in O
S O
. O
cerevisiae O
and O
in O
B O
cells O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

We O
also O
demonstrate O
that O
TPB B
interaction O
with O
Rel B
activation I
regions I
leads O
to O
synergistic O
activation O
of O
transcription O
of O
a O
kappa B
B I
- I
linked I
reporter I
gene I
. O

Combined O
with O
the O
observation O
that O
the O
mouse B
c I
- I
Rel I
and I
human I
RelA I
proteins I
also O
interact O
with O
TBP B
and O
TFIIB B
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B
transcription I
factors I
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B
family I
proteins I
. O

Combined O
with O
the O
observation O
that O
the O
mouse B
c I
- I
Rel I
and I
human I
RelA I
proteins I
also O
interact O
with O
TBP B
and O
TFIIB B
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B
transcription I
factors I
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B
family I
proteins I
. O

p21ras B
and O
calcineurin O
synergize O
to O
regulate O
the O
nuclear B
factor I
of O
activated O
T O
cells O
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

One O
immediate O
consequence O
of O
T O
cell O
activation O
via O
the O
TCR B
is O
an O
increase O
in O
cytosolic O
calcium O
. O

Calcium O
signals O
are O
important O
for O
NFAT O
induction O
, O
and O
recent O
studies O
have O
identified O
calcineurin B
, O
a O
calcium B
- I
calmodulin I
dependent I
serine I
- I
threonine I
phosphatase I
, O
as O
a O
prominent O
component O
of O
the O
calcium O
signaling O
pathway O
in O
T O
cells O
. O

A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine B
nucleotide I
binding I
protein I
, O
p21ras B
, O
which O
is O
coupled O
to O
the O
TCR B
by O
a O
protein B
tyrosine I
kinase I
dependent O
mechanism O
. O

A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine B
nucleotide I
binding I
protein I
, O
p21ras B
, O
which O
is O
coupled O
to O
the O
TCR B
by O
a O
protein B
tyrosine I
kinase I
dependent O
mechanism O
. O

The O
experiments O
presented O
here O
show O
that O
expression O
by O
transfection O
of O
mutationally O
activated O
calcineurin B
or O
activated O
p21ras B
alone O
is O
insufficient O
for O
NFAT O
transactivation O
. O

The O
experiments O
presented O
here O
show O
that O
expression O
by O
transfection O
of O
mutationally O
activated O
calcineurin B
or O
activated O
p21ras B
alone O
is O
insufficient O
for O
NFAT O
transactivation O
. O

These O
data O
identify O
calcineurin B
and O
p21ras B
as O
cooperative O
partners O
in O
T O
cell O
activation O
. O

These O
data O
identify O
calcineurin B
and O
p21ras B
as O
cooperative O
partners O
in O
T O
cell O
activation O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

The O
timing O
and O
pattern O
of O
expression O
of O
these O
different O
mRNAs B
during O
avian O
erythroid O
development O
and O
differentiation O
suggests O
that O
temporally O
regulated O
changes O
in O
GATA B
factor I
expression O
are O
required O
for O
vertebrate O
hematopoiesis O
. O

Distinct O
functional O
T O
- O
cell O
subsets O
, O
differing O
in O
the O
patterns O
of O
lymphokines B
produced O
, O
regulate O
cell O
- O
mediated O
and O
humoral O
immune O
responses O
. O

We O
have O
explored O
the O
possibility O
of O
using O
antibodies B
against O
purified O
rat O
liver O
glucocorticoid B
receptors I
to O
study O
the O
immunochemical O
properties O
of O
glucocorticoid B
receptors I
from O
murine O
and O
human O
malignant O
lymphocytes O
. O

Protein B
tyrosine I
kinase I
activation O
is O
required O
for O
lipopolysaccharide O
induction O
of O
cytokines B
in O
human O
blood O
monocytes O
. O

Bacterial O
LPS O
induce O
production O
of O
cytokines B
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
, O
and O
TNF B
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O

Bacterial O
LPS O
induce O
production O
of O
cytokines B
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
, O
and O
TNF B
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O

However O
, O
the O
mechanisms O
by O
which O
LPS O
activates O
these O
cells O
to O
express O
cytokines B
are O
not O
completely O
characterized O
. O

The O
present O
study O
addressed O
the O
role O
of O
different O
protein B
kinases I
in O
the O
LPS O
induction O
of O
cytokines B
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

Some O
liberated B
dimers I
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B
kappa I
B I
alpha I
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B
kappa I
B I
alpha I
and O
not O
of O
c B
- I
rel I
or O
p65 B
. O

No O
effect O
of O
LPS O
treatment O
was O
detected O
on O
p105 B
or O
p100 B
, O
which O
also O
retain O
rel B
family I
members I
in O
the O
cytoplasm O
. O

No O
effect O
of O
LPS O
treatment O
was O
detected O
on O
p105 B
or O
p100 B
, O
which O
also O
retain O
rel B
family I
members I
in O
the O
cytoplasm O
. O

The O
gene O
encoding O
the O
cytolytic B
protein I
perforin B
is O
selectively O
expressed O
by O
activated O
killer O
lymphocytes O
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell O
- O
type O
- O
specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA O
- O
protein O
interactions O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
mouse B
perforin I
gene I
( O
Pfp B
) O
. O

Following O
activation O
with O
phytohemagglutinin B
, O
patients O
with O
hypercalcitriolemia O
demonstrated O
significantly O
greater O
VDR O
concentrations O
. O

Patients O
with O
AH O
demonstrated O
a O
normal O
value O
for O
the O
group O
, O
but O
6 O
patients O
had O
significantly O
greater O
concentrations O
of O
VDR B
despite O
normal O
plasma O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
four O
of O
the O
patients O
. O

Taken O
together O
, O
the O
results O
suggest O
that O
PBMC O
provide O
a O
useful O
system O
for O
studying O
VDR B
status O
in O
transient O
or O
acquired O
states O
of O
hypercalcitriolemia O
. O

The O
combined O
inhibition O
of O
phosphatases B
and O
activation O
of O
kinases B
provides O
a O
potent O
mechanism O
for O
the O
synergistic O
effects O
of O
H2O2 O
plus O
vanadate O
. O

The O
combined O
inhibition O
of O
phosphatases B
and O
activation O
of O
kinases B
provides O
a O
potent O
mechanism O
for O
the O
synergistic O
effects O
of O
H2O2 O
plus O
vanadate O
. O

The O
influence O
of O
human B
serum I
albumin I
and O
sex B
hormone I
binding I
globulin I
( O
SHBG B
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

Total O
plasma O
and O
albumin B
delayed O
the O
conversion O
rate O
of O
androstenedione O
, O
while O
SHBG B
increased O
it O
markedly O
. O

Total O
plasma O
and O
albumin B
delayed O
the O
conversion O
rate O
of O
androstenedione O
, O
while O
SHBG B
increased O
it O
markedly O
. O

The O
effect O
of O
SHBG B
was O
largely O
abolished O
by O
heating O
to O
60 O
degrees O
C O
for O
1 O
h O
and O
by O
saturating O
its O
binding O
sites O
by O
DHT O
. O

It O
appears O
that O
the O
binding O
sites O
of O
albumin B
provide O
a O
mechanism O
for O
retarding O
androstenedione O
uptake O
by O
the O
erythrocytes O
and O
that O
the O
high O
binding O
affinity O
of O
SHBG B
for O
testosterone O
facilitates O
the O
diffusion O
of O
this O
steroid O
out O
of O
the O
cell O
and O
thus O
, O
displaces O
the O
chemical O
equilibrium O
within O
the O
cell O
. O

It O
appears O
that O
the O
binding O
sites O
of O
albumin B
provide O
a O
mechanism O
for O
retarding O
androstenedione O
uptake O
by O
the O
erythrocytes O
and O
that O
the O
high O
binding O
affinity O
of O
SHBG B
for O
testosterone O
facilitates O
the O
diffusion O
of O
this O
steroid O
out O
of O
the O
cell O
and O
thus O
, O
displaces O
the O
chemical O
equilibrium O
within O
the O
cell O
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
resulted O
in O
clear O
induction O
of O
luciferase B
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B
kappa I
B I
enhancers I
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV B
long I
terminal I
repeat I
constructs I
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

